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Latent membrane protein 1 (LMP1) is an oncogene expressed in a subset of germinal 
centre (GC)-derived lymphomas including Hodgkin’s lymphoma (HL) and diffuse large B 
cell lymphoma (DLBCL). However, LMP1 shares functional homology with CD40, a 
receptor required for normal GC B cell development. Dissecting how LMP1 functions 
differently from CD40 in GC cells is central to a better understanding of 
lymphomagenesis and is the subject of this thesis.  
In Chapter 3, I show that GC B cells can be successfully isolated from normal human 
tonsils and that these cells retain a GC phenotype upon short-term culture.  
In Chapter 4 I explore how the transcriptional programmes of LMP1 and CD40 differ in 
GC B cells and identify a subgroup of genes regulated by LMP1 but not by CD40, which 
are also concordantly regulated in primary HL cells from which I focus on sphingosine-
1-phosphate receptor 2 (S1PR2). I confirm that S1PR2 is an LMP1 target in GC B cells and 
show that it is not expressed in the tumour cells of the majority of cases of HL and DLBCL. 
In DLBCL, S1PR2 loss is associated with LMP1 expression. I also provide preliminary 
evidence that the over-expression of S1PR2 can inhibit the HL cell migration. 
In Chapter 5, I report my initial attempts to optimise a method for the measurement of 
the activity of transcription factors in GC B cells which can be used to delineate those 





I would like to acknowledge the University of Birmingham for supporting my stipend and 
Leukaemia and Lymphoma Research whose support of the Murray lab made my 
research possible.  
I would like to thank my supervisors Dr Martina Vockerodt and Professor Paul Murray 
for all their support. I am especially grateful for the patience with which you imparted 
your advice over the last four years, even if I may not have shown it at the time. Further 
thanks to Dr Vockerodt for introducing me to an eclectic repertoire of music in tissue 
culture.  
I would also like to say thanks to all members of the Murray group past and present who 
not only supported me through my time in the lab, but made the last four years 
enjoyable. I would especially like to say thanks to Dr Zumla Cader, Dr Jenifer Anderton 
and Dr Jessica Edwards who were always ready to console and offer me their wisdom in 
times of need. Special thanks to Naheema Gordon and Daniela Liebelt and who were 
always there to listen (and provide the occasional distraction when needed).  
Lastly, I would like to thank my friends and family, without who I would not be where I 
am today. In particular I want to thank my parents and my sister for their unconditional 
love and support. I could not have done it without you. 
  
iii 
Table of Contents 
1 Introduction 2 
1.1 The germinal centre reaction 2 
1.1.1 Entry into the GC 2 
1.1.2 Overview of the GC reaction 4 
1.1.3 Control of the GC reaction 8 
1.1.4 Exit from the GC 11 
1.2 EBV 13 
1.2.1 EBV latency 14 
1.2.2 Latent membrane protein 1 16 
1.2.3 CD40 20 
1.2.4 Studies of LMP1 and CD40 functional homology 24 
1.3 GC derived lymphomas 27 
1.3.1 Hodgkin’s lymphoma 27 
1.3.2 Diffuse large B cell lymphoma 33 
1.4 Aims 36 
2 Materials and methods 39 
2.1 Cell culture 39 
2.1.1 Maintenance of cell lines 39 
2.1.2 Cryopreservation and thawing of cells 39 
iv 
2.1.3 Cell counting 40 
2.2 Isolation and maintenance of primary human GC B cells 41 
2.2.1 Tonsil specimens 41 
2.2.2 Purification of tonsillar mononuclear cells (TMCs) 41 
2.2.3 Purification of CD10+ GC B cells 42 
2.2.4 CD40L stimulation of GC B cells 43 
2.3 Plasmid preparation 43 
2.3.1 Agar and broth preparation 43 
2.3.2 Making competent bacteria 43 
2.3.3 Transformation 44 
2.3.4 Plasmid purification 44 
2.4 Transfection and enrichment of cell lines and primary GC B cells 45 
2.4.1 Transfection of BL2 and DG75 cell lines by electroporation 45 
2.4.2 Transfection of L428 and GC B cells by nucleofection 46 
2.4.3 MoFlo enrichment of transfected GC B cells 48 
2.5 RNA analysis 48 
2.5.1 RNA extraction from cultured cells and stimulated GC B cells 49 
2.5.2 RNA extraction and amplification from nucleofected GC B cells 49 
2.5.3 Reverse transcription (RT) of RNA to cDNA 50 
2.5.4 Quantitative polymerase chain reaction (qPCR) 50 
v 
2.6 Protein analysis 52 
2.6.1 Western blotting 52 
2.6.2 Immunohistochemistry and immunofluorescence 55 
2.6.3 Flow cytometry 58 
2.7 Migration assay 59 
2.8 Proliferation assay 60 
2.9 Statistical analysis 60 
2.9.1 Re-analysis of published microarrays 60 
3 An investigation of the phenotype of germinal centre B cells following their in 
vitro separation and short term culture 63 
3.1 Introduction 63 
3.2 Results 64 
3.2.1 Isolated CD10 positive tonsillar mononuclear cells are viable 64 
3.2.2 Isolated CD10 positive tonsillar mononuclear cells display a GC B cell 
phenotype 66 
3.2.3 Isolated GCB cells undergo apoptosis in culture but a proportion remains 
viable for up to 12 hours 73 
3.2.4 Isolated CD10 positive cells do not retain a germinal centre phenotype in 
culture  75 
3.3 Discussion 78 
vi 
4 Comparison of the transcriptional programmes of LMP1 and CD40 in primary 
human GC B cells with a focus on the effects of the expression of lipid signalling 
genes 84 
4.1 Introduction 84 
4.2 Results 85 
4.2.1 Validation of the overlapping transcriptional programme of CD40 and 
LMP1 in primary human GC B cells 85 
4.2.2 Validation of LMP1 target genes not regulated by CD40 in primary human 
GC B cells and relevant to the pathogenesis of HL 90 
4.2.3 S1PR2 mRNA expression predicts survival in DLBCL and its over-expression 
reduces tumour cell migration in a HL cell line model 98 
4.3 Discussion 113 
5 Optimisation of the PathDetect system for detection of LMP1 and CD40 induced 
signalling pathways in GC B cells 121 
5.1 Introduction 121 
5.2 Results 125 
5.2.1 Optimisation of the CHOP and ATF2 PathDetect systems in BL2 cells 125 
5.2.2 Optimisation of the CHOP and ATF2 PathDetect systems in GC B cells 127 
5.3 CD40L stimulation of the ATF2 PathDetect system in GC B cells 129 
5.4 Summary 131 
6 Future Work 134 
vii 
7 Appendix 137 




List of Figures 
 
FIGURE 1.1: THE GERMINAL CENTRE REACTION (KLEIN AND DALLA-FAVERA, 2008) ...............................5 
FIGURE 1.2: S1PR2 AND RGS13 REGULATE GC B CELL PROLIFERATION AND MIGRATION .....................10 
FIGURE 1.3: DIFFERENTIATION OF CENTROCYTES (KLEIN AND DALLA-FAVERA, 2008) ..........................12 
FIGURE 1.4: LMP1 SIGNALLING IN B CELLS .............................................................................................18 
FIGURE 1.5: CD40 SIGNALLING IN B CELLS .............................................................................................22 
FIGURE 1.6: ABERRANT SIGNALLING PATHWAYS IN HODGKIN’S LYMPHOMA ......................................30 
FIGURE 3.1: VIABILITY AND GATING STRATEGY FOR ISOLATED CELL POPULATIONS .............................65 
FIGURE 3.2: PHENOTYPE OF ISOLATED CD10 POSITIVE CELLS ................................................................68 
FIGURE 3.3: LEVELS OF CENTROBLASTS AND CENTROCYTES ..................................................................70 
FIGURE 3.4: CELLS OF NON-GC B CELL ORIGIN IN THE ISOLATED CELLS .................................................72 
FIGURE 3.5: CD10 ENRICHED CELLS DISPLAY SIGNS OF APOPTOSIS IN CULTURE ...................................74 
FIGURE 3.6: CD10 ENRICHED CELLS DO NOT RETAIN THEIR GC B CELL PHENOTYPE IN CULTURE ...........76 
FIGURE 3.7: EFFECT OF CULTURE ON THE PHENOTYPE OF ISOLATED GC B CELLS ..................................77 
FIGURE 4.1: SUMMARY OF ARRAY COMPARISON .................................................................................88 
FIGURE 4.2: LMP1 IS STRONGLY EXPRESSED FOLLOWING TRANSFECTION IN ALL FOR GC B CELL 
SAMPLES .......................................................................................................................................88 
FIGURE 4.3: UP-REGULATION OF ICAM1 AND NF-ΚB FOLLOWING LMP1 TRANSFECTION OF GC B CELLS
 ......................................................................................................................................................89 
FIGURE 4.4: SUMMARY OF ARRAY COMPARISONS SHOWING GENES CONCORDANTLY REGULATED BY 
LMP1 AND IN HL ...........................................................................................................................91 
FIGURE 4.5: VALIDATION OF GENES CONCURRENTLY REGULATED BY LMP1 AND IN HRS CELLS ...........95 
FIGURE 4.6: VALIDATION OF THE S1PR2 ANTIBODY IN IHC ....................................................................99 
FIGURE 4.7: S1PR2 AND LMP1 EXPRESSION IN HL ............................................................................... 101 
FIGURE 4.8: S1PR2 AND LMP1 EXPRESSION IN DLBCL.......................................................................... 102 
FIGURE 4.9: S1PR2 PROTEIN EXPRESSION AND DLBCL SURVIVAL ........................................................ 104 
ix 
FIGURE 4.10: S1PR2 EXPRESSION IN PRE-TREATMENT TUMOUR PREDICTS SURVIVAL ....................... 106 
FIGURE 4.11: S1PR2 EXPRESSION DOES NOT PREDICT SURVIVAL IN ABC AND GCB DLBCL STRATIFIED BY 
TREATMENT ................................................................................................................................ 107 
FIGURE 4.12: S1PR2 EXPRESSION IN HL CELL LINES .............................................................................. 109 
FIGURE 4.13: S1PR2 EXPRESSION IN DLBCL CELL LINES ........................................................................ 110 
FIGURE 4.14: OVER-EXPRESSION OF S1PR2 IN L428 CELLS LEADS A REDUCTION IN MIGRATION ........ 112 
FIGURE 5.1: THE PATHDETECT TRANS-SYSTEM .................................................................................... 123 
FIGURE 5.2: THE P38 MAPK AND JNK SIGNALLING PATHWAYS ........................................................... 124 
FIGURE 5.3: OPTIMISATION OF THE PATHDETECT SYSTEM IN BL2 CELLS ............................................. 126 
FIGURE 5.4: OPTIMISATION OF THE PATHDETECT SYSTEM IN GC B CELLS ........................................... 128 
FIGURE 5.5: COMBINATION OF THE PATHDETECT SYSTEM WITH CD40L STIMULATION ...................... 130 
 
x 
List of Tables 
 
TABLE 1.1: MUTATIONS AFFECTING THE KEY SIGNALLING PATHWAYS IN HL ........................................32 
TABLE 1.2: GENETIC ALTERATIONS IN DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) ..............................35 
TABLE 2.1: CELL LINES ............................................................................................................................40 
TABLE 2.2: PLASMID DETAILS .................................................................................................................45 
TABLE 2.3: PATHDETECT PLASMID TITRATION .......................................................................................46 
TABLE 2.4: TAQMAN PRIMER/PROBES FROM APPLIED BIOSYSTEMS (ABI) ...........................................51 
TABLE 2.5: ANTIBODIES USED FOR IHC ..................................................................................................56 
TABLE 2.6: FLUORESCENTLY LABELLED ANTIBODIES USED FOR FLOW CYTOMETRY ..............................59 
TABLE 3.1: MARKERS USED FOR IDENTIFYING CELLULAR SUBSETS ........................................................66 
TABLE 4.1: GENE ONTOLOGY ANALYSIS OF LMP1 AND HRS CELL TARGET GENES..................................92 
TABLE 4.2: LMP1 TARGET GENES SELECTED FOR VALIDATION ...............................................................93 
TABLE 4.3: LMP1 AND S1PR2 EXPRESSION IN 155 HODGKIN'S LYMPHOMA CASES * .......................... 103 
TABLE 4.4: LMP1 AND S1PR2 EXPRESSION IN 169 DIFFUSE LARGE B CELL LYMPHOMA CASES * ......... 103 
TABLE 7.1: GENES CONCURRENTLY REGULATED BY LMP1 AND CD40 IN GC B CELLS ........................... 137 
TABLE 7.2: GENES REGULATED BY LMP1 BUT NOT BY CD40 IN GC B CELLS.......................................... 140 
TABLE 7.3: GENES REGULATED BY LMP1, NOT CD40 IN GC B CELLS, WHICH ARE ALSO CONCURRENTLY 




List of common abbreviations 
 
ABC activated B cell like  
AID activation-induced cytidine deaminase 
APC allophycocyanin 
ATF2 activating transcription factor 2 
BCR B cell receptor 
BL Burkitt’s lymphoma 
CD40L CD40 ligand 
CHOP C/EBP homologous protein 
CSR class-switch recombination  
CTAR carboxy-terminal activating region 
CXCL CXC chemokine ligand  
CXCR CXC chemokine receptor  
DLBCL diffuse large B cell lymphoma 
EBV Epstein-Barr virus 
FDC follicular dendritic cell 
FITC fluorescein isothiocyanate 
GC germinal centre 
GCB germinal centre B cell like  
HL Hodgkin’s lymphoma 
HRS Hodgkin and Reed-Sternberg 
Ig immunoglobulin   
IHC immunohistochemistry 
IL interleukin 
JAK janus kinase 
JNK c-Jun N-terminal kinase  
LCL lymphoblastoid cell line 
LMP latent membrane protein 
MAPK mitogen-activated protein kinase  
mRNA messenger-RNA 
NF-κB nuclear factor kappa –light chain- enhancer of activated B cells 
PE phycoerythrin 
PI3K phosphatidylinositol 3–kinase 
qPCR quantitative polymerase chain reaction 
S1P sphingosine 1 phosphate  
S1PR Sphingosine 1 phosphate receptor  
SHM somatic hypermutation  
STAT signal transducer and activator of transcription 
Tfh T follicular helper  











1.1 The germinal centre reaction 
The germinal centre (GC) reaction takes place in secondary lymphoid organs and is the 
process in which naïve B cells encountering antigen proliferate, undergo somatic 
hypermutation and class-switch recombination to give rise to antigen specific plasma 
and memory B cells (MacLennan, 1994, Klein and Dalla-Favera, 2008). Several types of 
lymphoma derive from GC B cells. They include: Hodgkin’s lymphoma, Burkitt’s 
lymphoma, follicular lymphoma, post-transplant lymphomas and a subset of diffuse 
large B cell lymphomas (Kuppers, 2005). In order to understand the pathogenesis of 
these lymphomas, it is important to consider the GC reaction and how the disruption of 
the processes involved can lead to lymphomagenesis. 
1.1.1 Entry into the GC  
B cells produced in the bone marrow exit as mature B cells that express surface 
immunoglobulin (Ig)M. They are referred to as naïve B cells and upon exit from the bone 
marrow they migrate to lymphoid organs where they can interact with antigen 
presenting cells. Upon entry into a lymphoid organ, through the high endothelial venules 
(HEV), these naïve B cells migrate towards the outer follicle. This migration is a 
chemotactic response mediated by two receptors expressed on the surface of naïve B 
cells, CXCR5 and Epstein-Barr virus induced molecule 2 (EBI2), the ligands for which are 
produced by cells in the follicle (Cyster et al., 2000, Gatto and Brink, 2013). 
Once a naïve B cell encounters its cognate antigen (presented by dendritic cells residing 
in the outer follicle), it up-regulates specific chemokine receptors that enable it to home 
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to the T cell zone of the follicle (Cyster, 2010, MacLennan, 1994, Pereira et al., 2010). 
These receptors include CCR7 which responds to the chemokines CCL19 and CCL21 
produced in the T cell zone (Reif et al., 2002). In the T cell zone, the B cells become fully 
activated through their interactions with CD4+ T follicular helper (Tfh) cells, and the GC 
reaction is initiated. One of the most important interactions for GC B cell survival and 
differentiation within the GC occurs between the CD40 receptor on B cells and its ligand 
(CD40 ligand, CD40L also known as CD154) on Tfh cells. 
Following B cell activation by cognate antigen the cells migrate away from the T cell zone 
into the outer follicle. This migration is initiated by the EBI2 receptor in response to its 
ligand 7α,25-dihydroxycholesterol (Pereira et al., 2009, Gatto and Brink, 2013). The B 
cells then either differentiate into low affinity plasma cells directly in the extra follicular 
areas or mature into GC precursor B cells and migrate to the primary follicle (Klein and 
Dalla-Favera, 2008). B-cell lymphoma 6 (BCL6) is essential for GC formation and is highly 
expressed in GC B cells. It has been shown to be induced in activated B cells located in 
the outer follicle (Kitano et al., 2011). BCL6 can down-regulate EBI2 (Shaffer et al., 2001), 
leading to migration to the follicle centre where the GC reaction takes place (Pereira et 
al., 2009, Gatto et al., 2009). 
Once in the primary follicle, the GC B cells undergo rapid proliferation, pushing the 
surrounding cells aside which form the mantle zone, forming the secondary follicle. 
Following further proliferation and differentiation the GC structure fully develops, 
displaying the dark and light zones. 
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1.1.2 Overview of the GC reaction 
The GC reaction takes place within the dark and light zones of the GC, home to 
centroblasts and centrocytes respectively, depicted in Figure 1.1 (MacLennan, 1994). 
The process of somatic hypermutation (SHM) occurs in the rapidly proliferating 
centroblasts and results in variation in the immunoglobulin (Ig) genes of centroblasts 
(Klein and Dalla-Favera, 2008). The process of SHM starts with the production of double 
strand breaks in the DNA induced by the activity of activation-induced cytidine 
deaminase (AID). This is followed by the error prone repair of the break, which leads to 
the introduction of mutations into the DNA, thus leading to somatically mutated heavy 
and light chain immunoglobulins.  
SHM also induces mutations in non-Ig genes, for example, BCL6 and CD95 (Pasqualucci 
et al., 1998, Müschen et al., 2000). The importance of SHM of non-IG genes in lymphoma 
development is highlighted by the finding that in over 50% of diffuse large B cell 
lymphomas one or more non-Ig genes are hypermutated, for example MYC, paired box 
protein 5 (PAX5) and proto-oncogene serine/threonine-protein kinase 1 (PIM1) 







Figure 1.1: The germinal centre reaction (Klein and Dalla-Favera, 2008) 
Following antigen encounter, naïve B cells enter the primary follicle and initiate the GC reaction, resulting in the 
formation of the characteristic GC structure composed of the mantle zone, dark zone and light zone. The dark zone 
is home to the highly proliferative centroblasts and is where clonal expansion and somatic hypermutation occur. The 
light zone GC B cells are the centrocytes and this is the site of affinity maturation, positive selection by follicular 
dendritic and follicular T helper cells, and class switch recombination. Throughout the process, cells with 
disadvantageous mutations are induced to undergo apoptosis. 
  
6 
Centroblasts express telomerase and their DNA damage response is suppressed in order 
to support their proliferation (Klein and Dalla-Favera, 2008). BCL6 is important for the 
suppression of the DNA damage response, firstly by suppressing p21, a key molecule 
involved in the initiation of cell cycle arrest and secondly, by down-regulating p53, a 
molecule involved in DNA damage mediated apoptosis (Phan et al., 2005, Phan and 
Dalla-Favera, 2004). 
Centrocytes are smaller, non-proliferating cells undergoing selection for high affinity 
antibodies and class-switch recombination (CSR) before they are permitted to 
differentiate into either memory B cells or plasma cells (MacLennan, 1994). This 
selection process is crucial, as GC B cells have been shown to be highly prone to 
apoptosis (Liu et al., 1989). It has been shown that many anti-apoptotic molecules are 
down regulated in GC B cells, such as B-cell lymphoma 2 (BCL2), whereas pro-apoptotic 
molecules are up regulated, for example Bcl-2-associated X protein (BAX) and Bcl-2-
associated death promoter (BAD) (Martinez-Valdez et al., 1996, Peperzak et al., 2012). 
Selection for high affinity antibodies is a dual process requiring both FDCs and Tfh cells 
(Zotos and Tarlinton, 2012). First, centrocytes with B cell receptor (BCR) that binds the 
antigens presented on FDCs receive a survival signal upon successful interaction of the 
BCR with FDCs. Second, centrocytes with high affinity for antigen receive further survival 
signals through CD40 engagement by CD40L present on Tfh cells. Additionally, GC B cells 
have a high expression of CD95/Fas, a key receptor involved in apoptosis (Martinez-
Valdez et al., 1996, Takahashi et al., 2001). The ligand for CD95 (CD95L/FasL) is found on 
T cells and can induce apoptosis in GC B cells that recognise self-antigens. This tight 
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control allows for the selection of B cells with a functional BCR and high affinity for 
antigen, but which are not auto reactive. Any GC B cell that does not meet these criteria 
fails to receive these survival signals and undergoes rapid apoptosis. 
Centrocytes then undergo class-switch recombination (CSR), an irreversible somatic 
recombination affecting the immunoglobulin heavy chain constant region. This process 
results in a switch of Ig class without affecting the antigen specificity of the antibody. 
The process of CSR can be T cell dependent or independent, but is always directed by 
the presence of specific cytokines and co-stimulatory molecules (Klein and Dalla-Favera, 
2008). The main co-stimulatory signals include CD40-CD40L and B7-related protein-1 
(B7RP)-inducible T cell co-stimulator (ICOS) interactions between B cells and T helper 
cells, and engagement of B cell activating factor receptor (BAFFR) and trans-membrane 
activator and calcium-modulating cyclophilin ligand interactor (TACI) on the B cells 
(McAdam et al., 2001, Tafuri et al., 2001, Castigli et al., 2005). E2A activity and 
interleukin (IL)-21 are also required for CSR (Bartholdy and Matthias, 2004, Linterman 
et al., 2010). 
The process of CSR requires DNA strand breaks and therefore poses the risk of malignant 
translocations. Examples include the t(8;14) immunoglobulin heavy chain variable 
region (IgH)/c-myc chromosomal translocation in endemic Burkitt’s lymphoma and the 
t(3;14)(q27;q32) translocation of IgH and BCL6 observed in diffuse large B cell lymphoma 
(DLBCL) (Haluska et al., 1987, Hartl and Lipp, 1987, Baron et al., 1993, Ye et al., 1993, 
Iqbal et al., 2007). 
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Although the GC structure is morphologically distinguishable into dark and light zones, 
it is now clear that centroblasts and centrocytes can move between these zones (Allen 
et al., 2007, Schwickert et al., 2007). This movement is achieved through the expression 
of specific cytokines and their receptors. Centroblasts express the CXC chemokine 
receptor 4 (CXCR4) which is responsive to CXC chemokine ligand 12 (CXCL12) expressed 
in the light zone, whereas centrocytes express CXCR5 which is responsive to CXCL13 
expressed in the dark zone (Allen et al., 2004, Caron et al., 2009). The previous dogma 
of the GC B cell as a rather stable structure has recently been challenged by the 
observation that non-GC B cells can enter the GC, and on occasion other B cells with 
higher affinity to antigen can outgrow the GC B cell population which initiated the 
reaction (Schwickert et al., 2007). 
For the GC reaction to take place, it is essential that the GC B cells do not differentiate. 
BCL6 can inhibit plasma cell and memory B cell differentiation through multiple 
mechanisms (Basso and Dalla-Favera, 2012). For example, BCL6 down regulates genes 
needed for plasma cell differentiation, such as B-lymphocyte-induced maturation 
protein 1 (BLIMP1) and (interferon regulatory factor 4) IRF4. 
1.1.3 Control of the GC reaction 
The GC reaction is also tightly controlled through a variety of mechanisms which involve 
the regulation of cell migration as well as survival. GC B cells, more specifically 
centroblasts, are rapidly proliferating cells so what is stopping these cells from 
outgrowing their GC niche? Recently, two molecules have been implicated in the 
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maintenance of GC homeostasis; sphingosine 1 phosphate receptor 2 (S1PR2) and 
regulator of G-protein signalling (RGS13) (Figure 1.2). 
Both S1PR2 and RGS13 are highly expressed in GC B cells and they both interact with G 
proteins (Shi et al., 2002, Green and Cyster, 2012). S1PR2 is a G protein coupled receptor 
that signals mainly through G12/13, and can inhibit GC B cell migration in response to 
sphingosine 1 phosphate (S1P), a molecule present at high concentrations on the outer 
edge of the GC, leading to the retention of these cells within the GC structure. S1PR2 
has also been implicated in the regulation of GC B cell survival (Green et al., 2011); in 
mice, S1PR2 deficient GC B cells showed increased growth in response to antigen 
stimulation compared to wild type cells. 
RGS13 is a negative regulator of Gα, a G protein involved in CXCL12 and CXCL13 signalling 
(Shi et al., 2002, Han et al., 2006). CXCL12 and CXCL13 are key mediators of the GC 
structure by homing CXCR4 expressing centroblasts and CXCR5 expressing centrocytes 
to distinct areas within the GC (Allen et al., 2004). As with S1PR2, the loss of RGS13 
expression lead to increased GC B cell growth compared to wild type in response to 
antigen stimulation (Hwang et al., 2013). Thus the high expression of S1PR2 and RGS13 






Figure 1.2: S1PR2 and RGS13 regulate GC B cell proliferation and migration 
S1PR2 and RGS13 are highly expressed in GC B cells and interact with G proteins G12/13 and Gα respectively.  
Upon S1P binding, S1PR2 recruits G12/13 resulting in the activation of Rho and subsequent inhibition of Rac and Akt, 
resulting in the inhibition of GC B cell migration. Rac inactivation is mediated by Rac GTPase proteins (RacGAP), while 
Akt inactivation is a consequence of Rho mediated inhibition of PI3K.  
RGS13 can inhibit Gα and thus CXCR4 and CXCR5 signalling in GC B cells. Signalling via Gα activated PI3K and its down-
stream effectors, such as Rac and Akt as depicted on the diagram. Inhibition of Gα by RGS13 results in reduced cell 




1.1.4 Exit from the GC  
Centrocytes can differentiate into either memory B cells or plasma cells (Figure 1.3). Not 
much is understood about GC B cell differentiation into memory B cell, however PAX5, 
CD40 signalling and phosphorylated STAT5 are all implicated in memory B cell 
development (Klein and Dalla-Favera, 2008, Victora and Nussenzweig, 2012).  
The signals regulating plasma cell differentiation are better characterised. PAX5 
inactivation and BCL6 repression appear to be involved in this process (Klein and Dalla-
Favera, 2008). BCL6 repression results in increased expression of BLIMP1, a regulator of 
plasma cell differentiation. T cell help via CD40L is key, leading to CD40 mediated 
activation of NF-κB, which leads to the induction of IRF4 and the eventual down 
regulation of BCL6 (Sciammas et al., 2006, Klein et al., 2006). PD-1 signalling on T helper 
cells has recently been shown to contribute to long term plasma cell survival (Good-








Figure 1.3: Differentiation of centrocytes (Klein and Dalla-Favera, 2008) 
Centrocytes can differentiate into either memory B cells or plasma cells. Not much is understood about GC B cell 
differentiation into memory B cell. PAX5, CD40 signalling and phosphorylated STAT5 are all implicated in memory B 
cell development. The signals regulating plasma cell differentiation are better characterised. PAX5 inactivation and 
BCL6 repression are involved in this process. T cell help via CD40L is key, leading to activation of NF-κB, the induction 
of IRF4 and the eventual down regulation of BCL6 resulting in increased expression of BLIMP1, the master regulator 




Differentiated B cells, as well as other lymphocytes, exit from lymph nodes through the 
medullary sinuses into the lymphatic vessels. Lymphocyte egress is dependent on the 
cell surface receptor S1PR1 (sphingosine 1 phosphate receptor 1 or EDG1) and on the 
increased concentration of sphingosine 1 phosphate (S1P) in the blood and lymph 
compared to tissue (Cyster, 2005). Several studies have shown that S1P signalling 
through S1PR1 is essential for lymphocyte egress. The immunosuppressive S1P receptor 
agonist, FTY720, leads to lymphopenia in several animal models and in humans (Chiba 
et al., 1998, Yagi et al., 2000, Rosen et al., 2003). FTY720, when phosphorylated is a 
structural homologue of S1P, and leads to S1PR1 internalisation and thus inhibition of 
S1P signalling (Cyster, 2005). Other studies have shown that knock-down of S1PR1 in the 
haematopoietic cells of mice lead to B and T cell retention in the bone marrow and 
thymus respectively as well as in the secondary lymphoid organs (Allende et al., 2004, 
Matloubian et al., 2004, Allende et al., 2010). 
1.2 EBV 
Epstein-Barr virus (EBV), a B lymphotropic ϒ-herpesvirus, was originally identified in 
1964 from Burkitt’s lymphoma samples (Epstein et al., 1964). The virus has a double-
stranded DNA genome of 172 kilobase pairs (Baer et al., 1984). EBV is widespread in the 
human population and is transmitted via the oral route. Primary infection in children is 
generally asymptomatic, following which the virus establishes a latent infection in B 
cells. When individuals are infected in adolescence or as adults, primary infection can 
manifest as infectious mononucleosis, a self-limiting lymphoproliferative disease (Young 
and Rickinson, 2004). EBV is, however, an oncogenic virus that is associated with the 
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development of several cancers including Hodgkin’s lymphoma (HL), Burkitt’s lymphoma 
(BL), and nasopharyngeal carcinoma (NPC) (Young and Murray, 2003). 
1.2.1 EBV latency 
A key feature of the EBV lifecycle is how the virus establishes latency, leading to the 
persistent infection of its host. The current model suggests the virus makes use of the 
normal B cell lifecycle to drive infected naïve B cells into the memory compartment, 
where the virus resides in latency (Thorley-Lawson and Babcock, 1999). 
In this model EBV infects circulating naïve B cells, either during primary infection, when 
the virus enters the tonsillar crypts, or during persistent infection, where virus is 
produced by lytic replication in B cells (Thorley-Lawson, 2001, Thorley-Lawson and 
Babcock, 1999). Following infection, it is proposed that the naïve B cells become 
activated and proliferate in a manner similar to naïve B cells encountering cognate 
antigen for the first time. This is referred to as the virus growth programme or latency 
III, where all viral proteins are expressed (Babcock et al., 2000, Thorley-Lawson, 2001). 
In latency III all nine latent EBV genes are expressed including the six EBV nuclear 
antigens (EBNA1, EBNA2, EBNA3a, EBNA3b, EBNA3c and EBNA-LP) and the three latent 
membrane proteins (LMP1, LMP2a and LMP2b). 
Following this initial activation, the EBV infected naïve B cells migrate into the follicles 
where they proliferate and can undergo a germinal centre reaction. During this process 
the viral transcription programme switches to the default programme (latency II), in 
which only EBNA1, LMP1 and LMP2a are expressed (Babcock et al., 2000). The germinal 
centre reaction leads to the clonal expansion of EBV infected B cells and to their 
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differentiation into memory B cells. The two latent membrane proteins of EBV, LMP1 
and LMP2a, are thought to play a crucial role in this process by mimicking the key 
survival signals required for GC B cell survival. LMP2a can provide a B cell receptor (BCR) 
signal (Caldwell et al., 1998), whereas LMP1 is a functional homologue of CD40 (Gires et 
al., 1997). 
The resulting EBV infected memory B cells express the latency programme (latency 0), 
where no latent viral genes are expressed (Thorley-Lawson, 2001). Thus the virus can 
avoid immune detection and can therefore persist for many years within long-lived 
memory B cells. When memory B cells are activated by antigen, they undergo terminal 
differentiation into plasma cells. If an EBV infected memory B cell is activated in this way 
the virus will undergo lytic replication and produce infectious progeny. This results in 
virus shedding in saliva, and may also lead to infection of new naïve B cells, thus allowing 
for lifelong persistence. 
Furthermore, a study looking at tonsils of healthy virus carriers showed that the EBV 
infected B cells expressing the latency II program are not only physically located in the 
GCs, but they also express the phenotypic markers of GC B cells (Roughan and Thorley-
Lawson, 2009). In addition, a study examining latently infected memory B cells in the 
peripheral blood of infectious mononucleosis patients found evidence of both somatic 
hypermutation and class switch recombination, which are hallmarks of the germinal 
centre process. (Souza et al., 2005). 
However, other studies provided data which conflicts with this model. First, although 
LMP1 is believed to be expressed in germinal centre B cells, it has been shown to inhibit 
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germinal centre formation (Uchida et al., 1999). Second, a study examining tonsils from 
infectious mononucleosis patients found that the EBV infected B cells were not 
physically located in the GC (Kurth et al., 2003). Third, a recent study found that EBV 
infection of naïve B cells results in the outgrowth of LCLs that can express both GC and 
memory B cell markers without having gone through the GC reaction (Siemer et al., 
2008). 
1.2.2 Latent membrane protein 1 
LMP1 is essential for the transformation of B cells and is expressed in Latency II and III 
(Kaye et al., 1993, Middeldorp and Pegtel, 2008). It is an integral membrane protein of 
63kDa and is a functional homologue of CD40 (Zimber-Strobl et al., 1996, Gires et al., 
1997). However, LMP1 signalling is ligand independent, and is mediated through the 
aggregation of its trans-membrane domain (Gires et al., 1997). 
LMP1 signals through its cytoplasmic domain (C-terminal region) (Figure 1.4). This 
domain does not have an intrinsic kinase activity and therefore signals through a family 
of adaptor proteins called tumour necrosis factor receptor associated factors (TRAFs) 
(Lam and Sugden, 2003). The LMP1 C-terminal region contains two motifs, carboxy-
terminal activating regions 1 and 2 (CTAR1 and CTAR2), which interact with TRAFs. 
CTAR1 preferentially recruits TRAF1-3 (Lam and Sugden, 2003). Both domains are 
required for efficient activation of nuclear factor kappa-light chain-enhancer of 
activated B cells (NF-κB) and p38/mitogen-activated protein kinase (MAPK); however 
the CTAR2 domain is largely responsible for canonical NF-κB activation. Additionally, the 
recruitment of TRAF6 by CTAR2 has been implicated in LMP1 mediated NF-κB, and p38 
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MAPK activation (Luftig et al., 2003, Wu et al., 2006, Wan et al., 2004, Schultheiss et al., 
2001) More recently, recruitment of TRAF5 has been shown to activate c-Jun N-terminal 
kinase (JNK) (Kraus et al., 2009). In addition to the TRAF binding domains, LMP1 has a 
proposed third domain, CTAR3, located between CTAR1 and CTAR2, which interacts with 
Janus kinase 3 (JAK3) to activate signal transducer and activator of transcription (STAT) 
(Gires et al., 1999). However, the association of this domain with JAK proteins is debated 





Figure 1.4: LMP1 signalling in B cells 
LMP1 signals through its cytoplasmic domain consisting of CTAR1 and CTAR2 domains which recruit TRAFs. Both 
domains can activate the non-canonical NF-κB, JNK and p38 MAPK pathways, while the CTAR2 domain is largely 
responsible for the activation of the canonical NF-κB pathway. LMP1 has a proposed third domain, CTAR3, which 
interacts with the JAK3 leading to STAT activation.  
Abbreviations: CTAR (carboxy-terminal activating regions) TRAF (tumour necrosis factor receptor associated factor), 
MAPK (mitogen-activated protein kinase), MKK (MAPK kinase), JNK (c-Jun-N-terminal kinase), JAK (janus kinase), STAT 
(signal transducer and activator of transcription). 
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LMP1 has a wide range of functions: 
LMP1 itself is poorly immunogenic, and is suggested to have an immune modulatory 
function. LMP1 can affect the expression of several chemokines, cytokines, adhesion 
molecules, co-stimulatory molecules and also antigen presenting/processing genes 
(Middeldorp and Pegtel, 2008). This strongly indicates a role for LMP1 in immune 
evasion. LMP1 can block interferon α (IFNα) mediated antiviral activity by inhibiting 
tyrosine kinase 2 (Tyk2) (Geiger and Martin, 2006). 
LMP1 has been shown to contribute to the regulation of EBV latency. LMP1 was found 
to suppress lytic cycle induction through the inhibition of the transcription of BamHI Z 
fragment leftward open reading frame 1 (BZLF1), an immediate early protein of EBV that 
is required for the induction of the lytic cycle (Adler et al., 2002).  
LMP1 provides an essential proliferative signal to B cells. This has been shown by 
examining the growth characteristics of immortalised B cells which contained a 
conditional LMP1 gene. The presence of high levels of LMP1 lead to cell proliferation; 
however, in the presence of only low levels of LMP1 this proliferation was hardly 
detectable (Kilger et al., 1998). 
LMP1 expression in rodent fibroblasts and endothelial cells leads to transformation of 
cells to anchorage-independent growth (Wang et al., 1985, Moorthy and Thorley-
Lawson, 1993). NF-κB activation has been shown to play an important role in LMP1 
mediated transformation of Rat-1 fibroblasts (He et al., 2000). LMP1 expression in the B 
cells of transgenic mice leads to a block in GC development (Uchida et al., 1999) and the 
development of B cell lymphomas in old age (Kulwichit et al., 1998), further underlining 
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the role of LMP1 in oncogenesis. These lymphomas displayed elevated levels of BCL2 
and c-MYC, indicating that these genes could play a role in LMP1-mediated 
lymphomagenesis. 
More recently, LMP1 expression in GC B cells was shown to induce a Hodgkin and Reed-
Sternberg (HRS) cell like phenotype (Vockerodt et al., 2008). HRS cells are the GC B cell 
derived tumour cells of HL. LMP1 transfection of GC B cells up-regulated the expression 
of several signalling pathways including NF-κB, STAT, phosphatidylinositol 3–kinase 
(PI3K) and CD95 signalling components, while down-regulating several B cell phenotypic 
markers including BCR signalling molecules, co-receptors and downstream targets as 
well as B cell associated transcriptional regulators, consistent with observations made 
in HRS cells. 
1.2.3 CD40 
CD40 is a 48-kDa type 1 trans-membrane protein of the tumour necrosis factor receptor 
(TNFR) family (van Kooten and Banchereau, 2000, Graham et al., 2010). CD40 was 
originally identified as a molecule expressed exclusively on B cells. However, it is now 
known that CD40 is also expressed on several other cell types, such as monocytes, 
dendritic cells, endothelial cells and also on epithelial cells (van Kooten and Banchereau, 
2000). 
Activation of CD40 by its ligand CD40L results in the clustering of CD40 into lipid rafts. 
Lipid rafts are patches of cell membrane which contain high concentrations of 
cholesterol and glycosphingolipids where receptors are often found and thus are 
involved in the regulation of signalling. Like LMP1, the cytoplasmic signalling domain of 
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CD40 then recruits TRAF1, TRAF2 and TRAF3 at a distal, as well as TRAF6 at a membrane 
proximal site (Lam and Sugden, 2003, Graham et al., 2010, Bishop, 2004).Together these 
molecules lead to the activation of NF-κB, while TRAF2 activates JNK and TRAF6 activates 
p38 (Figure 1.5). In contrast to LMP1 signalling, CD40 signalling is self-regulated through 
the proteasomal degradation of TRAF2 and TRAF3 upon CD40 activation (Brown et al., 
2001, Brown et al., 2002). This degradation is mediated by TRAF2.  
CD40 signalling in B cells is important in T cell mediated humoural immune responses. 
CD40 signalling is achieved through the activation of the CD40 receptor on B cells via the 
CD40L, which is mainly expressed on CD4 positive T helper cells, along with the help of 
cytokines specifically secreted by these T cells (Carbone et al., 1995b). 
The importance of this CD40-CD40L interaction in the formation of T cell dependent 
immune responses can be seen in patients suffering from X-linked hyper-IgM syndrome 
(HIGM) (Korthauer et al., 1993, DiSanto et al., 1993). HIGM is a severe immunodeficiency 
caused by mutations in the CD40L gene. These patients have elevated IgM levels with 
low levels of the other immunoglobulin types (IgA, IgG and IgE). Furthermore, these 
patients fail to form GCs and have impaired memory B cell formation. These effects can 







Figure 1.5: CD40 signalling in B cells  
Activation of CD40 by its ligand CD40L results in the clustering of CD40 into lipid rafts and the recruitment of TRAFs. 
Interaction of TRAF5 with TRAF3 results in the activation of the non-canonical NF-κB pathway leading to p52/RelB 
accumulation in the nucleus, while TRAF6 and TRAF2 activate the canonical NF-κB pathway leading to p50/p65 
accumulation in the nucleus. TRAF5, TRAF6 and TRAF2 all contribute to the activation of the JNK and p38 MAPK 
pathways via various MEKKs, such as ASK1/2, MLK3 and TAK1. CD40 also interacts with JAK3 leading to STAT3 
activation.  
CD40 signalling is self-regulated through TRAF2 mediated proteasomal degradation of TRAF2 and TRAF3. CD40 also 
interacts with JAK3 leading to STAT3 activation.  
Abbreviations: TRAF (tumour necrosis factor receptor associated factor), MAPK (mitogen-activated protein kinase), 
MEKK (MAPk/ERK kinase kinase), MKK (MAPK kinase), JNK (c-Jun-N-terminal kinase), JAK (janus kinase), STAT (signal 
transducer and activator of transcription). 
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Signalling through CD40 can induce proliferation, differentiation, immunoglobulin 
expression and survival of B cells (van Kooten and Banchereau, 2000). Activation of CD40 
induces GC formation, isotype switching, affinity maturation and selection, leading to 
the differentiation of B cells into memory cells. CD40 also prevents the differentiation 
of B cells into plasma cells. 
There is evidence that alterations in this physiological CD40 signal can lead to malignant 
transformation of B cells. The malignant cells of HL, the Hodgkin and Reed-Sternberg 
(HRS) cells express functional CD40 on their cell surface and as CD40L expressing T cells 
are found in the tumour microenvironment, it is likely that CD40 signalling is important 
for HRS cell survival. In fact, a study looking at CD40L stimulation of a HL cell line, L428, 
showed that CD40 signalling supports cell growth (Carbone et al., 1995a). Furthermore, 
it has been shown in vivo that constitutive CD40 signalling in B cells can to lead to 
transformation (Homig-Holzel et al., 2008). 
A study of non-Hodgkin’s lymphomas identified a structure called a CD40 Signalosome 
within the membranes of the tumour cells (Pham et al., 2002). The formation of this 
structure is initiated through CD40L production by the tumour cell, leading to CD40-
CD40L interaction in the membrane. This interaction results in the recruitment of 
scaffolding proteins that anchor it to the membrane, giving rise to the CD40 
Signalosome. This prolonged CD40-CD40L interaction within the structure leads to 
constitutive NF-κB activation, which is of key importance in the proliferation and viability 
of the tumour cells.  
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1.2.4 Studies of LMP1 and CD40 functional homology 
A number of studies have investigated the functional links between LMP1 and CD40 
signalling. In 1996, it was observed that constitutive expression of LMP1 in EREB2-5 cells 
(EBV-immortalised B cell line) leads to a phenotype similar to CD40 stimulation (Zimber-
Strobl et al., 1996). Oligomerisation of the carboxy-terminal of LMP1 is required for NF-
κB activation, thus although LMP1 mimics a ligand activated receptor, itself is ligand 
independent (Gires et al., 1997). A different study showed that in a cell line dependent 
on LMP1 for proliferation, CD40 activation can replace LMP1 (Kilger et al., 1998). In a 
more recent study it has been shown that both LMP1 and CD40 activation can inhibit 
lytic cycle induction in EREB2 cells (Adler et al., 2002). 
Several studies utilised LMP1 and CD40 chimeric molecules to directly compare LMP1 
and CD40 signalling. For example, LMP1CD40 chimeras containing the N-terminal trans-
membrane domain of LMP1 and the C-terminal signalling domain of CD40 was shown to 
act as a constitutively active CD40 molecule (Hatzivassiliou et al., 1998, Homig-Holzel et 
al., 2008, Panagopoulos et al., 2004). Expression of this chimeric LMP1CD40 construct in 
Rat1 fibroblasts can, like LMP1, lead to loss of contact inhibition and anchorage 
independent growth (Hatzivassiliou et al., 2007). This suggests that a constitutive CD40 
like signal is sufficient for transformation. 
Another study examined the effect in vivo of a similar chimera (Homig-Holzel et al., 
2008). In transgenic mice expressing this chimera there is a strong accumulation of 
follicular and marginal zone B cells in secondary lymphoid organs. These B cells displayed 
an activated phenotype, and failed to form GC when the mice were immunised. 
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Furthermore, over 60% of these transgenic mice over the age of 1 year developed B cell 
lymphomas. Additionally, it was shown that the expression of the LMP1CD40 chimera, 
like LMP1, leads to constitutive activation of the non-canonical NF-κB pathway. These 
findings provided further evidence that constitutive CD40 signalling could be important 
for B cell transformation. 
A second study in mice compared the effect of LMP1 and the LMP1CD40 chimera 
expression in B cells (Panagopoulos et al., 2004). The molecules were expressed under 
the control of the CD19 promoter, allowing for B cell specific expression. It was observed 
that LMP1CD40 expressing mice, like LMP1 expressing mice, showed similar suppression 
of the humoural immune response, measured by defective GC formation and antibody 
production when stimulated with thymus-dependent (TD) antigens. It was also observed 
that the expression of both LMP1 and the LMP1CD40 chimera in B cells lead to the 
suppression of the BCL6 promoter, thus antagonizing GC formation. However, the 
LMP1CD40 chimera did not fully mimic LMP1. First, its ability to suppress the humoural 
immune response was greater than that of LMP1. Second, expression of the chimera led 
to an increased accumulation of macrophages, polymorphonuclear cells and marginal 
zone B cells in the spleen. This alteration in B cell populations was associated with 
autoimmunity, and mice expressing LMP1CD40 showed signs of spontaneous 
inflammatory responses. 
A further two studies used a different approach. In these studies, the chimeric molecules 
(CD40LMP1) consisted of the C-terminal signalling domain of LMP1 fused to the trans-
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membrane and ligand-binding domains of CD40, allowing them to study the effects of 
transient LMP1 signalling. 
One study used transgenic mice bred onto a CD40 deficient background, with the 
CD40LMP1 chimera under the control of the mouse major histocompatibility complex 
(MHC) class II Eα promoter (Stunz et al., 2004). This resulted in CD40LMP1 expression 
replacing that of physiological CD40. The results showed that the LMP1 signalling 
domain could replace that of CD40. However, the transgenic mice had enlarged lymph 
nodes and spleens with elevated serum IL-6 and increased GC formation. These mice 
also showed signs of autoimmunity. 
Another study used transgenic mice expressing a CD40LMP1 chimera upon Cre-
mediated recombination, controlled by the CD19 promoter (Rastelli et al., 2008). As with 
the previous study, LMP1 signalling was able to completely substitute CD40 signalling in 
B cells leading to normal B cell development and activation. However, as opposed to 
CD40 signalling, CD40LMP1 was able to induce class-switch recombination independent 
of cytokines. This ability of LMP1 could provide a survival advantage to infected B cells 
by increasing their life span and can force B cells towards becoming long lived memory 
B cells.  
Altogether, these studies confirm the role of LMP1 as a CD40 mimic, while at the same 
time identify some differences in their signalling, such as LMP1 but not CD40 signalling 
causing cytokine independent CSR in B cells. It is becoming increasingly clear, as shown 
in two of the above studies, that aberrant constitutive CD40 signalling has the potential 
to transform B cells. 
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1.3 GC derived lymphomas 
The GC is a site of extensive cell proliferation, SHM and CSR. As described in the previous 
section, all of these processes carry a high risk of inducing mutations in GC B cells. There 
is a tight regulation of the GC reaction, but it is not always sufficient in eliminating 
mutated and thus potentially cancerous cells. It is therefore not surprising that the 
majority of B cell lymphomas are derived from germinal centre B cells, or B cells that 
have undergone the GC reaction (Kuppers et al., 1999). 
Lymphomas derived from GC B cells include Burkitt’s lymphoma, Hodgkin’s lymphoma 
and diffuse large B cell lymphoma (DLBCL) (Kuppers, 2005). There are several 
transforming processes implicated in B cell lymphomas including chromosomal 
translocations between immunoglobulin loci and proto-oncogenes and somatic 
hypermutation of non-immunoglobulin genes. In this section I will focus on two GC B 
cell derived lymphomas: Hodgkin’s lymphoma and diffuse large B cell lymphoma 
(DLBCL). In particular I will highlight the involvement of EBV in these cancers. 
1.3.1 Hodgkin’s lymphoma 
Hodgkin’s lymphoma (HL) was first described in 1832 (Hodgkin, 1832). It is currently 
treated by chemotherapy or radiation therapy and is curable in 80-90% of cases. HL is 
characterised by low numbers of tumour cells (typically around 1%), surrounded by a 
mixed infiltrate of cells in the lymphoma tissue. The infiltrate contains non-malignant 
immune and inflammatory cells such as T cells, B cells, macrophages, neutrophils, 
eosinophils and mast cells. CD4 positive T cells are usually the largest population of 
reactive cells in the infiltrate (Schmitz et al., 2009b). 
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Hodgkin’s lymphoma is subdivided into classical HL (cHL) and nodular lymphocyte-
predominant HL (NLPHL). Classical HL accounts for 95% of cases, and is further divided 
into four subtypes; nodular sclerosis, mixed cellularity, lymphocyte depletion and 
lymphocyte rich, of which nodular sclerosis is the most common (Kuppers et al., 2012). 
Around 40% of cases of cHL are positive for EBV, and this virus is found mainly in the 
mixed cellularity and lymphocyte depletion subtypes (Aldinucci et al., 2010). Rare cases 
of HL (1-2%) originate from T cells (Muschen et al., 2000, Seitz et al., 2000, Tzankov et 
al., 2005). 
The tumour cells of cHL are called Hodgkin and Reed-Sternberg (HRS) cells. Hodgkin cells 
are large mononuclear cells that have pronounced nucleoli. Reed-Sternberg cells are 
multinuclear cells which are generally larger then Hodgkin cells (Kuppers, 2009). HRS 
cells are derived from B cells but show a global loss of B cell specific gene expression and 
have a varied immunophenotype (Schwering et al., 2003, Tiacci et al., 2012).  
The unique gene expression profile of HRS cells can in part be explained by the de-
regulation of key B cell specific transcription factors in HRS cells, such as Oct-2, Pu.1 and 
BOB1 which are not expressed (Stein et al., 2001, Torlakovic et al., 2001) and E2A, EBF1 
and PAX5, which are expressed in HRS cells and in HL cell lines, but are inactivated 
(Mathas et al., 2006, Renne et al., 2006, Jundt et al., 2008). The inactivation of E2A by 
ABF1 and inhibitor of DNA binding (ID2) has been implicated in the down-regulation of 
B cell specific genes (CD19, AID, CD79a and Oct-2) and the up-regulation of non-B lineage 
genes (transcription factor 7 (TCF7), colony stimulating factor 1 receptor (CSF1R), 
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musculoaponeurotic fibrosarcoma oncogene homolog (MAF) and GATA3) (Mathas et al., 
2006). 
CD30, CD40, RANK and CD95 are highly expressed in the majority of HRS cells (Kim et al., 
2003). Despite the high expression of CD95, resistance to CD95 mediated apoptosis, 
through the over-expression of the FADD-like interleukin 1β–converting enzyme-
inhibitory protein (c-FLIP), is a key feature of HRS cells (Dutton et al., 2004, Mathas et 
al., 2004). Several receptor tyrosine kinases (RTKs) not normally expressed in B cells are 
aberrantly expressed in HRS cells (Renne et al., 2005, Renne et al., 2007). 
Several signalling pathways are aberrantly activated in HRS cells, including the NF-κB, 
Janus kinase (JAK)/STAT, mitogen-activated kinase (MEK)/Extracellular signal-regulated 
kinase (ERK) and the PI3K/AKT pathways, as displayed in Figure 1.6. Some are activated 








Figure 1.6: Aberrant signalling pathways in Hodgkin’s lymphoma 
Key pathways involved in HL pathogenesis: NF-κB pathway, PI3K/AKT pathway, MAPK/ERK pathway and JAK/STAT 
pathway. Activation by CD30, CD40 and RANK contribute to the aberrant activation of the MAPK/ERK pathway. The 
NF- κB is activated via CD40 and mutations targeting signalling components. In EBV positive cases, LMP1 contributes 
to NF- κB activation. LMP1 can also contribute to the activation of the JAK/STAT pathway, which is also activated by 
interleukins and is targeted by mutations. The PI3K pathway is also aberrantly activate in HRS cells.  
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The components of the NF-κB pathway are de-regulated in HRS cells, leading to 
constitutive NF-κB activation (Bargou et al., 1997, Krappmann et al., 1999). Two 
mechanisms have been described for the de-regulation of the NF-κB pathway in HRS 
cells. First, components of the pathway are often targeted by mutations, listed in Table 
1.1. Second, CD40 signalling can contribute to the constitutive activation of NF-κB. CD40 
is highly expressed on the surface of HRS cells, while CD40L is expressed on the non-
malignant tumour infiltrating T cells (Carbone et al., 1995a, Carbone et al., 1995b).  
STAT3, STAT5 and STAT6, components of the JAK/STAT pathway have all been shown to 
be constitutively activated in HRS cells and HL cell lines (Hinz et al., 2002, Kube et al., 
2001, Skinnider et al., 2002). As with NF-κB, this pathway is targeted by mutations in 
HRS cells (Table 1.1). Autocrine and paracrine activation by interleukins (IL) also 
contribute to STAT activation. IL13 activates STAT6 via its receptor IL13R (Wurster et al., 
2000), both of which are highly expressed in HRS cells (Ohshima et al., 2001, Kapp et al., 
1999). Similarly, IL21-IL21R has been shown to activate STAT3 and STAT5 in HRS cells 
(Lamprecht et al., 2008, Scheeren et al., 2008). 
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Table 1.1: Mutations affecting the key signalling pathways in HL 
Pathway Gene affected Type of mutation Outcome References 
NF-κB  REL Amplification Constitutive NF- κB 
activation 
(Joos et al., 2002, Martin-
Subero et al., 2002) 
 IκBα and IκBε Inactivating mutations Constitutive NF- κB 
activation 
(Jungnickel et al., 2000, 
Emmerich et al., 1999, 
Emmerich et al., 2003, 
Cabannes et al., 1999) 
 A20 (TNFAIP3) Deletions, inactivating 
mutations, mostly in 
EBV negative HL 
Constitutive NF- κB 
activation 
(Schmitz et al., 2009a, Kato 
et al., 2009) 
 NIK 
(MAP3K14) 
Gains Constitutive NF- κB 
activation 
(Otto et al., 2012, Steidl et 
al., 2010) 




(Joos et al., 2000, Van 
Roosbroeck et al., 2011) 
 SOCS1 Inactivating mutations Activation of 
STAT5 and STAT6 
(Mottok et al., 2007, 
Weniger et al., 2006) 
 
The activation of CD30, CD40 and receptor activator of NF-κB (RANK) all contribute to 
the aberrant activation of the MEK/ERK pathway in HRS cells (Zheng et al., 2003). The 
PI3K/AKT pathway is also constitutively active in HRS cells and HL cell lines and inhibition 
of this pathway leads to apoptosis in HL cell lines (Morrison et al., 2004, Dutton et al., 
2005, Georgakis et al., 2006). Additionally, the EBV protein LMP1 has been shown to 
activate the NF-κB, JAK/STAT and JNK and p38 MAPK pathways in B cells (Lam and 
Sugden, 2003). As approximately 40% of cHL cases are positive for EBV, LMP1 signalling 
can contribute to the aberrant activation of signalling pathways in HRS cells.  
Despite the varied expression of markers expressed in HRS cells, they are now known to 
derive from GC B cells. HRS cells are clonal and have somatically mutated and re-
arranged immunoglobulin genes, indicating that these cells have undergone the GC 
reaction (Kuppers et al., 1994, Marafioti et al., 2000, Hummel et al., 1995, Küppers et 
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al., 1998). There is also evidence of immunoglobulin class switching in HRS cells (Martin-
Subero et al., 2006) as well as in HL cell lines (Irsch et al., 2001). 
In approximately 25% of cHL, HRS cells harbour destructive somatic mutations in their 
IgV genes that make the gene non-functional (Brauninger et al., 2003, Kanzler et al., 
1996, Marafioti et al., 2000). These mutations are nonsense mutations or deletions that 
alter the reading frame of the gene and would normally result in the apoptosis of the B 
cell in the germinal centre (Kanzler et al., 1996). As nearly all HRS cells harbouring these 
crippling mutations are latently infected with EBV, the virus may have role in the rescue 
of these pre-apoptotic GC B cell and their transformation (Brauninger et al., 2006). 
In fact, LMP2a can rescue BCR negative B cells (Caldwell et al., 1998, Casola et al., 2004). 
Furthermore, it has been shown in three studies that EBV infection can not only 
transform normal but also BCR negative GC B cells into lymphoblastoid cell lines (LCLs) 
(Bechtel et al., 2005, Chaganti et al., 2005, Mancao et al., 2005).  
1.3.2 Diffuse large B cell lymphoma 
Diffuse large B cell lymphoma (DLBCL) is highly heterogeneous and is the most common 
form of lymphoma (Coiffier, 2001, Frick et al., 2011). In 2008 the WHO classified DLBCL 
into two major groups: DLBCL associated with chronic inflammation and DLBCL not 
otherwise specified (NOS) (Campo et al., 2011). This latter group is further divided into: 
T cell/histiocyte-rich large B cell lymphoma (THRLBCL), primary DLBCL of the CNS 
(central nervous system), primary cutaneous DLBCL leg type and a new, provisional 
entry, EBV-positive DLBCL of the elderly. 
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Recent studies have delineated three molecular subtypes. These are germinal centre B 
cell like (GCB), activated B cell like (ABC) and primary mediastinal B cell lymphoma 
(PMBL) (Frick et al., 2011). These subtypes differ in their clinical outcomes as well as in 
their genetic make-up. Patients with the GCB subtype have a better prognosis (Alizadeh 
et al., 2000, Rosenwald et al., 2002, Wright et al., 2003). 
GCB DLBCL is thought to originate from GC B cells, by virtue of their expression of several 
GC B cell associated genes, such as CD10, LMO2 and BCL6 (Alizadeh et al., 2000, 
Rosenwald et al., 2002). Furthermore, ongoing somatic hypermutation is often detected 
in the Ig heavy chain variable region of these lymphomas (Lossos et al., 2000). GCB DLBCL 
harbour several abnormalities some of which so far have not been detected in ABC type 
(Table 1.2). The most common genetic alterations target BCL2, PTEN, and various 
tumour suppressors (Rosenwald et al., 2002, Lenz et al., 2008c). 
The ABC subtype is believed to originate from B cells in the process of differentiating 
into plasma cells, and thus is characterised by the up-regulation of many genes 
associated with plasma cells, such as XBP-1 (Wright et al., 2003, Rosenwald et al., 2002). 
However, a hallmark of ABC DLBCL is that full plasmacytic differentiation is blocked in 
these cells (Frick et al., 2011), probably through several genetic abnormalities directed 
at the PR domain zinc finger protein 1 (PRDM1) gene encoding BLIMP1 (Table 1.2). 
Another hallmark is the constitutive activation of the NF-κB pathway which is essential 
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centre B cell 
(GCB) 
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EZH2 Somatic mutation 
(approx. 20%) 
 (Morin et al., 2010) 




(Rosenwald et al., 2002) 
PTEN deletion or miR-17-92 
amplification 
activation of AKT and mTOR 
pathways leading to cell 
survival, growth and 
proliferation 
(Lenz et al., 2008c) 
TP73 Deletion anti-apoptotic (Lenz et al., 2008c) 
ING1 Deletion anti-apoptotic (Lenz et al., 2008c) 
MDM2 Amplification negative regulator of tumour 
suppressor p53 









Regulator of plasma cell 
differentiation 
(Pasqualucci et al., 
2006, Tam et al., 2006) 
BCL6 Translocation t(3;14) 
(approx. 25%) 
BCL6 overexpression, 
resulting in the repression of 
BLIMP1 
(Iqbal et al., 2007, Frick 
et al., 2011)  
SPIB Amplification (approx. 
25%) 
transcription factor known to 
repress BLIMP1 
(Lenz et al., 2008c, 
Frick et al., 2011) 
CARD11 Activating (approx. 
10%) 
Activation of CBM complex, 
leading to NF-κB activation 
(Lenz et al., 2008a, Ngo 
et al., 2006) 
CD79a and 
CD79b 
Somatic/activating BCR co-receptors. Leads to 
chronic BCR signalling 
activation of CBM complex 
and constitutive NF-κB 
signalling  





negative regulator of NF-κB (Compagno et al., 2009, 
Kato et al., 2009) 
MYD88 Activating (approx. 
30%) 
links toll-like receptor (TLR) 
and interleukin (IL-1 and IL-
8) signalling to NF-κB 
activation  
(Ngo et al., 2011) 
BCL2 Amplification of 18q Overexpression, anti-
apoptotic 
(Lenz et al., 2008c, Bea 
et al., 2005) 
INKa/ARF Deletions Tumour suppressor  (Lenz et al., 2008c) 
FOXP1 Trisomy 3  (Lenz et al., 2008c, Bea 




Epstein Barr virus (EBV)-associated DLBCL of the elderly is a recently identified subtype 
of DLBCL (Campo et al., 2011). It was first described in 2003 (Oyama et al., 2003) and is 
defined as an “EBV-positive monoclonal large B-cell lymphoproliferative disorder arising 
in immunocompetent patients over 50 years of age” with no prior history of the disease 
(Ok et al., 2013). It is more frequent in Asian population, with very low frequency in 
western populations (Oyama et al., 2007, Park et al., 2007, Hoeller et al., 2010). 
EBV-associated DLBCL of the elderly is associated with immune senescence. This tumour 
has a phenotype close to that of ABC DLBCL, with increased NF-κB activation as a result 
of LMP1 expression (Montes-Moreno et al., 2012). The tumour cells usually display a 
latency III expression of EBV genes, with the majority of cells positive for LMP1 and a 
subset also positive for EBNA2 (Oyama et al., 2003). Overall, EBV-associated DLBCL is 
more aggressive then EBV negative DLBCL, with more extranodal involvement and a 
worse clinical outcome (Park et al., 2007). Even when compared to the subtype of EBV 
negative DLBCL with the worst prognosis (ABC DLBCL), EBV associated DLBCL has a 
poorer clinical outcome (Montes-Moreno et al., 2012). 
1.4 Aims 
The EBV oncogene LMP1 shares functional homology with CD40, a cell surface receptor 
that is important for GC B cell survival and differentiation. This thesis investigates the 
transcriptional and signalling differences that underpin the pathogenic effects of LMP1 
in GC B cells, the presumed progenitors of several important EBV-associated 
malignancies, including HL and DLBCL. 
The specific aims of this work are to: 
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1.  Characterise in vitro isolated and cultured human GC B cells 
2.  Compare the transcriptional programmes of LMP1 and CD40 in isolated GC B 
cells. 
3.  Investigate the expression and function of selected LMP1 target genes in B cell 
lymphomas. 
4.  Optimise a flow cytometry based method for the measurement of the 
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2 Materials and methods 
2.1 Cell culture 
2.1.1 Maintenance of cell lines 
Cell lines were maintained in RPMI 1640 medium (Gibco®, Life Technologies Ltd, Paisley, 
UK), supplemented with 10% v/v selected foetal calf serum (FCS; PAA the cell culture 
company, Somerset, UK) and 1% v/v penicillin/streptomycin (Gibco®, Life Technologies 
Ltd, Paisley, UK) at 37oC with a humidified atmosphere and CO2 at 5% (Galaxy R CO2 
Incubator, RS Biotech, Livingston, UK). Information for all cell lines used are summarised 
in Table 2.1. To split cells and replenish media, cells were pelleted by centrifugation at 
173g for 10 minutes (Eppendorf Centrifuge 5810R, Eppendorf UK Limited, Stevenage, 
UK), media was aspirated using a VACUSAFE aspirator (INTEGRA Biosciences AG, Zizers, 
Switzerland) and pellets were re-suspended at a concentration of 5x105cells/ml in fresh 
media, pre-warmed to 37oC in a Heratherm™ Compact Microbiological Incubator 
(Thermo Fisher Scientific Inc, Waltham, MA, USA). All cell lines were negative for 
mycoplasma, tested using the MycoAlert® mycoplasma detection kit (Lonza, Slough, 
UK).  
2.1.2 Cryopreservation and thawing of cells 
Aliquots of 5 x 106 cells were pelleted by centrifugation at 173g for 10 minutes at 4oC 
and re-suspended in 500µl of chilled freezing solution (90% v/v FCS and 10% v/v 
dimethyl sulphoxide (DMSO; Sigma-Aldrich Ltd., Gillingham, UK). Cells were transferred 
to cryopreservation tubes (Nunc® Cryo Tubes®; Sigma-Aldrich Ltd., Gillingham, UK) and 
cooled slowly overnight to -80oC in a cryo container (Nalgene® Mr. Frosty; Sigma-Aldrich 
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Ltd., Gillingham, UK). Cells were subsequently stored at -80oC. Cryopreserved cells were 
thawed quickly to minimize exposure to DMSO. Thawed cells were re-suspended in 10ml 
of medium and grown in a 25 cm3 flask overnight.  
2.1.3 Cell counting 
Cell concentration were determined using a Neubauer haemocytometer (Marienfeld, 
Harsewinkel, Germany). To exclude dead cells, directly before counting cells were mixed 
1:1 with Trypan Blue (Sigma-Aldrich Ltd., Gillingham, UK) and 10µl of suspension was 
pipetted onto the glass slide. Live (bright) cells were counted using an Olympus CK30 
inverted light microscope in four zones of the grid following which the number was 
averaged. This number was then multiplied by 104 and the dilution factor of the Trypan 
Blue to obtain the number of cells per ml of culture.  
Table 2.1: Cell lines 
Cell line Cancer type Origin References 
L591 Nodular 
Sclerosis HL 
EBV-positive cell line originated from the pleural 
effusion of 31 year old female patient. 
(Diehl et al., 1982) 
L1236 Mixed 
Cellularity HL 
EBV-negative cell line established from the 
peripheral blood of a 34 year old male patient with 
advanced HL.   
(Wolf et al., 1996) 
L540 T–cell derived 
Nodular 
Sclerosis HL 
EBV-negative HL cell line derived from bone 
marrow of a female patient with stage IV disease. 
(Diehl et al., 1982, Falk 
et al., 1987) 
L428 Nodular 
Sclerosis HL 
EBV-negative cell line established from the 
pleural effusion of a 37 year old female patient 
with refractory disease. 
(Schaadt et al., 1980) 
KM-H2 Mixed 
Cellularity HL  
EBV-negative cell line established from the 
pleural effusion of a 37 year old male patient  
(Kamesaki et al., 1986) 
DG75 BL Established from the pleural effusion of a 10-year-
old boy with sporadic BL. 
(Ben-Bassat et al., 1977) 
BL2 BL Established from the bone marrow of a relapsed 7 
year old Caucasian boy with non-endemic BL. 
(Cohen et al., 1987, 
Bertrand et al., 1981) 
SUDHL4 DLBCL, GCB 
subtype 
Established from the peritoneal effusion of a 38 
year old man with B-NHL  
(Epstein et al., 1978) 
U2932 DLBCL, ABC 
subtype 
Established from the ascites of a 29 year old 
woman with DLBCL, who 16 years earlier was 
diagnosed with advanced stage HL 
(Amini et al., 2002) 
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2.2 Isolation and maintenance of primary human GC B cells 
All steps of the isolation (except for Ficoll-Isopaque centrifugation) were performed on 
ice, with ice cold reagents to prevent the apoptosis of cells. All centrifugation steps were 
at 173g at 4°C for 10 minutes unless otherwise specified. 
2.2.1 Tonsil specimens 
Paediatric tonsils were obtained from the Birmingham Children’s Hospital, under local 
ethics committee approval (Ref No.06/Q2702/50) and transported in cold phosphate 
buffered saline (PBS) on ice.  
2.2.2 Purification of tonsillar mononuclear cells (TMCs) 
Tonsils were minced with a scalpel in RPMI 1640 medium (Gibco®, Life Technologies Ltd, 
Paisley, UK), without foetal calf serum, supplemented with 0.5% ciproxin (Bayer, 
Newbury, UK) and 1% penicillin-streptomycin solution (Gibco®, Life Technologies Ltd, 
Paisley, UK), to obtain a suspension of tonsillar cells.  
Mononuclear cells were then isolated by Ficoll-Isopaque centrifugation, whereby 15ml 
of lymphoprep solution (Axis-Shield Diagnostics Ltd. UK, Dundee, UK) was pipetted into 
tubes and carefully overlaid with 35ml of tonsillar cells. Tubes were centrifuged with the 
breaks off at 839g at room temperature for 30 minutes creating the visible layers of: 
plasma (top), mononuclear cells (middle), lymphoprep solution (bottom) and 
erythrocytes (pellet). Mononuclear cells were transferred to a fresh tube, washed twice 
with cold media and once with cold autoMACS solution (Miltenyi Biotec Ltd, Surrey, UK) 
supplemented with ciprofloxacin and penicillin-streptomycin as per RPMI and 5% 
MACS® BSA stock solution (Miltenyi Biotec Ltd, Surrey, UK).  
42 
2.2.3 Purification of CD10+ GC B cells 
Isolated TMCs were counted and cells were resuspended at a concentration of 
107cells/100µl of autoMACS solution with anti-CD10-Phycoerythrin (PE) antibody 
(eBioscience, Hatfield, UK) added at a 1/50 dilution. Cells were incubated for 10 minutes 
at 4oC in the dark and washed with 10x staining volume of autoMACS. Cells were then 
resuspended at a concentration of 107cells/100µl of autoMACS solution with anti-PE 
microbeads (Miltenyi Biotec Ltd, Surrey, UK) added at a 1/10 dilution. Cells were 
incubated for 15 minutes at 4oC in the dark and washed with 10x staining volume of 
autoMACS.  
Finally, cells were resuspended at a concentration of 108 cells/500µl of autoMACS (using 
the assumption that approximately 40% of cells are labelled). LS columns were placed 
on the pre-cooled separation magnet (both Miltenyi Biotec Ltd, Surrey, UK) with 50µm 
cell filters (CellTrics®, Partec UK Limited, Canterbury, UK) placed on each column. LS 
columns were pre-washed with 3ml of autoMACS and cells were applied at a ratio of 
500µl per column. Once the cells passed through, the LS columns and filters were 
washed three times with 3 ml of autoMACS, the filters discarded following the first wash. 
To elute the CD10+ cells, LS columns were removed from the magnet, 5ml of autoMACS 
was added and gentle pressure was applied with a plunger until the cells were eluted. 
Cells were kept on ice until further use, or pelleted at 106 cells/pellet and frozen at -
80oC. 
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2.2.4 CD40L stimulation of GC B cells 
Freshly isolated GC B cells were pelleted by centrifugation at 1000rpm, 4oC for 10 
minutes and re-suspended in RPMI 1640 medium (supplemented as per section 2.1.1) 
at a concentration of 2x106 cells/ml. Cells were stimulated with 200ng/ml soluble CD40L 
(Autogen Bioclear UK Ltd, Wiltshire, UK) or of equivalent volume of sterile 0.1% bovine 
serum albumin (BSA) solution made using tissue culture grade BSA (Sigma-Aldrich Ltd., 
Gillingham, UK). Cells were maintained at 37oC with a humidified atmosphere and 5% 
CO2 for up to 12h.  
2.3 Plasmid preparation 
2.3.1 Agar and broth preparation 
L-broth agar (LBA) plates were prepared using 2g of L-broth and 1.5g select agar powder 
(Life Technologies Ltd, Paisley, UK) per 100 ml distilled water. LBA was autoclaved and 
antibiotic added prior to being poured into petri dishes (Bibby Sterilin Ltd., Stone, UK). 
Plates were left to dry at room temperature and were sealed and stored at 4oC until use. 
L-broth (LB) was prepared using 2g L-Broth powder in 100 ml distilled water, autoclaved 
and stored at room temperature. Antibiotics were added prior to use. Ampicillin (Sigma-
Aldrich Company Ltd., Gillingham, UK) was added at a final concentration of 100µg/ml 
to both LB and LBA. Kanamycin monsulphate (Sigma-Aldrich Company Ltd., Gillingham, 
UK) was added at a final concentration of 30µg/ml. 
2.3.2 Making competent bacteria 
TOP10 competent E. coli cells (Life Technologies Ltd, Paisley, UK) or XL-1 Blue competent 
cells (Stratagene; Agilent technologies, Santa Clara, CA, USA) were plated on non-
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selective LBA plates and incubated overnight at 37oC. XL1-blue cells are tetracycline 
resistant and can be grown under 10µg/ml tetracycline (Sigma-Aldrich Company Ltd., 
Gillingham, UK) selection for this process, while TOP10 bacteria need to be grown 
without antibiotics. Individual colonies were picked into 2ml LB and shaken at 37oC until 
reaching OD600 of 0.6-0.8. Cells were pelleted by centrifugation at 1560g at 4oC for 10 
minutes. Pellets were resuspended in 5mMCaCL2/10MTris-HCL and incubated on ice for 
15 minutes. Cells were then pelleted as before and resuspended in 10ml of 
5mMCaCL2/15% Glycerol (Life Technologies Ltd, Paisley, UK) aliquoted and frozen at -
80oC.  
2.3.3 Transformation 
Competent bacteria were thawed on ice. Plasmid DNA was added to 50µl of competent 
bacteria at a ratio of 1:50, incubated on ice for 30 minutes, heat shocked at 42°C on a 
heat block for 1 minute and immediately returned to ice for 2 minutes. Bacteria were 
then grown in 250µl of LB without antibiotics at 37°C for one hour before being 
transferred onto pre-warmed LBA plates and incubated at 37°C overnight. For long-term 
storage, transformed bacteria were grown in 2ml LB under antibiotic selection 
overnight, following which 850µl of bacteria were mixed with 150µl Glycerol and frozen 
at -80oC.  
2.3.4 Plasmid purification  
A single colony from a freshly streaked LBA plate was incubated in a starter culture of 
2ml of LB under antibiotic selection for 6 hours at 37°C with shaking. The starter culture 
was then added to 100 ml of LB and further incubated at 37°C overnight under antibiotic 
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selection. Following the incubation, bacteria were harvested by centrifugation at 
6000rcf for 15 minutes at 4°C. Cell pellets were lysed and plasmid purified using the 
Nucleobond Xtra Midi Plus EF kit and as per manufacturer’s instructions (MACHEREY-
NAGEL, Düren, Germany). Details of the plasmids used are listed in Table 2.2.  




pFR-zsGreen Ampicillin Based on pFR-LUC, Agilent technologies, Santa Clara, CA, 
USA. GFP coding region was cloned into plasmid to replace the 
luciferase gene by Dr Vockerodt. 
pFC-MEKK Ampicillin Agilent technologies, Santa Clara, CA, USA 
pFC-MEK3 Ampicillin Agilent technologies, Santa Clara, CA, USA 
pFA-CHOP Kanamycin Agilent technologies, Santa Clara, CA, USA 
pFA-ATF2 Kanamycin Agilent technologies, Santa Clara, CA, USA 
pNF-κB hr-GFP Ampicilin Agilent technologies, Santa Clara, CA, USA 
pSG5 Ampicillin Agilent technologies, Santa Clara, CA, USA 
pSG5 LMP1 Ampicillin Provided by Prof. Elliott D. Kieff (Brigham and Women's 
Hospital and Harvard Medical School, Boston, MA). 
pcDNA3.1+ Ampicillin Life Technologies Ltd, Paisley, UK 
pcDNA3.1 S1PR2-HA Ampicillin UMR cDNA Resource Center, University of Missouri, Rolla, 
MO, USA 
pMACS 4.1 Ampicillin Miltenyi Biotec Ltd, Surrey, UK 
pMACS LNGFR-IRES Ampicillin Miltenyi Biotec Ltd, Surrey, UK 
pMACS LNGFR-IRES 
LMP1 
Ampicillin Cloned based on pSG5 LMP1 by Dr Vockerodt 
 
2.4 Transfection and enrichment of cell lines and primary GC B 
cells 
2.4.1 Transfection of BL2 and DG75 cell lines by electroporation 
Cells were seeded at a concentration of 5 x 105 cells/ml 24 hours prior to transfection. 
Cells were centrifuged at 173g at 4oC for 10 minutes and resuspended at a concentration 
of 107cells/250µl of ice cold cell media per transfection reaction. The cell suspensions 
were then supplemented with 25mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid (HEPES; Gibco®, Life Technologies Ltd, Paisley, UK) and up to a total of 20µg of 
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plasmid, as detailed below. The supplemented cell suspensions were transferred into 
ice cold 4mm electroporation cuvettes (Geneflow Limited, Lichfield, UK). Cells were 
electroporated at 250V, and high capacity of 950µF using a Bio-Rad Gene Pulser® II 
electroporator (Bio-Rad Laboratories Ltd., Hemel Hempstead, UK), following which they 
were immediately transferred into 10ml of pre-warmed media and incubated at 37°C in 
5% CO2 for 24h before analysis. 
For S1PR2 expression, DG75 cells were transfected with 20µg of pcDNA3.1 or pcDNA3.1 
S1PR2-HA. For the optimization of the PathDetect system, BL2 cells were transfected 
with 3µg of either positive control (pFC-MEKK or pFC-MEK3) or pSG5 plasmid as well as 
a combination of trans-activator (pFA-ATF2 or pFA-CHOP) and pFR-zsGreen reporter 
plasmids detailed in Table 2.3. 
Table 2.3: PathDetect plasmid titration 
Plasmid   Amount (µg) 
Trans-activator 1 2 4 
pFR-zsGreen 11 10 8 
Plasmid of interest 3 3 3 
 
2.4.2 Transfection of L428 and GC B cells by nucleofection 
Nucleofection of L428 cells was carried out at room temperature, using Cell Line 
Nucleofector® Kit L and Nucleofector (1st generation) device (Lonza, Slough, UK). L428 
cells were seeded at a concentration of 5 x 105 cells/ml 24 hours prior to transfection. 
Cells were centrifuged at 90g at room temperature for 10 minutes and resuspended at 
a concentration of 3x106cells/100µl of nucleofection solution per reaction, with 4µg of 
pcDNA3.1+ or pcDNA3.1 S1PR2 plasmid per reaction. Cells were transferred into 
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nucleofection cuvettes supplied with the kit and electroporated using the X-01 setting 
on the Nucleofector device. Cells were incubated in cuvettes at room temperature for 
10 minutes post electroporation following which they were transferred into 2ml of pre-
warmed media and incubated at 37°C in 5% CO2 for 24h before analysis. 
Nucleofection of GC B cells was carried out within 1 hour of isolation, at room 
temperature, using Human B Cell Nucleofector® Kit and Nucleofector (1st generation) 
device (Lonza, Slough, UK). GC B cells were centrifuged at 90g at room temperature for 
10 minutes and resuspended at a concentration of 5x106cells/100µl of nucleofection 
solution per reaction, with 10µg of plasmid per reaction, as detailed below. Cells were 
transferred into nucleofection cuvettes supplied with the kit and electroporated using 
the U-15 setting on the Nucleofector device following which they were immediately 
transferred into 2ml of pre-warmed media and incubated at 37°C in 5% CO2 for 12-16h 
before analysis. 
For array validation, GC B cells were transfected with 7µg of pSG5 or pSG5LMP1 and 3µg 
of pMACS LNGFR-IRES. For the NF-κB reporter assay GC B cells were transfected with 
3.5µg of pSG5 or pSG5LMP1, 1.5µg of pMACS LNGFR-IRES and 5µg of pNF-κBhrGFP 
reporter plasmid. For the PathDetect assay GC B cells were transfected with 2µg of trans-
activator (pFA-ATF2 or pFA-CHOP) and 4µg of pFR-zsGreen reporter plasmid and 1.5µg 
of pMACS LNGFR-IRES, pMACS LNGFR-IRES LMP1 or positive control (pFC-MEKK or pFC-
MEK3). A further 1.5µg of pMACS LNGFR-IRES was added to the positive control samples 
to allow for selection transfected cells in later analysis. To control for plasmid amount, 
1.5µg of pSG5 was added to the rest of the samples.  
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2.4.3 MoFlo enrichment of transfected GC B cells  
Following incubation, transfected GC B cells were washed twice with 10x volume of 
autoMACS, using centrifuge at 173g at 4oC for 10 minutes. Pellets were resuspended in 
250µl of autoMACS with anti-LNGFR-Allophycocyanin (APC) antibody (Miltenyi Biotec 
Ltd, Surrey, UK) at a 1/10 dilution. Cells were incubated for 10 minutes at 4oC in the dark, 
following which they were washed with 40x volume of autoMACS. Cells were 
resuspended in 250µl of autoMACS and passed through a pre-washed 50µl filter into 
5ml Polypropylene Round Bottom Falcon tubes (BD Biosciences, USA). The same volume 
of autoMACS was applied onto the filter to wash all the cells through and cells were kept 
at 4oC in the dark until cell sorting. Immediately prior to cell sorting, propidium iodide 
(PI; Sigma-Aldrich Ltd., Gillingham, UK) was added at a 1/10 dilution, to identify viable 
cells (PI negative). LNGFR-APC and CD10-PE positive, PI negative cells were collected by 
fluorescence-activated cell sorting (FACS) on a MoFlo sorter (Dako UK Ltd., 
Cambridgeshire, UK). Cells were collected into RNase free tubes with 750µl of RNase 
free phosphate buffered saline (PBS) solution (Gibco®, Life Technologies Ltd, Paisley, 
UK). Cells were pelleted by centrifugation at 3000rpm, 4oC for 10 min using a Heraeus 
Pico 17 Microcentrifuge (Thermo Fisher Scientific Inc, Waltham, MA, USA). Pellets were 
immediately stored at -80oC. 
2.5 RNA analysis 
All procedures were carried out on ice, with RNase free equipment. Work surfaces were 
decontaminated using RNaseZap® Decontamination Solution (Ambion®, Life 
Technologies Ltd, Paisley, UK).  
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2.5.1 RNA extraction from cultured cells and stimulated GC B cells 
Cells were washed once with ice cold PBS prior to pelleting at a concentration of 3x106 
cells/pellet (cell lines) and 2x106 cells/pellet (stimulated GC B cells). RNA was extracted 
from cell lines and stimulated GC B cells using the QIAGEN RNeasy® mini kit according to 
the manufacturer's protocol (QIAGEN Ltd, Manchester, UK). RLT buffer was 
supplemented with 14.3M β-mercaptoethanol (β-ME; Sigma-Aldrich Company Ltd., 
Gillingham, UK) as per kit instruction. On-column DNase digestion was performed as per 
manufacturer’s instructions using the RNase-Free DNase Set (QIAGEN Ltd., Manchester, 
UK). RNA was eluted from the columns provided with the kit using 30µl of DEPC-treated 
water (supplied in kit) pipetted directly onto the membrane. The concentration of RNA 
was determined using a NanoDrop ND-1000 spectrophotometer (Thermo Fisher 
Scientific Inc, Waltham, MA, USA). 
2.5.2 RNA extraction and amplification from nucleofected GC B cells 
Cell pellets from sorted, nucleofected GC B cells (approximately 10000 cells) were lysed 
in 100µl RLT buffer supplemented with 1µl of 14.3M β-ME and 1µl N-carrier (AmpTec, 
supplied by AMS Biotechnology (Europe) Ltd, Abingdon, UK). RNA was extracted using 
the QIAGEN RNeasy® micro kit according to the manufacturer's protocol (QIAGEN Ltd, 
Manchester, UK). The quality of the isolated RNA was determined using a NanoDrop ND 
1000 (Thermo Fisher Scientific Inc, Waltham, MA, USA) and a Bioanalyzer 2100 (Agilent, 
Waldbronn, Germany). Only those samples with a 260/280 nm ratio between 1.8-2.1 
and a 28S/18S ratio within 1.5-2.0 were processed for RNA amplification. RNA 
amplification was carried out using the ExpressArt® mRNA Amplification Kit Nano 
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version as per manufacturer’s instructions for two rounds of amplification (AmpTec, 
supplied by AMS Biotechnology (Europe) Ltd, Abingdon, UK).  
2.5.3 Reverse transcription (RT) of RNA to cDNA  
For reverse transcription of RNA to copy DNA (cDNA), 500ng of RNA was used from cell 
lines and stimulated GC B cells, while only 300ng was used from 2nd round of GC B cell 
RNA amplification. RNA was made up to 11µl volume in sterile 0.2ml PCR tubes using 
sterile DEPC treated water (Invitrogen®, Life Technologies Ltd, Paisley, UK). To this, 2µl 
of a 1:1 mix of 100µg/ml random hexamer primers (Promega UK Ltd, Hampshire, UK) 
and 10mM deoxyribonucleotide triphosphates (dNTP; Roche Diagnostics Limited, UK) 
was added. Samples were incubated at 65oC for 5 minutes using the Veriti® Thermal 
Cycler (Applied Biosystems®; Life Technologies Ltd, Paisley, UK). Samples were then 
cooled on ice for 1 minute, before the addition of 7µl of the following master mix (made 
up to the ratio of 4:1:1:1): 5x First Strand buffer, 0.1 M dithiothreitol (DTT), RNaseOUT™ 
and SuperScript® III reverse transcriptase (Invitrogen ™; Life Technologies Ltd, Paisley, 
UK). The sample was mixed and incubated using the Veriti® Thermal Cycler with the 
following protocol: 5 minutes at 25oC, 1 hour at 50oC, 15 minutes at 70oC and hold at 
4oC. The cDNA samples were stored at -20oC until required.  
2.5.4 Quantitative polymerase chain reaction (qPCR) 
The qPCR reaction was set up as a multiplex reaction in a 20µl volume in a 96-well optical 
reaction plate (Applied Biosystems®; Life Technologies Ltd, Paisley, UK). Each reaction 
contained 5 µl of diluted cDNA (typically 1:20 with DEPC treated water), 10 µl of 
FastStart Universal Probe Master mix (Roche Diagnostics Limited, UK), 1 µl of 20x 
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primer/probe of gene of interest (FAM labelled) and 1 µl of 20x primer/probe of GAPDH 
endogenous control (VIC TAMRA labelled) (Taqman® Life Technologies Ltd, Paisley, UK) 
and 3 µl of DEPC treated water. All primers and probes are listed in Table 2.4. All samples 
were set up in triplicate and a non-target (water) control was included. The plate was 
sealed with optically clear adhesive film (Applied Biosystems; Life Technologies Ltd, 
Paisley, UK).  
Table 2.4: Taqman primer/probes from Applied Biosystems (ABI) 
Gene ABI probe ID  Dye label 
ATM Hs01112355 FAM 
TNFAIP3 Hs00234713 FAM 
HSPA1A Hs00359163 FAM 
CCL5 Hs00174575 FAM 
STAT5A Hs00234181 FAM 
ID2 Hs00747379 FAM 
PTEN Hs02621230 FAM 
RASSF6 Hs00698249 FAM 
CD72 Hs00233564 FAM 
VPREB3 Hs00353682 FAM 
GAPDH Hs02758991 VIC TAMRA 
RGS13 Hs00243182 FAM 
S1PR2 Custom ABI assay containing:  
5’ primer: GTGCTAGGCGTCTTTATCGTC 
3’ primer: GTAGTGGGCTTTGTAGAGGATC 
Probe: AGGAGTGGACGGGACAGGCATA  
FAM 
 
The reaction for the detection of LMP1 transcripts was set up in a final volume of 25µl, 
with 12.5µl of FastStart Universal Probe Master mix, 2.5µl of the 5’ and 3’ primers, 1µl 
of probe, 1µl of 20x primer/probe of endogenous control and 1.5µl of DEPC treated 
water. The sequences of the LMP1 primers and probe have been previously described 
(Bell et al., 2006) and were ordered accordingly (Sigma-Aldrich Company Ltd., 
Gillingham, UK). 
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Samples were amplified using the standard relative quantification method of the 7500 
Fast Real-Time PCR System (Applied Biosystems®; Life Technologies Ltd, Paisley, UK). 
Briefly, samples were subjected to enzyme activation (50oC for 2 minutes) and 
denaturation (95°C for 10 minutes) followed by 40 cycles of amplification (denaturation 
at 95°C for 15 seconds and extension at 60°C for 1 minute). 
The delta-delta (ΔΔ) Ct method was used to determine relative gene expression of the 
samples. This is a two-step method, first normalising the sample values against an 
endogenous control (e.g. GAPDH), second relative gene expression is determined based 
on the selection of a reference sample to act as a baseline for gene expression, resulting 
in an absolute value of fold change (Livak and Schmittgen, 2001).  
2.6 Protein analysis 
2.6.1 Western blotting 
2.6.1.1 Protein extraction from GC B cells 
GC B cell pellets were lysed in 20µl RIPA lysis buffer (140mM NaCl, 10mM Tris-HCl pH8, 
1mM EDTA, 1% triton, 0.1% SDS, 0.1% Sodium deoxycholate (Deoxycholic acid)) 
supplemented with 1mM of activated sodium vanadate and 4% v/v protease inhibitor 
(cOmplete Tablets, EDTA-free; Roche Diagnostics Limited, UK). Cells were vortexed with 
lysis buffer, left on ice for 30 minutes and centrifuged at maximum speed, 4oC for 15 
minutes on a Heraeus Pico 17 Microcentrifuge (Thermo Fisher Scientific Inc, Waltham, 
MA, USA) to collect cell debris. The supernatant was transferred to a clean 0.5 ml tube 
and either used immediately or frozen at -20oC.  
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2.6.1.2 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) 
SDS-PAGE gels were made as per Lab FAQs booklet (Roche Diagnostics Limited, UK). Due 
to the low cell numbers in the sample, the extracted protein was not quantified, instead 
whole lysate was diluted 1:1 with 2x SDS-PAGE buffer (10%SDS, 1.5M Tris-HCl (pH6.8), 
1% Bromophenol blue, 1M dithiothreitol (DTT) in H2O). Protein was denatured by 
heating the sample at 95oC for 10 minutes prior to loading samples along with Spectra™ 
Multicolor Broad Range Protein ladder (Thermo Fisher Scientific Inc, Waltham, MA, 
USA). Gels were placed in Tris-Glycine-SDS PAGE Buffer (Geneflow Ltd, Lichfield, UK) and 
the solubilised proteins were separated by electrophoresis in Mini Trans-Blot® Cell tank 
(Bio-Rad Laboratories Ltd., Hemel Hempstead, UK), at 125 V, (300 mA limit) for 1.5-2 
hours depending on protein size. 
2.6.1.3 Protein transfer 
Six sponges, six pieces of Whatman® chromatography paper (Sigma-Aldrich Company 
Ltd., Gillingham, UK) and one piece of nitrocellulose membrane (Amersham Hybond-C 
extra; GE Healthcare Life Science, Buckinghamshire, UK) were pre-soaked in 1x Tris-
Glycine Electro-Blotting Buffer (Geneflow Ltd, Lichfield, UK). To set up the protein 
transfer, the components were stacked in the following order: 3 sponges, 3 pieces of 
filter paper, gel, 1 nitrocellulose membrane, 3 pieces of filter paper, and 3 sponges in an 
XCell II Blot Module within the XCell Surelock Mini-Cell (Invitrogen; Life Technologies Ltd, 
Paisley, UK). The tank was topped up with 1x transfer buffer, placed in ice and in a cold 
room. Transfer was run at 40 V, 400 mA for 2 hours.  
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2.6.1.4 Immunoblotting and visualisation 
Non-specific protein binding was blocked by incubating the membrane for 1 hour at 
room temperature in 5% non-fat dried milk dissolved in TRIS buffered saline-tween 
(Milk/TBST). TBST consists of 1.21 g TRIS and 8.77 g NaCl in 1 litre distilled water (pH 
adjusted to 7.6 using concentrated HCl) with 0.5 ml Tween20 (Fisher Scientific). 
Membranes were incubated with primary antibody (BCL6 and PARP, Cell Signaling) 
diluted 1:1000 in 5% BSA/TBST overnight at 4oC on a roller. Membranes were washed 
3x in TBST before incubation for 1 hour at room temperature with polyclonal goat anti-
Rabbit-HRP secondary antibody (Dako UK Ltd., Cambridgeshire, UK), diluted 1:1000 in 
5% BSA/TBST.  
The membrane was again washed 3x in TBST, following which antibody-protein 
complexes were detected using the ECL Western Blotting System (GE Healthcare Life 
Science, Buckinghamshire, UK). The two ECL reagents were mixed 1:1 immediately prior 
to use, the membrane was incubated in the ECL mixture for 1 minute and then the 
excess liquid drained off. The membrane was transferred to an autoradiography 
cassette and developed in a dark room using a sheet of Hyperfilm™ (GE Healthcare Life 
Science, Buckinghamshire, UK) and a Kodak X-OMAT 1000 processor (Kodak Limited). 
Following the detection of the protein of interest, the membrane was washed in TBST 
and re-probed for β-actin-HRP (clone AC-15; Sigma-Aldrich Ltd., Gillingham, UK) for 1 
hour at room temperature, at a 1:10000 dilution in 5% BSA/TBST. Membrane was 
developed as described.  
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2.6.2 Immunohistochemistry and immunofluorescence 
2.6.2.1 Cytospin preparation 
2 x 106 cells were centrifuged, washed in serum-free RPMI 1640 and resuspended in 1 
ml serum-free RPMI 1640 with 10% v/v formaldehyde (Sigma-Aldrich Ltd., Gillingham, 
UK). Cells were attached on X-tra Adhesive micro slides (Surgipath Europe, 
Peterborough, UK) in Cytospin3 cytocentrifuge (Shandon, Runcorn, UK) using 
Cytofunnel® disposable sample chambers, filter cards and Cytoclips™ (all Thermo Fisher 
Scientific Inc, Waltham, MA, USA) and centrifuged at 1000rpm for 5 minutes. Cytospin 
preparations were air dried and stored at -20°C until required. When required, slides 
were thawed and the endogenous peroxidase activity was blocked by immersing the 
slides for 10 minutes in 0.3% hydrogen peroxide (Sigma-Aldrich Ltd., Gillingham, UK), 
following which slides were rinsed in running tap water. 
2.6.2.2 Preparation of tissue sections 
Paraffin-embedded blocks of HL and DLBCL patients were obtained from the Queen 
Elisabeth Hospital, Birmingham, UK. 
Paraffin-embedded blocks were cut to 4µm thickness and placed onto X-tra Adhesive 
micro slides (Surgipath Europe, Peterborough, UK). Sections were then de-waxed by 
immersing the slides for 10 minutes in Histo-Clear (National Diagnostics, supplied by 
AGTC Bioproducts t/a National Diagnostics UK, Hessle, UK), and re-hydrated by 
immersing the slides for 5 minutes in 100% ethanol (Sigma-Aldrich Ltd., Gillingham, UK), 
followed by tap water. Next, the endogenous peroxidase activity was blocked by 
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immersing the slides for 10 minutes in 0.3% hydrogen peroxide (Sigma-Aldrich Ltd., 
Gillingham, UK), following which slides were rinsed in running tap water. 
2.6.2.3 Antigen retrieval 
Citrate buffer (1.26 g sodium citrate and 0.25 g citric acid in 1l distilled water, pH 6.0) 
was boiled in a glass beaker for 10 minutes at full power in a microwave before 
immersing the slides pre-loaded on a rack into the buffer. The beaker was covered with 
cling film and was returned to the microwave and heated for 10 minutes at moderate 
power then 10 minutes at low power. The buffer was allowed to cool completely before 
the slides were removed and rinsed in running water. 
2.6.2.4 Detection of antigen by immunohistochemistry 
After antigen retrieval, slides were placed in a metal microscope slide staining tray 
(Richardsons of Leicester Ltd., Leicester, UK) and the tissue section encircled using an 
ImmEdge Hydrophobic Barrier Pen (Vector Laboratories Ltd., Peterborough, UK). Slides 
were washed with PBS-Tween-20 (0.1%) (PBST) for 5 minutes and then blocked in 100µl 
of 5X casein blocking solution (Vector Laboratories Ltd., Peterborough, UK) to reduce 
non-specific background staining. The sections were incubated with 100µl of diluted 
primary antibody (Table 2.5), with the slide tray filled a thin layer of water and covered 
with a lid to minimize evaporation.  
Table 2.5: Antibodies used for IHC 
Antibody Clone Source dilution incubation DAB time 
S1PR2 polyclonal Sigma 1/400, 1/200 for IF Overnight at 4  6min 
HA Y-11 Santa 
Cruz 
1/50 1 hour at room 
temperature 
3min 
LMP1 cs1-4 Dako 1/50 for cytospin, 
1/25 for tissue 
Overnight at 4  6min 
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Following incubation, samples were washed with PBST for 5 minutes and incubated with 
2 drops of DAKO Envision secondary antibody (Dako UK Ltd., Cambridgeshire, UK) for 30 
minutes at room temperature. Visualization was carried out using the ImmPact DAB 
substrate system (Vector Laboratories Ltd., Peterborough, UK) which generated a brown 
product that is insoluble in water and organic solvents. Slides were further rinsed with 
distilled water and counterstained with Mayer’s haematoxylin (Sigma-Aldrich Ltd., 
Gillingham, UK) for 30-60 seconds and washed under hot running tap water for 2 
minutes. Slides were then dehydrated by immersing the slides for 5 minutes in 100% 
ethanol, followed by 10 minutes in Histoclear and mounted with cover slips using DPX 
mounting medium (Sigma-Aldrich Ltd., Gillingham, UK).  
2.6.2.5 Detection of antigen by immunofluorescence 
After antigen retrieval, slides were placed in a metal microscope slide staining tray 
(Richardsons of Leicester Ltd., Leicester, UK) and the tissue section encircled using an 
ImmEdge Hydrophobic Barrier Pen (Vector Laboratories Ltd., Peterborough, UK). Slides 
were washed with PBS-Tween-20 (0.1%) (PBST) for 5 minutes and then blocked in 100µl 
of 5X casein blocking solution (Vector Laboratories Ltd., Peterborough, UK) to reduce 
non-specific background staining. The sections were incubated with 100µl of diluted 
primary antibody (Table 2.5), with the slide tray filled a thin layer of water and covered 
with a lid to minimize evaporation.  
Following incubation, samples were washed with PBST for 5 minutes and incubated with 
Alexa Fluor® secondary antibody diluted 1:1000 at 37oC for 1 hour. Secondary antibodies 
used: Alexa Fluor® 594 Goat Anti-Mouse IgG (H+L) and Alexa Fluor® 488 Goat Anti-
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Mouse IgG (H+L) (Invitrogen; Life Technologies Ltd, Paisley, UK). Slides were washed 
with PBST for 5 minutes and mounted with cover slips using VECTASHIELD Mounting 
Medium with DAPI (Vector Laboratories Ltd., Peterborough, UK). Cells were visualised 
using a Nikon E600 UV microscope.  
2.6.3 Flow cytometry 
To detect cell-surface marker expression, cells were washed 2x with autoMACS and 
resuspended in 50µl of autoMACS containing a 1/10 dilution antibody (antibodies are 
listed in Table 2.6). Cells were incubated with antibody for 15 minutes in the dark at 4oC, 
following which they were washed in 10x volume of autoMACS and resuspended in 
500µl of autoMACS (or 200µl for GC B cell samples which contained less cells). Cells were 
kept on ice in the dark and analysed within 1h. Propidium iodide (PI) was added to all 
stained samples immediately before measurement. Cells were analysed by flow 
cytometry using the FACSCalibur and the CellQuest software (BD Biosciences, USA). Data 
was analysed using Flowjo software (TreeStar Inc.). Only the viable cells were considered 
for analysis based on their light scatter (FSC/SSC) characteristics and PI negativity.  
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Table 2.6: Fluorescently labelled antibodies used for flow cytometry 
Antibody Clone Fluorescent label Source 
ICAM1 (CD54) 15.2 FITC AbDserotec 
CD10 eBioCB-CALLA PE eBioscience 
CD19 LT19 APC Miltenyi Biotech 
CD77 5B5 FITC BD biosciences 
CXCR4 (CD184) 12G5 APC eBioscience 
CD95 DX2 FITC eBioscience 
CD3 UCHT1 FITC eBioscience 
CD24 SN3 FITC eBioscience 
CD38 T16 FITC Coulter/Immunotech 
CD27 O323 FITC Biolegend 
CD83 HB15e FITC eBioscience 
CD86 B-T7 FITC abcam 
CD271 (NGFR) ME20.4-1.H4 APC Miltenyi Biotech 
 
2.7 Migration assay 
Migration assay on transfected L428 cells was performed using DiOC16(3) dye (Biotium, 
supplied by Cambridge BioScience, Cambridge, UK) and 5µM Transwell permeable 
supports (Corning B.V. Life Sciences, Amsterdam, Netherlands). Transfected cells were 
pelleted 24h post transfection, washed 2x with autoMACS and re-suspended at a 
concentration of 5x105cells/ml in autoMACS with DiOC(3) dye at a final concentration of 
2.5µM. Cells were incubated at 37oC, 5% CO2 for 30 minutes, washed 1x with autoMACS 
and resuspended at a concentration of 5x105cells/200µl in serum-free RPMI 1640. A 24 
well plate was prepared with 600µl of supplemented RPMI 1640 (described in section 
2.1.1), transwells were inserted and 200µl of labelled cells were added to each insert. At 
each time point, the inserts were removed onto a separate 24 well plate and 
fluorescence in the bottom of the wells was read on a Wallac 1420 Victor2 Microplate 
Reader (PerkinElmer, Cambridge, UK), with excitation/emission filters F485/F510. 
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Fluorescence measurements across all experiments were averaged, the media only 
control fluorescence was subtracted and the values from S1PR2 transfected cells were 
normalised to vector control for each time point.  
2.8 Proliferation assay 
Proliferation assay on transfected L428 cells was performed using CellTiter-GLO ® 
Luminescent Cell Viability Assay (Promega UK Ltd, Hampshire, UK). 106 transfected cells 
were pelleted 24h post transfection, washed 1x with supplemented RPMI 1640 and re-
suspended at a concentration of 2x105cells/ml and incubated at 37oC, 5% CO2. At each 
time point cells were mixed and 2x 50µl were removed into opaque 96 well plates. Cells 
and CellTiter-GLO reagent were left for 30 minutes to equilibrate to room temperature, 
prior to adding reagent to cells at a 1:1 ratio. Plates were shaken for 2 minutes and left 
to stand for 10 minutes prior to reading luminescence on a Wallac 1420 Victor2 
Microplate Reader. Luminescence measurements across all experiments were averaged 
and the media only control fluorescence was subtracted for each time point. 
2.9 Statistical analysis 
2.9.1 Re-analysis of published microarrays 
The three arrays re-analysed in Chapter 4 section 4.2.1 were Affymetrix HG-U133 Plus2 
transcriptional arrays. Probe level quantile normalisation (Bolstad et al., 2003) and RMA 
(robust multi-array analysis) (Irizarry et al., 2003) were performed using the affy package 
of the Bioconductor project (http://www.bioconductor.org). Differentially expressed 
probe sets were identified using limma (Smyth, 2004) using criteria of fold change >1.5 
and p < 0.001.  
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For the survival analysis of the DLBCL array, GSE10846 was downloaded from GEO. 
Probe level quantile normalisation (Bolstad et al., 2003) and RMA (Irizarry et al., 2003) 
were performed using the affy package of the Bioconductor project 
(http://www.bioconductor.org) and the custom cdf HGU133Plus2_Hs_ENTREZG 
(version 16). Survival analysis was performed using the R survival package 
(http://www.r-project.org/). Both of the above analysis were performed by Dr Wenbin 
Wei, Senior Bioinformatician, School of Cancer Sciences, University of Birmingham.  
Analysis of the DLBCL IHC result was performed by Dr Judy Powell, Senior Lecturer, 
Public Health, Epidemiology and Biostatistics, School of Health and Population Sciences, 
University of Birmingham. Survival time was analysed using Kaplan-Meier survival 
analysis, and the results were plotted as survival curves. For overall survival, survival 
time was defined as the time in months between the disease diagnosis and death. Event-
free survival was defined as the time between diagnosis and the first disease event 
(relapse, progression or death without relapse or progression). Subjects not 
experiencing death or an event were censored at the last date known to be alive or 
disease free respectively. The log-rank test was used to determine if observed 
differences between the survival curves were statistically significant, significance being 







An investigation of the 
phenotype of germinal 
centre B cells following their 




3 An investigation of the phenotype of germinal 
centre B cells following their in vitro separation 
and short term culture 
 
3.1 Introduction 
The majority of B cell lymphomas, including Burkitt’s lymphoma (BL), Hodgkin’s 
lymphoma (HL) and diffuse large B cell lymphoma (DLBCL), are believed to derive from 
germinal centre (GC) B cells (Kuppers et al., 1999, Klein and Dalla-Favera, 2008). In the 
absence of animal models and primary cell lines, the manipulation of primary human GC 
B cells in vitro provides an alternative approach to interrogate the mechanisms of 
lymphomagenesis. 
The isolation of tonsillar GC B cells using CD10 directed MACS separation has already 
been described (Vockerodt et al., 2008). Following their isolation CD10 positive GC B 
cells can be transfected and maintained in short term culture (Vockerodt et al., 2008). 
Subsequent chapters in this thesis explore the transcriptional consequences of virus 
gene expression and CD40 stimulation in tonsillar GC B cells.  
The purpose of the work described in this chapter is to describe the phenotype of CD10 




3.2.1 Isolated CD10 positive tonsillar mononuclear cells are viable 
I first wanted to measure the viability of isolated CD10 positive GC B cells. Tonsillar 
mononuclear cells (TMCs) were isolated and CD10 positive cells enriched by magnetic 
cell sorting as described in Materials and Methods, section 2.2.  
Flow cytometry was used to measure the viability of CD10 positive cells (Figure 3.1). I 
used two methods to do this. In the first method, I measured cell size by forward scatter 
(FSC) and morphology by side scatter (SSC). Gates were drawn around the dense 
population of live cells (Figure 3.1a). In this way cell debris (seen at the bottom end of 
the FSC scale) and dead cells which have a higher granularity (top end of SSC) are gated 
out from the analysis. In the second method, I stained cells with propidium iodide (PI) 
which can only enter cells with disrupted cell membranes, leaving healthy cells 
unstained (Figure 3.1b). 
I found that following their isolation the mean viability of CD10 positive cells as 
measured by forward scatter was 91.7% (range: 88.3-95.6%) and by PI staining was 
95.7% (range: 89.2-96.7%). This observation was based on the analysis of tonsillar 






Figure 3.1: Viability and gating strategy for isolated cell populations 
Gating is shown for a representative experiment of isolated CD10 positive cells (12 replicates)  
A) Viable cells are gated based on size (FSC) and granularity (SSC) Gates were drawn around the dense population of 
live cells to exclude cell debris (seen at the bottom end of the FSC scale) and dead cells which have a higher granularity 
(top end of SSC). 
B) Viable cells are gated based on PI negativity. Propidium iodide can only enter cells with disrupted cell membranes, 





3.2.2 Isolated CD10 positive tonsillar mononuclear cells display a GC B 
cell phenotype 
Having shown that the majority of isolated CD10 positive are viable, I next wanted to 
investigate the phenotype of these cells. To do this, I repeated the CD10 based isolation 
above from a further 3 tonsils and assessed cell surface marker expression by flow 
cytometry (Table 3.1). I first stained tonsillar mononuclear cells (TMCs) to assess the 
proportion of GC B cells and T cells in the population. I used anti-mouse IgG1 specific 
fluorescent antibodies (isotype control) to identify non-fluorescent cells and set the 
gates for further analysis (Figure 3.2a). A large proportion of TMCs express CD10, and 
nearly all CD10 expressing TMCs are also positive for CD77. Approximately 20% of TMCs 
are T cells, of which only a minority are CD8 positive T cells.  
Table 3.1: Markers used for identifying cellular subsets 
Gene Cell type References 
CD10 GC B cell (Bm3, Bm4) and GC founder cell (Bm2’, Bm3δ-4δ) (Bohnhorst et al., 2001, Pascual 
et al., 1994) 
CD19 B cell marker (Bohnhorst et al., 2001) 
CD77 Centroblast (Bm3) (Klein et al., 2003, Pascual et al., 
1994) 




GC B cell (Bm3, Bm4) (Hao et al., 2008, Lagresle et al., 
1995) 
CD3 T cells (McClory et al.) 
CD24 Immature B cell and transitional B cells (Palanichamy et al., 2009, Sims 
et al., 2005) 
CD38 GC B cell, plasma cell   (Jego et al., 1999, Bohnhorst et 
al., 2001) 
CD27 Memory B cell (Bm5) (Klein et al., 1998) 
CD83 Dendritic cell marker. Can identify centrocytes (Bm4) in 
conjunction with CXCR4 
(Victora et al., 2012) 
CD86 Dendritic cell marker. Can identify centrocytes (Bm4) in 
conjunction with CXCR4 
(Victora et al., 2012) 




Figure 3.2b shows that the majority of the isolated CD10 positive cells express CD19, a 
known B cell surface antigen. In addition, the majority of CD10 expressing cells also 
express CD38, a molecule expressed in haematopoietic cells, including GC B cells. A small 
population of cells display more intense staining for CD38; these could either be GC B 
cell founder cells or emerging plasmablasts, both of which also express CD10 (Bohnhorst 
et al., 2001, Jego et al., 1999). CD10 positive cells also express CD95 and BCL6 which is 
consistent with their GC phenotype. Approximately 15% of CD10 positive cells also 
express CD27, a molecule found on somatically hypermutated memory B cells (either 
GC B cells differentiating to memory or memory B cells re-entering the GC reaction) and 
only a small proportion of T cells (Klein et al., 1998). I have also confirmed the expression 







Figure 3.2: Phenotype of isolated CD10 positive cells  
Cells have been gated as per Figure 3.1 to identify viable cells and the population of the two gates were combined. 
The resulting population of viable cells were used for analysis. Cells were not gated for CD10 expression 
A) Tonsillar mononuclear cells (TMCs) were stained with isotype control antibody (anti-mouse IgG1) to determine the 
position of the gates for later analysis. A large proportion of TMCs express CD10, and nearly all CD10 positive TMCs 
are also positive for CD77 expression. Approximately 20% of TMCs are T cells, of which only a minority are CD8 positive 
T cells. Data is representative of 3 replicates 
B) CD10 sorted cells were stained for either: CD19, CD38, CD95 or CD27 to assess their GC phenotype.  
GC B cells are positive for CD10, CD19 and CD38, with most expressing CD95 on their surface. The percentage of CD27 
positive cells is low. Data is representative of 3 replicates 
C) Western blot of isolated CD10 positive cells from two tonsils showing that BCL6 is expressed in the GC B cells of 
both tonsils. BL2 Burkitt’s lymphoma cell line acts as a positive control and lymphoblastoid cell line (LCL) act as a 
negative control. β-actin acts as a loading control as expression of this housekeeping molecule should be identical in 
the samples.  
  
69 
I found that on average 82.1% (range: 77.2-87%) of CD10 positive cells also express CD77 
(Figure 3.3a). Although originally believed to be a specific marker of centroblasts, it has 
recently been reported that CD77+ and CD77- GC B cells have near identical transcription 
profiles and that CD77 alone does not discriminate between centroblasts and 
centrocytes (Hogerkorp and Borrebaeck, 2006, Pascual et al., 1994, Klein et al., 2003). 
CXCR4 and CXCR5 have been reported to be expressed on human centroblasts and 
centrocytes, respectively (Allen et al., 2004). Furthermore, a recent study has confirmed 
expression of CXCR4 on centroblasts (Caron et al., 2009). I analysed the expression of 
CXCR4 and CD77 on CD10 positive cells. Figure 3a shows that the majority of cells are 
double positive for CXCR4 and CD77 expression (average 72.9%, range 46-86.5%); with 
a large proportion of cells that express only CXCR4 (average 12%, range 3.1-25.4%) or 
CD77 (average 8.8%, range 5.5-11.3%). These observations indicate that the expression 
of CXCR4 and CD77 do not consistently overlap in GC B cells. As CD77 has been shown 
to be an inconsistent marker of centroblasts, CXCR4 positivity could provide a more 
accurate measure of these cells. Taken together, the data indicate that centroblasts 
comprise the most abundant population in the CD10 isolated cells.  
CD83 and CD86 have recently been identified on the surface of centrocytes and when 
used in conjunction with CXCR4 can distinguish centroblasts (CXCR4highCD83low or 
CXCR4highCD86low) and centrocytes (CXCR4lowCD83high or CXCR4lowCD86high) (Victora et 
al., 2012). Figure 3.3b shows that of the isolated CD10 positive cells 18.7% were 
CXCR4lowCD83high and 22.8% were CXCR4lowCD86high suggesting that only a minority of 





Figure 3.3: Levels of centroblasts and centrocytes  
Cells have been gated as per Figure 3.1 to identify viable cells and the population of the two gates were combined. 
The resulting population of viable cells were used for analysis. Cells were not gated for CD10 expression.  
A) CD10 sorted cells were stained for CXCR4 and CD77. Centroblasts are represented in the top right quadrants as 
CD10/CD77 double positive or CXCR4/CD77 double positive cells. (Representative of 3 replicates). 
B) Expression of centrocyte markers CD83 and CD86 and centroblast marker CXCR4 identifying centrocytes 




I found that a small fraction (less than 5%) of isolated cells were CD10 negative (Figure 
3.3a), therefore I wanted to check the purity of the isolated populations. I stained the 
isolated cells for CD3 (to distinguish T cells) and CD24 (to distinguish transitional B cells). 
CD24 in conjunction with other markers, such as CD10, can be used to identify 
transitional B cells in peripheral blood (Palanichamy et al., 2009, Sims et al., 2005). As 
these cells circulate from the bone marrow to the spleen, some could potentially be in 
(the blood vessels of) the tonsil and may be isolated during the CD10 magnetic 
enrichment.  
There is a low level, 1.5% of T cells in the sample (Figure 3.4a). Importantly, two thirds 
of the CD3 positive T cells express CD10, allowing for the selection of these cells during 
enrichment. However, the overall percentage of these cells in the total population is 
very low (<1%) and thus unlikely to skew any analysis. The level of CD10/CD24 double 
positive transitional B cells is very low, representing only 0.57% of the total isolated GC 
B cell population (Figure 3.4b). There is also a small population of CD10-CD24+ cells in 
the isolated sample. As all CD24 expressing cells are positive for CD19 (Figure 3.4b), this 








Figure 3.4: Cells of non-GC B cell origin in the isolated cells  
Cells have been gated as per Figure 3.1 to identify viable cells and the population of the two gates were combined. 
The resulting population of viable cells were used for analysis. Cells were not gated for CD10 expression.  
A) CD10 sorted cells were stained for CD3 to detect T cells, present as either CD3 positive CD10 negative cells (0.57%) 
or CD10/CD3 double positive cells (0.94%). 
B) CD10 sorted cells were stained for CD24 and CD19 to detect transitional B cell contamination, represented as 
CD10/CD24 double positive cells. In most CD24 positive cells express CD19, identifying them as B cells. 
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3.2.3 Isolated GCB cells undergo apoptosis in culture but a proportion 
remains viable for up to 12 hours 
I next investigated if the isolated CD10 positive cells undergo apoptosis in culture. I used 
both flow cytometry for the detection of viable cells (as described in section 3.2.1) and 
western blotting for the detection of PARP cleavage. Poly(ADP-ribose) polymerases 
(PARPs) have various functions, however PARP-1 has been shown to play a key role in 
the initiation of apoptosis through the release of the apoptosis-inducing factor (AIF) 
(Ame et al., 2004). PARP-1 cleavage is one of several consequences of apoptosis 
induction.  
Figure 3.5 shows that CD10 positive cells underwent apoptosis in culture which 
increased with time. As seen previously, the two different flow cytometric estimates of 
cell viability do not identify the same number of viable cells; however, the decrease in 
viability observed was similar with both methods. I found that the addition of CD40 
ligand (CD40L) partially rescued these cells from apoptosis. These data are consistent 
with previous reports showing that germinal centre B cells undergo apoptosis in culture, 
but are partially protected from cell death by CD40L (Hennino et al., 2001, Klein and 




Figure 3.5: CD10 enriched cells display signs of apoptosis in culture 
A) Cells were analysed by flow cytometry and Side Scatter: Forward Scatter analysis (top row) as well as inability to take up Propidium Iodide (bottom row) was used to identify viable 
cells as per Figure 3.1. Live cells are displayed inside the gates.  
B) Cells were analysed by western blotting for PARP cleavage at 1, 3 and 12 hours in culture in the presence or absence of CD40L (- or + respectively). Cleaved PARP is represented on 
the blots at a lower molecular weight. β-actin was used as a loading control. 
The data are representative of three experiments on three different donors.  
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3.2.4 Isolated CD10 positive cells do not retain a germinal centre 
phenotype in culture 
I next wanted to determine if the isolated and viable CD10+ cells retain their phenotype 
during short term culture. Figure 3.6a shows that while CD95 expression was retained, 
the intensity of CD10 and CD38 staining decreased over time in culture, with the loss of 
the high intensity (CD38++) population seen at the time of extraction. The expression of 
CD27 decreased by 3 hours in culture, with no further change at the later time point. 
The addition of CD40L did not affect CD10, CD38 and CD27 expression, whereas the 
expression of CD95 increased with CD40L stimulation compared to normal culture 
conditions. Decreased BCL6 expression was first observed after 3 hours in culture and 
was drastically reduced by 12 hours (Figure 3.6b). The addition of CD40L partially 
rescued this effect; an effect that was only consistently observed after 12 hours. 
I also observed some variation in the expression of centroblast and centrocyte markers 
during culture. I found that while CXCR4 expression increased over time in culture, CD77 
expression decreased (Figure 3.7). Both CXCR4 and CD77 intensity increase in the 
presence of CD40L. The starting population of CXCR4lowCD83high and CXCR4lowCD86high 
centrocytes decrease by 3 hours in culture regardless of the presence of CD40L. 
However, there is an increase in CD83 and CD86 intensity over time in culture, and this 
intensity is further increased in the presence of CD40L. This is reflected in the increase 




Figure 3.6: CD10 enriched cells do not retain their GC B cell phenotype in culture 
A-B) Cells were analysed by flow cytometry for CD10, CD38, CD95 and CD27 expression at time of extraction and 3 
and 12 hours in culture in the presence or absence of CD40L. Cells have been gated as per Figure 3.1 to identify viable 
cells and the population of the two gates were combined. The resulting population of viable cells were used for 
analysis. Cells were not gated for CD10 expression. The results are displayed as both dot plots (A) and Mean 
Fluorescence Intensity (MFI) (B). There is a reduction in CD10 and CD38 intensity over time in culture. CD95 expression 
is retained over time; however there is an increase with CD40L stimulation. CD27 expression is reduced after 3h in 
culture, but is not further changed at 12h.  
C) Cells were analysed by western blotting for BCL6 at 1, 3 and 12 hours in culture in the presence or absence of 
CD40L (- or + respectively). BCL6 expression is drastically reduced by 12 hours in culture. The presence of CD40L 
partially rescues this phenotype. β-actin was used as a loading control.  
Data is representative of 3 replicates.  
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Figure 3.7: Effect of culture on the phenotype of isolated GC B cells 
Cells were analysed by flow cytometry for CXCR4, CD77, CD83 and CD86 expression at the time of extraction and after 
3 and 12 hours in culture in the presence or absence of CD40L. Cells have been gated as per Figure 3.1 to identify 
viable cells and the population of the two gates were combined. The resulting population of viable cells were used 
for analysis. Cells were not gated for CD10 expression. The results are displayed as both dot plots (A) and Mean 
Fluorescence Intensity (MFI) (B). 
There is an increase in CXCR4 intensity over time in culture, while CD77 intensity decreases. Both CXCR4 and CD77 
intensity increase in the presence of CD40L. The starting population of CXCR4lowCD83high and CXCR4lowCD86high 
centrocytes decrease by 3 hours in culture regardless of the presence of CD40L. However, there is an increase in CD83 
and CD86 intensity over time in culture, and this intensity is further increased in the presence of CD40L. This is 




Studies of the pathogenesis of Hodgkin’s lymphoma and of other related lymphoid 
malignancies have been difficult due to the lack of suitable models. When attempting to 
describe the pathogenic events responsible for the development of these tumours, we 
have used as models, cell lines. However, these models are unlikely to reveal the 
mechanisms responsible for the early stages of transformation, since this a process is 
already complete in cell lines. These cell lines are isolated from relapse patients with 
advanced disease and who received extensive chemotherapy. Once these cells lines are 
established in vitro, they are fully immortalised and no longer rely on their 
microenvironment for survival and growth. In the absence of suitable animal models, 
the manipulation of primary human GC B cells in vitro provides an alternative approach 
to study the early steps in B cell lymphomagenesis. For several years our group has 
employed the in vitro analysis of primary human GC B cells to this effect (Vockerodt et 
al., 2008, Vrzalikova et al., 2011, Leonard et al., 2011, Anderton et al., 2011). 
Since the initial partial characterisation of isolated GC B cells by our group, several new 
important observations on the GC B cell phenotype have emerged. For example, 
although CD77 expression has been used to discriminate between centroblasts and 
centrocytes, recently it has been reported that CD77+ and CD77- GC B cells have near 
identical transcription profiles and that CD77 alone does not discriminate between 
centroblasts and centrocytes (Hogerkorp and Borrebaeck, 2006, Klein et al., 2003). 
CXCR4 is highly expressed on the surface of human centroblasts and is now thought to 
be a better discriminator of centroblasts and centrocytes (Caron et al., 2009). 
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Furthermore, CD83 and CD86 have recently been identified on the surface of 
centrocytes and when used in conjunction with CXCR4 can more effectively distinguish 
centroblasts (CXCR4highCD83low or CXCR4highCD86low) and centrocytes (CXCR4lowCD83high 
or CXCR4lowCD86high) (Victora et al., 2012). 
We have yet to show how the expression of these new GC markers varies during the 
isolation and culture of primary human tonsillar GC B cells. In this chapter, I set out to 
rectify this deficiency by extensively characterising the phenotype of isolated and 
cultured human GC B cells. I have shown that CD10 positive cells isolated from fresh 
paediatric tonsils are viable and express typical GC B cell markers including CD10, CD38, 
CD95 and BCL6. The majority of these cells have a centroblast phenotype 
(CXCR4highCD83low or CXCR4highCD86low), while a minor population are centrocytes 
(CXCR4lowCD83high or CXCR4lowCD86high). There is only a minor contamination of T cells 
(<1%) and CD10+CD24+ transitional B cells (0.57%) in the isolated population.  
I also observed the expected induction of apoptosis in isolated GC B cells upon culture. 
Over 50% of these cells appear viable at 12 hours as measured by flow cytometry. 
However, while flow cytometric analysis can identify late apoptotic and necrotic cells 
(disrupted cell membranes allowing PI uptake, highly granular morphology and cell 
debris) it does not identify cells undergoing the initial stages of apoptosis. Western blot 
analysis revealed high levels of PARP cleavage in GC B cells as early as 3h in culture, with 
majority of PARP cleaved by 12h. This indicates that a large proportion of cells identified 
as viable by flow cytometry have initiated apoptosis. Performing annexin staining by 
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flow cytometry would give a more informative analysis of the proportion of apoptotic 
GC B cells.  
Analysis for PARP cleavage revealed that the addition of soluble CD40L can partially 
rescue GC B cells from apoptosis. This is consistent with previous reports showing that 
germinal centre B cells are partially protected from cell death by CD40L in culture 
(Hennino et al., 2001, Klein and Dalla-Favera, 2008, Liu et al., 1989). This indicated that 
the soluble CD40L used is functional.  
The use of the trimeric soluble CD40 ligand used in these experiments was originally 
optimised by Dr Martina Vockerodt in our group. Soluble CD40L was titrated with 
concentrations ranging from 1ng/µl to 2µg/µl and the re-gain of CD77 expression was 
used as a functional readout. Cells showed a dose-dependent re-expression of CD77. 
The concentration of 200ng/µl of CD40L was found to be saturating, resulting in the 
highest increase in CD77 expression. Additionally, up-regulation of ICAM1 following 
CD40L stimulation, as shown in the subsequent chapter, also indicates that soluble 
CD40L is functional. 
I observed that the expression of the majority of typical GC B cell associated molecules 
do not remain stable over time in culture. The GC B cell markers CD10, CD38 and CD77 
decreased in culture, while there is an increase in CXCR4, CD83 and CD86 expression in 
culture. This increase is reflected in the decrease of CXCR4lowCD83high or 
CXCR4lowCD86high centrocytes and in the increase of a population of cells displaying an 
‘intermediate’ phenotype, expressing high levels of both CXCR4 and CD83/CD86 
(CXCR4highCD83high or CXCR4highCD86high) and thus cannot be classed as centroblasts or 
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centrocytes. These ‘intermediate’ cells could be GC B cells cycling between centroblastic 
and centrocytic states; however one would expect only low numbers of cells to cycle. 
Therefore a more likely explanation is that the cells are becoming activated.  
The serum activation of GC B cells in culture is supported by the finding that there is a 
slight increase in cell size as measured by forward scatter and the increase in CD83 and 
CD86 expression, which is especially marked upon CD40L stimulation. Both CD83 and 
CD86 have been shown to be up-regulated following serum activation, a process which 
can also result in increased cell size. These observations, coupled together with the fact 
that the cells are cultured in the presence of serum, indicate that the cells are becoming 
activated. It is unlikely that cells are undergoing differentiation into plasma cells as there 
is no increase in CD38high and CD27high cells.  
The expression of BCL6 shows a marked decrease following 12 hours in culture. 
However, whereas following 3h of CD40L stimulation leads to a decrease in BCL6 
expression, at 12h CD40L stimulation appears to rescue BCL6 expression in GC B cells. 
This is unexpected as CD40 activation leads to the down-regulation of BCL6 expression. 
Most likely, the presence of BCL6 expression with CD40L stimulation is a result of the 
apoptosis protection mediated by CD40L. This would explain the loss of BCL6 expression 
in un-stimulated GC B cells, which would be highly apoptotic. One caveat is that β-actin 
(house keeping control) levels remain stable throughout the culture. However, β-actin 
is a highly stable molecule and is therefore likely to remain intact for longer during 
apoptosis.  
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Taking all the observations together, isolation and culture of CD10 positive tonsillar 
mononuclear cells for up to 3 hours can yield sufficient numbers of viable cells with a 
phenotype representative of GC B cells for experiments. However, a short coming of this 
model is that longer culture, of 12 hours, leads to marked cell death and serum 
activation of the cells, making the model less representative. This needs to be taken into 
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4 Comparison of the transcriptional programmes 
of LMP1 and CD40 in primary human GC B cells 
with a focus on the effects of the expression of 
lipid signalling genes 
 
4.1 Introduction 
Although LMP1 has been shown to be an oncogene that is expressed in germinal centre 
(GC)-derived lymphomas such as Hodgkin’s lymphoma, it is also believed to be 
expressed in the GC B cells of the healthy, where together with LMP2 it is thought to 
drive antigen independent GC reactions (Thorley-Lawson and Gross, 2004). Indeed 
LMP1 is thought to promote the differentiation of EBV infected GC B cells by acting as a 
mimic of the CD40 receptor (Gires et al., 1997). 
However, it is not entirely clear how LMP1 can exert its oncogenic effects while at the 
same time promoting a physiological CD40-like signal. Previous studies suggest that it is 
the constitutive nature of the LMP1 signal that is oncogenic (Homig-Holzel et al., 2008, 
Rastelli et al., 2008). In order to gain more insight into potential differences between 
LMP1 and CD40 that may explain LMP1’s oncogenic effects I compared the global gene 




4.2.1 Validation of the overlapping transcriptional programme of CD40 
and LMP1 in primary human GC B cells 
The starting point for this study was three existing arrays: 
1. An array that identified the transcriptional consequences of CD40L stimulation 
in GC B cells. This array consisted of nine biological replicates with matched un-
stimulated controls, harvested 3h after stimulation with 200ng/ml CD40L. 
(Experiments were performed in our laboratory by Dr Schrader) 
2. A previously published array which identified LMP1 mediated transcriptional 
effects in GC B cells (Vockerodt et al., 2008). This array consisted of three GC B 
cell replicates transfected either with LMP1 or with appropriate vector control. 
3. Re-analysis of a previously published dataset which compared the transcriptional 
profile of HRS cells with that of normal centrocytes (Brune et al., 2008). This array 
consisted of twelve HRS cell samples and five centrocyte samples. 
All three arrays were performed using the Affymetrix HG-U133 Plus2 platform and all 
the data sets were re-analysed using limma analysis with a fold change cut off of 1.5 and 
p < 0.001.  
Stimulation of GC B cells with CD40L identified 194 up-regulated probe sets, 
representing 147 unique genes and 268 down-regulated probe sets, representing 233 
unique genes. Transfection of GC B cells with LMP1 revealed 420 up-regulated probe 
sets, representing 327 unique genes and 628 down-regulated probe sets, representing 
532 unique genes. Comparison of the two arrays showed that 60 genes were up-
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regulated and 43 genes were down-regulated by both CD40 and LMP1 (Figure 4.1, 
appendix Table 7.1). This significant overlap between LMP1 and CD40 transcriptional 
profiles confirms the well described overlapping functions of these receptors 
(hypergeometric probability, p<1.317e-111).  
It is worth noting that some genes may appear to be regulated in opposite direction 
when using alternative probe sets. There are various possibilities why this might be the 
case. The Affymetrix HG-U133 Plus2 array mostly contains probe sets measuring the 3’ 
end of genes, but has redundant probe sets, which measure different regions of the 
same gene and thus may identify alternative splice forms. Not all probe sets identify 
unique genes, instead they may measure multiple genes, and thus it is not clear which 
transcript is differentially regulated. Additionally, with some probe sets the full extent 
of gene recognition is unknown, and thus they could potentially measure transcripts 
other than the one named. These three probe set variants are all marked in the probe 
label thus can be examined when looking at gene expression.  
I repeated the LMP1 transfection and CD40 stimulation in GC B cells derived from 
different tonsils. LMP1 expression in these tonsils was confirmed by qPCR (Figure 4.2). I 
next went on to examine ICAM1 protein expression following LMP1 transfection and 
12h CD40L stimulation of four GC B cell replicates. I chose the 12h time point to allow 
for ICAM1 protein expression following the increase in transcription observed at 3h. 
ICAM1 protein expression was significantly up-regulated by LMP1 transfection, and by 
CD40 stimulation (Figure 4.3a-b).  
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As ICAM1 is an NF-κB target gene, I decided to use an NF-κB reporter system, to show 
that LMP1 expression in GC B cells leads to a functional readout. For this I transfected 
isolated GC B cells with the appropriate vector and an NF-κB reporter plasmid which 
expresses GFP upon NF-κB activation. Cells were left in culture for 12h before analysis. 
There is a low level of NF-κB activation in the system (2.16%), as seen in the vector 





Figure 4.1: Summary of array comparison 
Comparison of the transcriptional programmes of CD40 and LMP1 in GC B cells. 
Venn diagrams showing numbers or genes up- or down-regulated by CD40 and LMP1 in GC B cells. Genes identified 
as differentially regulated in LMP1 and CD40 arrays with a fold change cut off of 1.5 and p<0.001  
 
 
Figure 4.2: LMP1 is strongly expressed following transfection in all for GC B cell samples 
LMP1 mRNA expression in transfected GC B cells relative to vector control transfected GC B cell from Tonsil 4. RNA 
isolated form transfected GC B cells was subjected to two rounds of amplification prior to RT-PCR analysis. LMP1 CT 
values were normalised to GAPDH expression, following which LMP1 expression was calculated as relative gene 
expression compared to vector control transfected Tonsil 4. Relative expression values were then plotted. Expression 




Figure 4.3: Up-regulation of ICAM1 and NF-κB following LMP1 transfection of GC B cells  
For all flow cytometric analysis, live cells have been identified based on morphology and PI negativity and gated as 
per Figure 3.1. The population of the two gates were combined, with the resulting population of viable cells used for 
analysis. Cells were not gated for NGFR or CD10 expression therefore changes in ICAM1 and GFP expression are small. 
a) ICAM1 up-regulation by LMP1 transfection as observed by flow cytometry, shown for T98. ICAM1 expression is 
shown on x-axis, CD10 expression (used to identify GC B cells) is shown on the y-axis. There is a high expression of 
ICAM1 in GC B cells. Expression levels shift higher following LMP1 transfection.  
b) Mean fluorescence intensity of ICAM1 in GC B cells (isolated from four tonsils) following LMP1 transfection and 
CD40L stimulation. 
c) GFP expression (x-axis) as a result of the successful activation of NF- κB following transfection.  
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4.2.2 Validation of LMP1 target genes not regulated by CD40 in primary 
human GC B cells and relevant to the pathogenesis of HL 
 
Next, I wanted to identify LMP1 target genes that are potentially relevant to the 
pathogenesis of EBV positive Hodgkin’s lymphoma. First, genes whose expression was 
altered by LMP1 but not by CD40L stimulation were identified. I found that LMP1 up-
regulated 267 and down-regulated 489 genes that were not differentially expressed 
following CD40 stimulation (Figure 4.4, appendix Table 7.2). This set of LMP1 target 
genes were compared to those genes differentially expressed in HRS cells compared to 
centrocytes Figure 4.4. This yielded a list of 62 up-regulated and 145 down-regulated 








Figure 4.4: Summary of array comparisons showing genes concordantly regulated by LMP1 and in HL 
Venn diagrams showing overlap between genes identified as regulated by LMP1 but not CD40, with those genes 
differentially expressed in HRS cells compared to centrocytes (fold change cut off of 1.5 and p<0.001). 
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Gene ontology analysis of the genes concordantly regulated by LMP1 and in HRS cells 
revealed that the majority of the genes transcriptionally altered belonged to five major 
biological groups: cellular process, metabolic process, cell communication, immune 
system process and developmental (Table 4.1). The cellular process category covers 
genes involved in cell growth and motility while the cell communication category covers 
components of cellular signalling pathways. Interestingly the immune system process 
category not only covers immune response genes, but also genes involved in 
macrophage activation. Differential regulation of these genes may be important for the 
recruitment of macrophages to the HL microenvironment.  
 
Table 4.1: Gene ontology analysis of LMP1 and HRS cell target genes 
Up-regulated by LMP1 and in HRS cells Down-regulated by LMP1 and in HRS cells 
Biological Processes Number of 
genes 
Biological Processes Number of 
genes 
metabolic process  27 cellular process  67 
cellular process  22 cell communication  48 
immune system process 22 metabolic process  47 
response to stimulus  15 developmental process  27 
developmental process  15 immune system process  23 
cell communication  14 system process  21 
transport  8 transport  19 
apoptosis  6 cell cycle  18 
system process  6 response to stimulus 16 
cell cycle  6 apoptosis  13 
cellular component organization  5 cell adhesion 12 
cell adhesion  5 cellular component organization  11 
reproduction  2 reproduction  6 
generation of precursor metabolites and energy  1 localization  2 




Twelve genes concordantly regulated by LMP1 (but not CD40) and in HRS cells were 
selected for qPCR analysis. I selected these genes on the basis that they were previously 
reported to be differentially expressed in HL or are known LMP1 target genes or that 
they had a potentially lymphomagenic function (Table 4.2).  
Table 4.2: LMP1 target genes selected for validation 








ATM DNA damage Down Yes Yes (Ma et al., 2011, Dutton et 
al., 2007, Bose et al., 2007) 
TNFAIP3 TNFR signaling and 
apoptosis 
Up Yes Yes (Schmitz et al., 2009a, 
Dirmeier et al., 2005) 
HSPA1A Apoptosis Up Yes Yes (Vrzalikova et al., 2011, 
Vockerodt et al., 2008) 
CCL5 Chemokine Up Yes Yes (Fischer et al., 2003, 
Buettner et al., 2007) 
STAT5A Transcription factor Up  Yes (Hinz et al., 2002) 
ID2 Transcription factor Up Yes Yes (Vockerodt et al., 2008, 
Renne et al., 2006) 
PTEN Tumour suppressor Down Yes  (Chen et al., 2013) 
RASSF6 Tumour suppressor Down    
CD72 B cell associated Down    
VPREB3 B cell associated Down Yes  (Vockerodt et al., 2008) 
S1PR2 Germinal centre regulation Down    
RGS13 Germinal centre regulation Down    
 
I chose to include a set of genes that have been well described to be altered by LMP1 
and in HRS cells, including ATM, TNFAIP3, HSPA1A, CCL5, STAT5A and ID2. I expected 
these genes to validate as LMP1 target genes, thus confirming that my GC B cell 
transfections with a LMP1-expression vector were successful. Furthermore, confirming 
that these genes are not regulated by CD40 stimulation, a physiological signal required 
for GC B cell survival, could imply that aberrant regulation of these genes by LMP1 plays 
a role in LMP1 mediated lymphomagenesis. 
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I was also interested in those B cell associated and tumour suppressor genes that were 
down-regulated by LMP1 and in HRS cells. Any such genes down-regulated by LMP1 but 
not CD40 could have a role in LMP1 mediated lymphomagenesis. In particular I was 
interested in the down-regulation of S1PR2 and RGS13, two molecules involved in the 
regulation of GC size and morphology.  
For this analysis, I used the same samples shown in Figure 4.2 as well as three repeats 
of CD40L stimulation. Genes were defined as differentially expressed if they showed 
significant difference in 3 out of 4 LMP1 transfected GC B cells or 2 out of 3 CD40L 
stimulated GC B cells at either time point (1-tailed T-test, p<0.05). I failed to confirm the 
observed changes in PTEN (Figure 4.5a). I found a further 5 genes which were regulated 
by LMP1 and CD40; VPREB3, TNFAIP3, HSPA1A, STAT5a and ID2 (Figures 4.5b-f). Three 
genes, ATM, RASSF6 and RGS13 were regulated by CD40 alone (Figures 4.5g-i) and three 





Figure 4.5: Validation of genes concurrently regulated by LMP1 and in HRS cells 
Gene expression in LMP1 transfected GC B cells relative to vector control and in CD40L stimulated GC B cells, relative 
to 0h isolated control. RT-PCR analysed by ddCT method with resulting relative gene expression plotted on the y-axis. 
The LMP1 mediated fold change from the array analysis is indicated for each gene. Where multiple probe-sets were 
identified both fold change values are included.  
For the comparison of vector control and LMP1 transfected GC B cells, the cells were cultured for 12h post 
transfection followed by sorting based on CD10 and NGFR positivity and PI negativity prior to RNA isolation. For the 
CD40L stimulated samples the brackets indicate the samples that were compared, namely non-stimulated versus 
CD40L stimulated GC B cells at 3h and at 12h time points.  
* Denotes gene significantly altered (p<0.05) 
# Denotes gene significantly altered, but opposite direction to array result (p<0.05).  
The analysis shows that VPREB3, TNFAIP3, HSPA1A, STAT5a and ID2 were LMP1 and CD40 targets, ATM, RASSF6 and 
RGS13 were CD40 targets and CCL5, CD72 and S1PR2 were LMP1 targets.  




Validation shown for HSPA1A, STAT5a, ID2, ATM and RASSF6 (D-H). In STAT5A N/A, there was no STAT5 expression in 
vector control, but there was expression in the LMP1 transfected sample.  
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Validation shown for RGS13, CCL5, CD72 and S1PR2 (I-L). In RGS13 N/A, sample was exhausted. In S1PR2 N/A, there 
was no S1PR2 expression in Tonsil 3, and sample was exhausted for Tonsil 4. 
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4.2.3 S1PR2 mRNA expression predicts survival in DLBCL and its over-
expression reduces tumour cell migration in a HL cell line model 
S1PR2 is a receptor for sphingosine 1 phosphate (S1P), a bioactive lipid signalling 
molecule that has been implicated in cancer (Pyne and Pyne, 2010). There are 
indications that S1PR2 functions as a tumour suppressor. S1PR2 has been shown to 
reduce the migration of melanoma cells in response to S1P (Arikawa et al., 2003), 
somatic mutations in S1PR2 have been found in around a quarter of DLBCL cases tested 
in a study and S1PR2 null mice have been shown to develop DLBCL with age (Cattoretti 
et al., 2009). 
Having shown that S1PR2 transcription is down-regulated by LMP1 expression in GC B 
cells, I next wanted to look at S1PR2 expression in primary HL and DLCBL cases. I first 
optimised the S1PR2 antibody. I transfected DG75 cells, a Burkitt’s lymphoma cell line, 
with vector control and an S1PR2 expression plasmid which contained a haemagglutinin 
(HA) tag. I failed to validate the antibody in western blot or flow cytometry. I validated 
the antibody for immunohistochemistry (IHC), showing specific S1PR2 staining in the 
transfected cells, similar to that seen when staining for the HA tag (Figure 4.6). The faint 
S1PR2 staining seen in vector control cells is localised to the membrane and most likely 






Figure 4.6: Validation of the S1PR2 antibody in IHC 
DG75 cells were transfected with vector control or S1PR2-expression plasmid. Cells were stained for HA tag, showing 
no staining in vector control (A) and positive staining (in brown) in a proportion of S1PR2 transfected cells (B). S1PR2 
staining shows faint staining in vector control cells (C) and similar level of positive staining as HA, in S1PR2 transfected 
cells (D).  
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I then used immunohistochemistry to look at S1PR2 expression in 155 HL and 169 DLBCL 
cases that were available to me. Staining for S1PR2 revealed that only 13/155 HL and 
53/169 DLBCL cases had S1PR2 expression. Examples of S1PR2 and LMP1 staining in HL 
(Figure 4.7) and DLBCL (Figure 4.8) are shown. I then set out to examine LMP1 expression 
in these cases. I stained the HL cases for LMP1, while the DLBCL cases were subjected to 
EBER in situ hybridisation by Dr Gary Reynolds, Immunity and Infection, University of 
Birmingham. EBER positive cases were then stained for LMP1 expression. The results of 
the LMP1 and S1PR2 staining are summarised in Table 4.3 for the HL and Table 4.4 for 
the DLBCL cases. The correlation between LMP1 expression and S1PR2 status was 
significant in the DLCBL cases (Fisher’s exact test, p=0.0318), but not the HL cases 
(Fisher’s exact test, p=0.0635). 
I also examined the correlation between S1PR2 protein expression in DLBCL and patient 
survival in a cohort of 300 patients of which S1PR2 expression was measured in 167 
patients (53 positive and 114 negative cases). There was no significant correlation 
between S1PR2 expression and survival in these cases (Figure 4.9a-b). Furthermore, 





Figure 4.7: S1PR2 and LMP1 expression in HL 
Immunohistochemistry staining of tonsil (A) and HL (B-D) tissue for S1PR2 expression, and HL tissue for LMP1 
expression (E-F). Examples of both negative (B, E) and positive (C-D, F) staining shown. Black arrows indicate negative 
tumour cells (B, E) while positive tumour cells are stained in brown (C-D, F). White arrows indicate the internal control 
(staining of erythrocytes in HL). 
The GC of tonsil are positive for S1PR2, with the surrounding mantle zone (MZ) negative. Higher magnification of 
S1PR2 positive tumour cells shows membrane specific staining (D).  




Figure 4.8: S1PR2 and LMP1 expression in DLBCL  
Immunohistochemistry staining of tonsil (A) and DLBCL (B-D) tissue for S1PR2 expression, and DLBCL tissue for LMP1 
expression (E-F). Examples of both negative (B, E) and positive (C-D, F) staining shown. Black arrows indicate negative 
tumour cells (B, E) while positive tumour cells are stained in brown (C-D, F). White arrows indicate the internal control 
(staining of seminiferous tubules of the testis in DLBCL). 
The GC of tonsil are positive for S1PR2, with the surrounding mantle zone (MZ) negative. Higher magnification of 
S1PR2 positive tumour cells shows membrane specific staining (D).  




Table 4.3: LMP1 and S1PR2 expression in 155 Hodgkin's lymphoma cases * 
 S1PR2 + S1PR2 - Total 
LMP1 + 8 46 54 
LMP1 - 5 96 101 




Table 4.4: LMP1 and S1PR2 expression in 169 Diffuse large B cell lymphoma cases * 
 S1PR2 + S1PR2 - Total 
LMP1 + 0 10 10 
EBER - 53 106 159 




* Cases were reviewed by two independent pathologists and scored as 
positive when over 10% of tumour cells displayed positive staining. 
* Cases were reviewed by two independent pathologists and scored as 
positive when over 10% of tumour cells displayed positive staining. 
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Figure 4.9: S1PR2 protein expression and DLBCL survival  
Kaplan-Meier curve showing the correlation between survival and S1PR2 status or disease subtype. For event-free 
survival, an event is defined as relapse/progression or death without relapse/progression.  
S1PR2 expression does not correlate with overall survival (p=0.328) (A) or event-free survival (p=0.156) (B).  
DLBCL subtype does not correlate with overall survival (p=0.073) (C) or event-free survival (p=0.056) (D). 
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I also had access to a re-analysis of a published array of pre-treatment tumour gene 
expression profiles of 414 DLBCL patients (Lenz et al., 2008b) of which 181 patients 
received CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) and 233 
received R-CHOP (CHOP with addition of rituximab) therapy. Analysis revealed that low 
S1PR2 expression correlates with decreased survival in these patients in both treatment 
groups (Figure 4.10a-b). However, S1PR2 level was significantly higher in GCB DLBCL 
compared to ABC DLBCL in both treatment groups (Figure 4.10c), and GCB DLBCL has a 
significantly better survival then ABC DLBCL (Figure 4.10d-e). S1PR2 expression was not 
significantly correlated with survival in the ABC or GCB subtypes separated by the 




Figure 4.10: S1PR2 expression in pre-treatment tumour predicts survival  
a-b) Survival analysis showing that low S1PR2 expression (red line) correlates with reduced survival in the cohort of 
patients receiving CHOP (A) and R-CHOP (B) therapy (p=0.0000355 and p=0.000414 respectively). 
c) Boxplot showing S1PR2 expression is lower in the ABC compared to the GCB subtype of DLBCL for both the CHOP 
and R-CHOP treatment cohorts (Mann-Whitney p values: CHOP p=3.70e-20, R-CHOP p=3.48e-21) 
d-e) Survival analysis showing that ABC DLBCL (red line) correlates with reduced survival in the cohort of patients 




Figure 4.11: S1PR2 expression does not predict survival in ABC and GCB DLBCL stratified by treatment  
Kaplan-Meier curve showing the correlation between survival and S1PR2 status in four cohorts defined based on 
disease subtype and therapy received. These are patients with: ABC subtype DLBCL receiving CHOP therapy (A) GCB 
subtype DLBCL receiving CHOP therapy (B) ABC subtype DLBCL receiving R-CHOP therapy (C) GCB subtype DLBCL 
receiving R-CHOP therapy (D) 
The survival analysis showed no significant correlation between S1PR2 status and survival in the four patients cohorts 
(p=0.425 (A), p=0.864 (B), p=0.182 (C), p=0.536 (D)). 
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Having found that S1PR2 is low in most primary HL and DLCBL cases, I next set out to 
investigate which HL and DLBCL cell lines re-capitulate this phenotype, as this will be an 
important factor. I found that compared to normal isolated GC B cells, S1PR2 expression 
varies among the cell lines, with most having a lower expression than GC B cells (Figures 
4.12-4.13). Of the HL cell lines, L591 expresses the highest level of S1PR2 (Figure 4.12). 
This is unexpected as this cell line expresses high levels of LMP1. However, this cell line 
is highly heterogeneous for S1PR2 expression levels and it is possible that those cells 
with high S1PR2 expression do not express LMP1 or have low level of expression. In fact, 
when L591 cells are stained for LMP1 and S1PR2 expression by immunofluorescence the 
S1PR2 expressing cells appear to be either negative for LMP1 expression or have low 
LMP1 expression compared to cells expressing LMP1 alone, as shown in Figure 4.12b. 
However, this result is not conclusive. S1PR2 staining by immunofluorescence is weaker 
than staining by immunohistochemistry, thus cells with low S1PR2 expression may not 
be visible using this method.  
Of the DLBCL cell lines U2932 and Ocily3 appear to have the lowest S1PR2 expression 
(Figure 4.13). These cell lines are classed as ABC subtype and thus are expected to have 
lower S1PR2 expression than GCB subtype cell lines. As with the HL cell lines, the EBV 




Figure 4.12: S1PR2 expression in HL cell lines 
a) S1PR2 mRNA and protein expression HL cell lines. RT-PCR analysed by ddCT method with resulting gene expression 
relative to Tonsil 1 plotted on the y-axis. L591 is an EBV positive cell line, expressing high levels of LMP1. S1PR2 
staining (brown) on two cell lines with low S1PR2 expression (L540 and L428) and one with higher expression (L591, 
black arrow indicated positive, white arrow negative staining). Cell nucleus is stained in blue. Pictures taken at 40x 
magnification. 
b) S1PR2 (green) and LMP1 (red) expression in L591 cells as shown by immunofluorescence. Pictures taken at 40x 






Figure 4.13: S1PR2 expression in DLBCL cell lines 
S1PR2 mRNA and protein expression DLBCL cell lines (U2932 and OCILY3 are classed as ABC type, while the rest are 
GCB type).  
a) RT-PCR analysed by ddCT method with resulting gene expression relative to Tonsil 1 plotted on the y-axis. Farage 
is an EBV positive cell line that expresses LMP1.  
b) S1PR2 staining (brown) on one cell line with low S1PR2 expression (U2932) and one with higher expression 
(SUDHL4). Cell nucleus is stained in blue. Pictures taken at 40x magnification 
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Finally, I investigated if the over-expression of S1PR2 affected the migration of a HL cell 
line. I transfected L428 cells (which have low S1PR2 expression) with either vector 
control or an HA tagged S1PR2 expression plasmid. Before studying migration I first 
confirmed the expression of S1PR2 in S1PR2 transfected cells by qPCR (Figure 4.14a) and 
showed that in the five replicates transfection efficiency as observed by IHC for the HA 
tag was 18% (Figure 4.14b). The low transfection efficiency is consistent with previous 
observations from our lab that HA IHC underestimates transfection efficiency. 
Cell migration was determined using a fluorescent dye (DiOC) which incorporates into 
the cell membrane. Cells were stained and resuspended in serum free media prior to 
the assay, placed into transwells and media with 10% FCS used as a stimulus. Migration 
was measured by fluorescence at 6h, 24h and 48h. I found that S1PR2 overexpression 
significantly reduced the migration of L428 cells in all replicates (Figure 4.14c). I also 
measured cell proliferation using a luminescence based assay and found that S1PR2 




Figure 4.14: Over-expression of S1PR2 in L428 cells leads a reduction in migration  
a) S1PR2 mRNA expression in S1PR2 transfected samples showing S1PR2 up-regulation in transfected samples. RT-
PCR analysed by ddCT method with resulting relative gene expression to vector control (pcDNA3.1) plotted on the y-
axis. 
b) Immunohistochemistry for HA tag (brown) in transfected L428 cells, used to obtain transfection efficiency. Cell 
nucleus is dyed in blue. Pictures taken at 40x magnification. Overall 5 transfections with transfection efficiency 
ranging from 10-28% (mean 18%). 
c) Migration assay on cells from transfections. Cells were dyed with DiOC dye, resuspended in serum free media and 
placed into the top of the transwell chambers. The bottom of each well contained media with 10% FCS. At the 
indicated time points fluorescence in the bottom well was measured. Presence of S1PR2 lead to a significant reduction 
in migration at all of the time points (p<0.05). 
d) Proliferation assay on cells from transfections showing no significant difference in proliferation between vector 




Having established that the isolation and short-term culture of GC B cells can provide a 
representative in vitro model, I set out to address an important question in the 
lymphoma field, that of the difference between the apparently similar signalling 
molecules; LMP1, a viral oncogene, and its physiological homologue CD40. I showed that 
while there is considerable overlap between the transcriptional programmes of LMP1 
and CD40 in GC B cells, there are a subset of genes which were regulated by LMP1, but 
not by CD40, in these cells and which were also concordantly differentially expressed 
when primary HRS cells were compared to normal centrocytes. These genes have the 
potential to be involved in the oncogenic functions of LMP1, at least in the context of 
Hodgkin’s lymphoma.  
It is important to note that the microarray analysis of HRS cell transcriptional profile has 
limitations. Namely, as I have shown in the previous chapter, the majority of isolated GC 
B cells are centroblasts, and thus they are more representative of the GC B cell 
population, the non-pathogenic counterpart of HRS cells. By contrast, the analysis used 
centrocytes as the representative GC B cell population. Furthermore, the original paper 
used CD77 status to differentiate between centrocytes and centroblasts. Although 
originally believed to be a specific marker of centroblasts, it has recently been reported 
that CD77+ and CD77- GC B cells have near identical transcription profiles and that CD77 
alone does not discriminate between centroblasts and centrocytes (Hogerkorp and 
Borrebaeck, 2006, Pascual et al., 1994, Klein et al., 2003). Thus a new analysis comparing 
HRS cell transcriptional profile to that of centroblasts and centrocytes combines is in 
114 
progress. This analysis will provide a more accurate description of pathogenic 
transcriptional changes in HRS cells. 
I next repeated the LMP1 transfection and CD40 stimulation using GC B cells derived 
from different donors, following which I validated the samples. I used qPCR analysis to 
confirm LMP1 expression in the LMP1 transfected GC B cells. I chose this method as 
there are very low numbers of cells obtained following transfection and sorting of GC B 
cells, typically around 104 cells per treatment. As an alternative method, some of the 
sorted cells could be spotted onto microscope slides and analysed for LMP1 expression 
by immunohistochemistry, however, extremely low numbers of cells could be used for 
this. 
I showed LMP1 expression in all four replicates. However, there are limitations to this 
experiment. First, there are no controls, and the use of RNA from an LMP1 positive and 
a negative cell line would have been informative. Using an LCL control would in 
particular be valuable as LCLs express high levels of LMP1 and thus can give an 
estimation of the level of LMP1 expression following transfection. However, due to the 
nature of the RNA sample used, doing these comparisons was not possible. As the level 
of RNA obtained from the sorted GC B cells is extremely low, the RNA was subjected to 
two rounds of RNA amplification. As this process was not done with cell line RNA, direct 
comparison by qPCR is not informative. The amplification process itself is a limitation, 
as it cannot rule out the possibility of DNA amplification from the plasmid itself.  
I next showed ICAM1 up-regulation following both LMP1 transfection and CD40L 
stimulation of GC B cells. Although statistically significant, the changes in ICAM1 
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expression were marginal. This is a consequence of the flow cytometric analysis in which 
the total cell population was used for measuring ICAM1 expression. Sorting the GC B 
cells based on NGFR expression prior to analysis to select for transfected cells would 
result in a clearer measurement of ICAM1 expression following LMP1 transfection.  
I next selected 12 LMP1 but not CD40 target genes that were also concordantly 
regulated in HRS cells for validation. The majority of the selected genes (8 in total) were 
identified as CD40 targets using qPCR analysis. This can be in part explained by qPCR 
analysis being more sensitive than microarray. While the LMP1 and HRS cells microarray 
analysis showed robust fold changes in gene expression, the CD40 microarray analysis 
showed only small fold changes in transcription, rarely reaching 2 fold, and thus using 
the threshold of 1.5 fold change may exclude many CD40 target genes. Also, the probes 
for the qPCR validation were specifically selected for best overall coverage of each gene. 
Another explanation is that in the validation a shorter time point of 1h stimulation was 
also looked at. This allows for the identification of even shorter-term transcriptional 
changes induced by CD40L stimulation, then the 3h time point used for the array. 
I confirmed using qPCR, that three of these genes, CCL5, CD72 and S1PR2, were 
regulated by LMP1 but not CD40 in GC B cells. CCL5 is a known LMP1 target gene and its 
expression is believed to contribute to the microenvironment of HRS cells (Fischer et al., 
2003). CD72 is a B cell receptor (BCR) co-receptor that down-regulates BCR signalling (Li 
et al., 2006). S1PR2 is a receptor for sphingosine 1 phosphate (S1P), a bioactive lipid 
signalling molecule that has been implicated in cancer (Pyne and Pyne, 2010). Given its 
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emerging role in normal GC B cell physiology and lymphoma development I decided to 
focus on S1PR2. 
S1PR2 is a G protein coupled receptor that signals mainly through G12/13, and can 
regulate GC B cell survival and migration in response to sphingosine 1 phosphate (S1P) 
(Green and Cyster, 2012). In mice, S1PR2-null GC B cells display unlimited growth 
following chronic antigen stimulation in vivo resulting in enlarged and less well defined 
GCs (Green et al., 2011). Furthermore, S1PR2 deficiency in mice leads to the 
development of DLBCL, while in humans over one-quarter of patients with DLBCL have 
multiple somatic mutations in the 5' sequences of the S1PR2 gene (Cattoretti et al., 
2009). These observations suggest that LMP1 down-regulation of S1PR2 in GC B cells 
might promote lymphomagenesis by permitting the unlimited growth of these cells. 
In further support of the notion that LMP1 could disrupt normal GC development and 
promote lymphoma development, it has previously been shown that LMP1 expression 
in the B cells of transgenic mice leads to a block in GC development (Uchida et al., 1999). 
Immunisation of these transgenic mice with an antigen led to the secretion of high-
affinity IgG that could be detected in the serum and the follicular structures in the spleen 
were intact. This could imply that the block in GC formation observed in LMP1 expressing 
transgenic mice could in part be due to LMP1 mediated down-regulation of S1PR2 
leading to the disruption of GC architecture.  
I have made several observations which suggest that the loss of S1PR2 expression might 
contribute to lymphomagenesis. First, I showed that S1PR2 expression was absent in the 
tumour cells of the majority of cases of Hodgkin’s lymphoma and diffuse large B cell 
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lymphoma. Second, a re-analysis of a published microarray data set revealed that lower 
levels of S1PR2 mRNA expression were associated with adverse outcome in DLBCL; an 
observation that could be explained by the significantly lower expression of S1PR2 in the 
ABC subtype of DLCBL, the subtype associated with poorer outcome. In this context it is 
also important to note that EBV is associated with ABC-, but not GC-type, DLBCL (Oyama 
et al., 2007, Montes-Moreno et al., 2012).  
As I have shown that LMP1 leads to down-regulation of S1PR2 transcription in GC B cells, 
I was interested in examining if LMP1 is likely to mediate the loss of S1PR2 in primary HL 
and DLBCL cases. Using the immunohistochemistry data (summarised in Tables 4.2 and 
4.3), I performed statistical analysis and showed that LMP1 positive cases of DLBCL but 
not HL were significantly more likely to lack S1PR2 expression then their LMP1 negative 
counterparts. However, there are limitations to this analysis. Although I showed that the 
majority of LMP1 positive cases of HL and DLBCL are negative for S1PR2 expression, the 
staining was performed on separate sections, and thus it cannot be ruled out that a 
proportion of LMP1 expressing cells do in fact also express S1PR2.  
Ideally double-staining for LMP1 and S1PR2 expression on the same section would give 
a more accurate description of S1PR2 expression on the LMP1 positive tumour cells. 
Double staining by immunohistochemistry is challenging but possible when the proteins 
of interest are expressed in separate compartments of the cell. In this process the 
section would be stained first for one protein, then for the other, using different 
detection substrates that result in the formation of different coloured products. 
However, when both antigens of interest are expressed in the same location, such as 
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LMP1 and S1PR2 which are both membrane proteins, using double staining would not 
allow for differentiation between the two detection colours. Double-
immunofluorescence is a useful technique in visualising multiple proteins in cells. I am 
currently in the process of optimising this technique for the detection of LMP1 and 
S1PR2 on tissue sections.   
There is a further limitation to the analysis of LMP1 and S1PR2 expression in HL and 
DLBCL cases, namely that there are several LMP1 negative cases that also lack S1PR2 
expression. In these cases it is clearly not LMP1 that drives the loss of S1PR2 expression. 
As mentioned previously, over one-quarter of patients with DLBCL have multiple 
somatic mutations in the 5' sequences of the S1PR2 gene, thus it is highly likely that 
other factors are involved in the down-regulation of S1PR2 expression in the EBV 
negative cases of HL and DLBCL. This indicates that while LMP1 may play a role in the 
loss of S1PR2 in EBV positive disease, it is not the only contributing factor in this loss and 
other processes, such as mutations, may also contribute to S1PR2 loss in HL and DLBCL.  
In this chapter I have shown that there is a loss of S1PR2 expression in primary HL and 
DLBCL cases, and that in DLBCL the loss of S1PR2 at the RNA level can predict for worse 
disease outcome. The link between the loss of S1PR2 expression and adverse outcome 
in DLBCL can be explained in different ways. First, as the S1PR2 negative GC B cells in 
mice display increased growth, it is probable that loss of S1PR2 can contribute to the 
expansion of tumour cells in DLBCL. Furthermore, uncontrolled cell growth can increase 
the likelihood of cells acquiring and surviving secondary oncogenic hits. However, I 
observed no change in cell proliferation following S1PR2 over-expression in an HL cell 
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line. Second, loss of S1PR2 expression could result in increased tumour angiogenesis. 
The loss of S1PR2 has been shown to contribute to solid tumour growth and 
angiogenesis in mice (Du et al., 2010) while several studies have reported adverse 
outcomes for HL and DLBCL patients displaying increased tumour micro-vessel density 
(Korkolopoulou et al., 2005, Cardesa-Salzmann et al., 2011, Ribatti et al., 2013). Third, 
the loss of S1PR2 can increase cell survival. Mice with S1PR2 deficient GC B cells showed 
reduced apoptosis as compared to their wild type counterparts (Green et al., 2011). 
Finally, the loss of S1PR2 expression could contribute to the spread of lymphoma. S1PR2 
has been shown to reduce the migration of glioblastoma and melanoma cells in 
response to S1P (Arikawa et al., 2003, Lepley et al., 2005). In support of this latter 
possibility I showed that S1PR2 over-expression in an HL cell line inhibited migration 
toward serum. As serum is known to contain S1P, it is likely that the inhibition of cell 
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5 Optimisation of the PathDetect system for 
detection of LMP1 and CD40 induced signalling 
pathways in GC B cells 
 
5.1 Introduction 
In the previous chapter, I showed that while there was a considerable overlap between 
the transcriptional programmes of LMP1 and CD40 in GC B cells, a large group of genes 
were differentially regulated only by LMP1. However, I wanted to also examine the 
differences in signalling pathway activation between LMP1 and CD40 in GC B cells. 
Quantification of signalling pathway activation can be difficult in this cell system due to 
the very low numbers of cells available for analysis. Thus, in this chapter I set out to 
establish a method that allows for the detection of signalling pathway activation by 
LMP1 and CD40 in GC B cells with high sensitivity. 
The PathDetect trans-reporting system works through the transfection of the gene of 
interest, a trans-activator (such as ATF2) and a reporter gene into cells, whereby 
phosphorylation of the trans-activator can be measured by luciferase activity (Figure 
5.1). The reporter plasmid has been modified by Dr Vockerodt to express GFP upon 
activation. This allows direct detection of positive cells by flow cytometry allowing for 
the measurement of transcription factor activation in low numbers of cells. This is crucial 
when looking at GC B cells, where only low numbers of cells are available. 
There are six PathDetect trans-reporting systems available. Of these, I chose to analyse 
the C/EBP homologous protein (CHOP) and activating transcription factor 2 (ATF2) 
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PathDetect systems, which are available to measure p38 MAPK and JNK activity, 
respectively. I chose these two systems as aberrant activation of both the p38 MAPK 
and JNK pathways are implicated in the pathogenesis of Hodgkin’s lymphoma. 
Furthermore, these pathways are activated by numerous stimuli, including LMP1 and 
CD40 (Figure 5.2). Thus these two PathDetect systems provide strong read-outs for 
LMP1 and CD40 signalling making them ideal for the establishment of the system in GC 






Figure 5.1: The PathDetect trans-system 
The PathDetect trans-system works through the transfection of the gene of interest, a trans-activator (such as ATF2) 
and a reporter plasmid into the cells, whereby activation of specific pathways can be measured. The trans-activator 
is a fusion protein of GAL4 and a specific transcription factor, and upon phosphorylation by the protein of interest, 
the trans-activator forms dimers allowing the GAL4 fragment to bind to the GAL4 UAS site on the reporter plasmid, 
thus initiating transcription. In the modified reporter plasmid the luciferase gene is replaced by GFP, therefore 
reporter activation results in GFP production which can be measured by flow cytometry. Diagram taken from the 







Figure 5.2: The p38 MAPK and JNK signalling pathways  
Several internal and external stimuli activate the p38 MAPK and JNK pathways, through the action of a variety of cell 
surface receptors. Activation of MEKK (MAP3K) results in the activation of MKK4 and MKK7 (MAP2K4 and MAP2K7) 
which in turn phosphorylate JNK, leading to JNK dimerization and phosphorylation of ATF2. Activation of MEK3 




5.2.1 Optimisation of the CHOP and ATF2 PathDetect systems in BL2 
cells 
 
I first tested if I could activate the CHOP and ATF2 PathDetect systems in a Burkitt’s 
lymphoma cell line, BL2. I chose this cell line because transgene expression is efficient 
and cell death low after transfection. I transfected BL2 cells with the CHOP and ATF2 
PathDetect systems, consisting of the CHOP or ATF2 trans-activator plasmids, the GFP 
reporter plasmid and either a positive control plasmid or an empty vector control. The 
positive control for the CHOP system is MEK3, a known activator of p38 MAPK, while the 
positive control for the ATF2 system is MEKK, a known activator of JNK. Transfection 
with the empty plasmid should not lead to pathway activation. 
I used increasing amounts of trans-activator plasmid to test pathway activation in these 
systems. Figure 5.3 shows that both the CHOP and ATF2 systems can be activated by 
their respective positive control plasmids in BL2 cells, and that activation does not 
increase with increased concentrations of trans-activator. However, BL2 cells display a 




Figure 5.3: Optimisation of the PathDetect system in BL2 cells 
GFP expression (x-axis) as a result of the successful activation of the trans-activator (CHOP or ATF2) is plotted against an empty fluorescence channel. 
A) MEK3 positive control (top row) and vector control (bottom row) transfected BL2 cells with increasing amount of CHOP trans-activator (1, 2 and 4µg). Increasing the concentration of 
the CHOP trans-activator did not result in increased GFP production. There is a basal level of CHOP activation in these cells, as shown by low level GFP production in vector control cells.  
B) MEKK positive control (top row) and vector control (bottom row) transfected BL2 cells with 1µg and 4µg of ATF2 trans-activator. Increasing the concentration of the ATF2 trans-
activator did not result in increased GFP production.  
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5.2.2 Optimisation of the CHOP and ATF2 PathDetect systems in GC B 
cells 
 
I next tested the CHOP and ATF2 systems in primary GC B cells. I transfected GC B cells 
with the CHOP and ATF2 systems, using the positive control and control vector. I also 
transfected these cells with an LMP1 expression vector, to test if LMP1 signalling can 
activate ATF2 in GC B cells. The control and LMP1 expression vectors both express a 
truncated form of the low-affinity nerve growth factor receptor (ΔLNGFR). This molecule 
is expressed on the cell surface, but has no signalling capability, allowing transfected 
cells to be identified by flow cytometry. Figure 5.4a shows that only viable transfected 
(ΔLNGFR) expressing cells were selected for the analysis. For the purpose of the analysis, 
cells were visualised on CD10 positivity and GFP expression.  
Figure 5.4b shows that the positive control plasmid activated the ATF2 trans-activator. 
However, the positive control plasmid failed to activate the CHOP trans-activator above 





Figure 5.4: Optimisation of the PathDetect system in GC B cells  
A) Gating strategy showing gating for viable cells based on morphology (Forward scatter/side scatter) and propidium 
iodide negativity. Viable cells were further selected for CD10 and NGFR co-expression to identify transfected GC B 
cells. As the cells were not re-stained with CD10-PE prior to analysis, the large population of CD10 negative cells is 
most likely due to the loss of CD10-PE antibody from the cell surface during time spent in culture. 
B) GFP expression in viable CD10 positive GC B cells as a result of the successful activation of the trans-activator. 
MEK3 positive control fails to activate the CHOP trans-activator, while LMP1 expression results in activation, as shown 
by increased GFP production (top row). Both the MEKK positive control and LMP1 activate ATF2 (bottom row).  
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5.3 CD40L stimulation of the ATF2 PathDetect system in GC B cells 
 
I next wanted to use the PathDetect system to measure the effects of short-term CD40L 
stimulation on pathway activation in GC B cells. I chose the ATF2 system as it could be 
activated by the MEKK positive control plasmid and showed minimal basal activation in 
GC B cells.  
I transfected GC B cells with empty vector and with the components of the ATF2 
PathDetect system (including one sample with MEKK positive control). Six hours post 
transfection, half of the vector control cells were stimulated with 200ng/µl CD40L for 6 
hours (cells in culture for a total of 12 hours). Figure 5.5, shows that short-term CD40L 







Figure 5.5: Combination of the PathDetect system with CD40L stimulation  
GFP expression in viable CD10 positive GC B cells as a result of the successful activation of the trans-activator.  






One of the greatest challenges with working with GC B cells is the low cell numbers 
isolated. The use of the PathDetect system can overcome this limitation by providing 
information on pathway activation in less than 105 cells. I have shown that the CHOP 
and ATF2 PathDetect systems can be activated in BL2 cells and that the ATF2 system can 
also be activated in GC B cells. In contrast, both systems are activated by LMP1 in GC B 
cells.  
Combining the ATF2 PathDetect system with CD40L stimulation did not result in 
pathway activation. Six hours of CD40L stimulation provides only a momentary snapshot 
of pathway activation, and is most likely too long. It is highly likely that pathway 
activation induced by CD40 ligation is oscillating, resulting in varying levels of down-
stream pathway activation over-time. Therefore, a time course of CD40L stimulation 
ranging from 1-12 hours would provide a more comprehensive picture of CD40 
mediated ATF2 activation, from which the time point with the greatest activation can be 
selected. Additionally, 6 hours may not be long enough for the expression of the system 
component in the cells, and a longer time point may be required. Alternatively, GC B 
cells could be transfected with a constitutively active CD40 construct. Although signal 
provided by such construct may not be physiological, it may provide some insight into 
CD40 signalling.  
These results indicate that while the PathDetect system might be a useful method to 
detect LMP1 induced signalling pathway activation in GC B cells, it may not be good for 
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detecting short-term CD40 induced pathway activation. An alternative method would 
be to perform western blotting on the LMP1 transfected and CD40L stimulated GC B 
cells and examine the phosphorylation status of various pathway components. While 
this method works well with cell lines, using it with GC B cells, where only low numbers 
of cells are available, remains difficult. One way to overcome this limitation would be to 
pool cells from different experiments, thus increasing cell numbers. Alternatively, 
enzyme-linked immunosorbent assay (ELISA) could be performed to look for 
phosphorylation status of various pathway components. The advantage of performing 
an ELISA is that this assay is more sensitive than traditional western blotting, thus lower 











6 Future Work 
The work presented in this thesis identified a number of areas of future study. 
During the investigation of the transcriptional changes induced by LMP1 and CD40 in GC 
B cells, I have showed that LMP1 but not CD40 can down-regulate the expression of 
S1PR2 in GC B cells. It has previously been shown that the knock-down of S1PR2 
expression in the B cells of mice leads to unlimited growth following chronic antigen 
stimulation, the disruption of GC architecture and to the development of diffuse large B 
cell lymphoma. Exploring how LMP1 regulates S1PR2 expression might provide insights 
into the regulation of S1PR2 in normal tissue as well as in other cancers. 
I also showed that over-expression of S1PR2 in L428 cells can reduce cell migration in 
response to serum. The oncogenic lipid, S1P, is abundant in serum, and its binding to 
S1PR2 could contribute to the reduced migration of L428 cells. L428 cells express S1PR1 
on their cell surface and S1PR1 has been shown to be involved in lymphocyte migration 
from tissue to plasma in response to S1P (Matloubian et al., 2004). It will therefore be 
important to establish if the migration of L428 cells is dependent on S1P mediated 
activation of S1PR1, and whether this can be inhibited by the over-expression of S1PR2.  
Having shown that S1PR2 expression in tumour cells is absent in the majority of cases of 
HL and DLBCL, it will be important to establish if loss of S1PR2 expression contributes to 
the earlier stages of B cell lymphomagenesis. To do this I might employ the GC B cell 
system I have used in my project to investigate the effects of S1PR2 inhibition (using the 
specific antagonist, JTE-013 (Osada et al., 2002)) on the transcriptional programme 
(using microarrays) and on the activation of cell signalling pathways (using the 
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PathDetect system) in normal human GC B cells. These experiments might be extended 
to include a study of the effects of S1PR2 inhibition during the EBV-induced 
immortalisation of B cells in vitro; which a model which has been employed to study the 
transformation of B cells. 
Like S1PR2, RGS13 is also highly expressed in GC B cells. RGS13 is a negative regulator of 
Gα, a G protein involved in CXCR4 and CXCR5 chemotactic signalling in response to 
ligand, leading to reduced cell motility (Shi et al., 2002, Han et al., 2006). Furthermore, 
the loss of RGS13 expression leads to increased GC B cell growth compared to wild type 
in response to antigen stimulation (Hwang et al., 2013). This indicates that the down-
regulation of this molecule has the potential to contribute to lymphomagenesis.  
Although I failed to confirm RGS13 as an LMP1 target in GC B cells, RGS13 is down-
regulated in HL and DLBCL cell lines. The expression of RGS13 in primary HL and DLBCL 
cases should be examined. If RGS13 expression is lost at the protein level in primary 
tumour samples, the effect of RGS13 over-expression in a cell line, in terms of growth, 
survival and migration, could be investigated. Furthermore the impact of the 
simultaneous over-expression of S1PR2 and RGS13 on S1P signalling and the phenotype 
of HL cell lines could be examined. 
The PathDetect system described in this work has the potential to identify those 
signalling pathways activated by LMP1 but not by CD40 in GC B cells. Therefore, it will 
be important to optimise this system for the analysis of the short-term effects of CD40L 










Table 7.1: Genes concurrently regulated by LMP1 and CD40 in GC B cells 
Genes up-regulated by LMP1 and CD40 Genes down-regulated by LMP1 and CD40 
Probe Set ID 
NCBI Gene 
Symbol 




  LMP1 CD40   LMP1 CD40 
202897_at SIRPA 10.35 2.72 237137_at SCARNA2 -5.18 -1.79 
225897_at MARCKS 7.11 2.09 201416_at SOX4 -4.36 -1.74 
213002_at MARCKS 6.76 1.83 214516_at HIST1H4B -3.91 -1.50 
231978_at TPCN2 6.12 2.35 228707_at CLDN23 -3.86 -1.56 
219424_at EBI3 5.20 2.02 213931_at ID2 /// ID2B -3.80 -1.98 
231303_at LINC00158 5.16 1.76 210138_at RGS20 -3.68 -2.24 
207861_at CCL22 5.02 1.92 210387_at HIST1H2BG -3.36 -2.00 
239031_at SSTR2 4.81 1.53 239697_x_at C3orf67 -3.31 -1.54 
201670_s_at MARCKS 4.55 2.15 204689_at HHEX -3.23 -1.56 
214597_at SSTR2 4.31 1.58 230252_at LPAR5 -3.20 -1.52 
211269_s_at IL2RA 4.10 2.71 225548_at SHROOM3 -3.20 -1.59 
206341_at IL2RA 4.05 2.50 222958_s_at DEPDC1 -3.03 -1.75 
202896_s_at SIRPA 4.04 1.70 212915_at PDZRN3 -3.03 -1.90 
209210_s_at FERMT2 3.98 1.92 219371_s_at KLF2 -3.01 -1.71 
205599_at TRAF1 3.90 2.43 225762_x_at LOC284801 -2.84 -1.59 
237559_at GPR55 3.88 1.92 236295_s_at NLRC3 -2.63 -1.55 
201669_s_at MARCKS 3.85 1.82 227478_at SETBP1 -2.60 -1.86 
209695_at PTP4A3 3.85 1.56 206115_at EGR3 -2.57 -1.56 
1555573_at C10orf93 3.81 1.77 235410_at NPHP3 -2.51 -1.65 
204849_at TCFL5 3.75 2.13 227404_s_at EGR1 -2.44 -1.53 
220230_s_at CYB5R2 3.63 1.69 204162_at NDC80 -2.38 -1.54 
219045_at RHOF 3.57 1.92 202499_s_at SLC2A3 -2.38 -1.73 
202638_s_at ICAM1 3.54 2.07 223624_at ANUBL1 -2.29 -1.52 
211026_s_at MGLL 3.44 1.64 225767_at LOC284801 -2.28 -2.00 
201502_s_at NFKBIA 3.36 1.83 206060_s_at PTPN22 -2.18 -1.87 
212761_at TCF7L2 3.22 2.16 229584_at LRRK2 -2.17 -1.53 
217455_s_at SSTR2 3.20 1.57 226301_at C6orf192 -2.16 -1.62 
205103_at C1orf61 3.20 1.55 208079_s_at AURKA -2.16 -1.58 
227249_at NDE1 3.05 1.71 1559584_a_at C16orf54 -2.15 -2.16 
225316_at MFSD2A 3.00 1.67 222670_s_at MAFB -2.13 -2.04 
220161_s_at EPB41L4B 2.95 3.47 223434_at GBP3 -2.07 -1.54 
203835_at LRRC32 2.79 1.62 228531_at SAMD9 -2.06 -1.51 
212977_at CXCR7 2.78 1.67 203610_s_at TRIM38 -2.05 -1.52 
214787_at DENND4A 2.78 1.58 202207_at ARL4C -2.02 -1.53 
211744_s_at CD58 2.71 1.80 224983_at SCARB2 -2.02 -1.52 
218872_at TESC 2.70 2.10 238890_at BRWD1 -1.99 -1.95 
202637_s_at ICAM1 2.68 2.00 228962_at PDE4D -1.94 -1.52 
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212561_at DENND5A 2.64 1.51 203397_s_at GALNT3 -1.91 -1.85 
213497_at ABTB2 2.61 2.01 207165_at HMMR -1.90 -1.60 
205173_x_at CD58 2.58 1.91 74694_s_at RABEP2 -1.86 -1.54 
1554519_at CD80 2.57 1.96 236641_at KIF14 -1.83 -1.66 
235116_at TRAF1 2.51 1.97 239725_at PGAP1 -1.79 -1.74 
226056_at ARHGAP31 2.48 1.90 202741_at PRKACB -1.77 -1.53 
218414_s_at NDE1 2.42 1.60 38241_at BTN3A3 -1.66 -1.70 
210564_x_at CFLAR 2.35 1.76     
1554352_s_at DENND4A 2.35 1.58     
204562_at IRF4 2.32 1.68     
222812_s_at RHOF 2.30 1.73     
223427_s_at EPB41L4B 2.28 3.08     
212312_at BCL2L1 2.28 1.83     
210563_x_at CFLAR 2.27 1.75     
220002_at KIF26B 2.27 1.79     
207176_s_at CD80 2.25 1.79     
209636_at NFKB2 2.24 1.59     
201625_s_at INSIG1 2.24 1.58     
212923_s_at C6orf145 2.23 1.81     
209939_x_at CFLAR 2.23 1.68     
202431_s_at MYC 2.19 1.63     
222799_at WDR91 2.18 1.55     
205965_at BATF 2.18 1.75     
232682_at MREG 2.18 1.51     




2.15 1.61   
  
238567_at SGPP2 2.14 2.13     
234284_at GNG8 2.14 2.04     
211317_s_at CFLAR 2.12 1.88     




2.06 1.75   
  
230536_at PBX4 2.06 1.62     
208485_x_at CFLAR 2.05 1.67     
212019_at RSL1D1 2.00 1.56     
203045_at NINJ1 1.99 1.82     
207291_at PRRG4 1.99 2.20     
211862_x_at CFLAR 1.99 1.82     
211612_s_at IL13RA1 1.95 2.39     
216252_x_at FAS 1.93 2.76     
232746_at CXCR7 1.91 1.61     
203470_s_at PLEK 1.91 1.74     
223038_s_at FAM60A 1.90 1.51     
215346_at CD40 1.85 1.69     
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211316_x_at CFLAR 1.83 1.61     
201888_s_at IL13RA1 1.76 2.26     
205184_at GNG4 1.73 1.92     
205153_s_at CD40 1.72 1.90     
205686_s_at CD86 1.62 1.59     




Table 7.2: Genes regulated by LMP1 but not by CD40 in GC B cells 
Genes up by LMP1 not CD40 Genes down by LMP1 not CD40 
Probe Set ID NCBI Gene Symbol 
Fold Change 
LMP1 
Probe Set ID NCBI Gene Symbol 
Fold Change 
LMP1 
201564_s_at FSCN1 17.61 213317_at CLIC5 -5.12 
207900_at CCL17 8.39 217002_s_at HTR3A -4.72 
202796_at SYNPO 8.06 216615_s_at HTR3A -4.41 
231899_at ZC3H12C 7.66 215925_s_at CD72 -4.34 
232383_at TFEC 7.17 205903_s_at KCNN3 -3.85 
204897_at PTGER4 6.09 223503_at TMEM163 -3.75 
206715_at TFEC 5.79 206641_at TNFRSF17 -3.72 
201631_s_at IER3 5.53 226799_at FGD6 -3.71 
202734_at TRIP10 5.33 238520_at TRERF1 -3.71 
212097_at CAV1 5.32 227717_at ARHGEF37 -3.62 
235287_at CDK6 5.30 205902_at KCNN3 -3.61 
236013_at CACNA1E 5.26 34210_at CD52 -3.57 
232291_at MIR17HG 5.03 228377_at KLHL14 -3.40 
236831_at CCDC50 5.01 215933_s_at HHEX -3.40 
205872_x_at PDE4DIP 4.96 218935_at EHD3 -3.39 
236289_at LOC100506563 4.92 207761_s_at METTL7A -3.37 
214023_x_at TUBB2B 4.68 219684_at RTP4 -3.32 
235457_at MAML2 4.61 208046_at HIST1H4A -3.28 
203196_at ABCC4 4.58 204967_at SHROOM2 -3.28 
1555935_s_at HUNK 4.20 220068_at VPREB3 -3.25 
46665_at SEMA4C 4.17 213906_at MYBL1 -3.22 
201668_x_at MARCKS 4.12 219396_s_at NEIL1 -3.17 
202510_s_at TNFAIP2 4.11 203865_s_at ADARB1 -3.13 
206574_s_at PTP4A3 4.02 215813_s_at PTGS1 -3.12 
202007_at NID1 3.98 201677_at C3orf37 -3.10 
206176_at BMP6 3.98 230983_at FAM129C -3.08 
230188_at NIPAL4 3.87 235292_at FLJ32255 -3.06 
201170_s_at BHLHE40 3.79 219577_s_at ABCA7 -3.05 
202421_at IGSF3 3.78 230560_at STXBP6 -3.03 
225102_at MGLL 3.77 201678_s_at C3orf37 -3.01 
202341_s_at TRIM2 3.69 230740_at EHD3 -2.99 
227458_at CD274 3.67 229021_at MCTP2 -2.96 
236995_x_at TFEC 3.66 225540_at MAP2 -2.96 
1554242_a_at COCH 3.64 242525_at SLC2A5 -2.95 
233899_x_at ZBTB10 3.61 205718_at ITGB7 -2.93 
209835_x_at CD44 3.47 231254_at LOC100507635 -2.92 
217523_at CD44 3.45 218692_at SYBU -2.91 
213113_s_at SLC43A3 3.42 217853_at TNS3 -2.91 
228218_at LSAMP 3.42 226809_at LOC100216479 -2.90 
224327_s_at DGAT2 3.41 204880_at MGMT -2.87 
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243000_at CDK6 3.40 242794_at MAML3 -2.87 
205229_s_at COCH 3.38 200765_x_at CTNNA1 -2.87 
1555689_at CD80 3.36 203144_s_at KIAA0040 -2.86 
206729_at TNFRSF8 3.24 219190_s_at EIF2C4 -2.86 
205081_at CRIP1 3.20 214366_s_at ALOX5 -2.85 
201063_at RCN1 3.20 244467_at LOC100510485 -2.83 
207030_s_at CSRP2 3.20 216379_x_at CD24 -2.82 
227037_at PLD6 3.19 218285_s_at BDH2 -2.82 
220658_s_at ARNTL2 3.16 217983_s_at RNASET2 -2.79 
206825_at OXTR 3.15 208914_at GGA2 -2.78 
226064_s_at DGAT2 3.14 242334_at NLRP4 -2.76 
235051_at CCDC50 3.13 233463_at RASSF6 -2.75 




219159_s_at SLAMF7 3.11 203408_s_at SATB1 -2.73 
234306_s_at SLAMF7 3.05 224482_s_at RAB11FIP4 -2.73 
224851_at CDK6 3.04 225570_at SLC41A1 -2.71 
220358_at BATF3 3.00 220528_at VNN3 -2.71 
212014_x_at CD44 2.96 221908_at RNFT2 -2.71 
218627_at DRAM1 2.91 205418_at FES -2.71 
202643_s_at TNFAIP3 2.86 203283_s_at HS2ST1 -2.71 
202925_s_at PLAGL2 2.86 235486_at C11orf41 -2.69 
203010_at STAT5A 2.85 218025_s_at ECI2 -2.68 
231084_at WDR96 2.83 205128_x_at PTGS1 -2.68 
202644_s_at TNFAIP3 2.82 220169_at TMEM156 -2.68 
225331_at CCDC50 2.81 229383_at MARCH1 -2.66 
241871_at CAMK4 2.81 228258_at TBC1D10C -2.66 
212397_at RDX 2.79 222450_at PMEPA1 -2.65 
207169_x_at DDR1 2.79 1552807_a_at SIGLEC10 -2.64 
202085_at TJP2 2.79 203143_s_at KIAA0040 -2.64 
222774_s_at NETO2 2.78 225562_at RASA3 -2.64 
214460_at LSAMP 2.76 213385_at CHN2 -2.62 
1565868_at CD44 2.76 219518_s_at ELL3 /// SERINC4 -2.62 
201627_s_at INSIG1 2.76 214156_at MYRIP -2.62 
239629_at CFLAR 2.76 226906_s_at ARHGAP9 -2.61 
210749_x_at DDR1 2.74 203285_s_at HS2ST1 -2.60 
1554600_s_at LMNA 2.73 228964_at PRDM1 -2.60 
235444_at FOXP1 2.70 206100_at CPM -2.59 
206756_at CHST7 2.69 231929_at IKZF2 -2.59 
202449_s_at RXRA 2.68 227184_at PTAFR -2.58 
230875_s_at ATP11A 2.68 202742_s_at PRKACB -2.58 
222838_at SLAMF7 2.67 204430_s_at SLC2A5 -2.57 
1556308_at PRRT3 2.67 219313_at GRAMD1C -2.56 
204489_s_at CD44 2.66 219667_s_at BANK1 -2.56 
229228_at CREB5 2.63 211379_x_at B3GALNT1 -2.56 
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36711_at MAFF 2.62 206369_s_at PIK3CG -2.56 
229910_at SHE 2.61 228434_at BTNL9 -2.55 
1007_s_at DDR1 2.61 204164_at SIPA1 -2.54 
208779_x_at DDR1 2.60 1568751_at RGS13 -2.54 
230093_at RSPH1 2.59 203281_s_at UBA7 -2.54 
213418_at HSPA6 2.59 230710_at LOC100506211 -2.54 
210118_s_at IL1A 2.58 1552323_s_at FAM122C -2.53 
205920_at SLC6A6 2.57 204446_s_at ALOX5 -2.52 
204490_s_at CD44 2.57 212979_s_at FAM115A -2.52 
202910_s_at CD97 2.56 204392_at CAMK1 -2.51 
226713_at CCDC50 2.56 214772_at C11orf41 -2.50 
218868_at ACTR3B 2.55 201752_s_at ADD3 -2.50 
1558996_at FOXP1 2.53 203435_s_at MME -2.50 
220703_at IDI2-AS1 2.53 226666_at DAAM1 -2.49 
208683_at CAPN2 2.52 213045_at MAST3 -2.49 
219675_s_at UXS1 2.52 218729_at LXN -2.49 
203411_s_at LMNA 2.51 209771_x_at CD24 -2.49 
216952_s_at LMNB2 2.49 221643_s_at RERE -2.49 
202975_s_at RHOBTB3 2.49 214719_at SLC46A3 -2.48 




209949_at NCF2 2.46 218807_at VAV3 -2.47 
203836_s_at MAP3K5 2.46 205389_s_at ANK1 -2.47 
200800_s_at HSPA1A /// HSPA1B 2.44 225739_at RAB11FIP4 -2.45 
227645_at PIK3R5 2.44 219889_at FRAT1 -2.45 
204435_at NUPL1 2.44 222449_at PMEPA1 -2.44 
218786_at NT5DC3 2.44 209276_s_at GLRX -2.44 
1552671_a_at SLC9A7 2.43 204961_s_at 
NCF1 /// NCF1B /// 
NCF1C 
-2.44 
224204_x_at ARNTL2 2.42 1552626_a_at TMEM163 -2.43 
203837_at MAP3K5 2.42 210658_s_at GGA2 -2.43 
219279_at DOCK10 2.39 204220_at GMFG -2.41 
210407_at PPM1A 2.39 209570_s_at D4S234E -2.40 
242905_at PNO1 2.38 205213_at ACAP1 -2.40 
205681_at BCL2A1 2.37 236278_at HIST1H3E -2.40 
205569_at LAMP3 2.36 218458_at GMCL1 -2.40 
227230_s_at KIAA1211 2.35 235706_at CPM -2.39 
224848_at CDK6 2.35 1569065_s_at C15orf62 -2.39 
202976_s_at RHOBTB3 2.34 219183_s_at CYTH4 -2.39 
202014_at PPP1R15A 2.34 203153_at IFIT1 -2.39 
203684_s_at BCL2 2.34 214369_s_at RASGRP2 -2.39 
1555620_a_at PTGIR 2.33 1557321_a_at CAPN14 -2.38 
210663_s_at KYNU 2.32 208087_s_at ZBP1 -2.38 
200704_at LITAF 2.31 211368_s_at CASP1 -2.37 
209163_at CYB561 2.31 204429_s_at SLC2A5 -2.37 
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238790_at LOC374443 2.30 229147_at RASSF6 -2.36 
202933_s_at YES1 2.30 226456_at RMI2 -2.35 
1405_i_at CCL5 2.28 203418_at CCNA2 -2.35 
201566_x_at ID2 2.28 218862_at ASB13 -2.34 
1563638_at FAM18A 2.28 235291_s_at FLJ32255 -2.34 
208920_at SRI 2.27 221123_x_at ZNF395 -2.34 
214452_at BCAT1 2.26 219901_at FGD6 -2.33 
201426_s_at VIM 2.26 213888_s_at TRAF3IP3 -2.32 
229801_at C10orf47 2.24 226249_at SNX30 -2.32 
201307_at SEPT11 2.24 206348_s_at PDK3 -2.32 
213138_at ARID5A 2.23 231837_at USP28 -2.32 
203414_at MMD 2.23 227100_at B3GALTL -2.32 
225066_at PPP2R2D 2.21 1555037_a_at IDH1 -2.32 
212063_at CD44 2.20 207339_s_at LTB -2.31 
214662_at WDR43 2.19 1555137_a_at FGD6 -2.31 
212443_at NBEAL2 2.19 228622_s_at DNAJC4 -2.31 
219581_at TSEN2 2.19 218844_at ACSF2 -2.30 
243296_at NAMPT 2.18 223179_at YPEL3 -2.30 
203023_at NOP16 2.18 219517_at ELL3 /// SERINC4 -2.30 
211725_s_at BID 2.18 213772_s_at GGA2 -2.30 
226517_at BCAT1 2.18 209441_at RHOBTB2 -2.29 
236019_at RAB12 2.18 205297_s_at CD79B -2.29 
209900_s_at SLC16A1 2.17 234987_at SAMHD1 -2.29 
200916_at TAGLN2 2.17 225637_at DEF8 -2.29 
234411_x_at CD44 2.17 211685_s_at NCALD -2.29 
1555392_at LOC100128868 2.17 235400_at FCRLA -2.28 
1558292_s_at PIGW 2.16 201694_s_at EGR1 -2.28 
233409_at RHBDL3 2.16 1553196_a_at FCRL3 -2.28 
222442_s_at ARL8B 2.15 217989_at HSD17B11 -2.28 
242586_at FSD1L 2.15 203758_at CTSO -2.28 
223182_s_at AGPAT3 2.15 219691_at SAMD9 -2.28 
225071_at NUS1 2.14 243109_at MCTP2 -2.27 
212277_at MTMR4 2.14 217984_at RNASET2 -2.27 
219275_at PDCD5 2.13 221867_at N4BP1 -2.27 
202016_at MEST 2.13 209113_s_at HMG20B -2.26 
218032_at SNN 2.12 210719_s_at HMG20B -2.26 
223287_s_at FOXP1 2.11 215887_at ZNF277 -2.26 
224925_at PREX1 2.11 219677_at SPSB1 -2.25 
227985_at LOC100506098 2.11 210844_x_at CTNNA1 -2.25 
237159_x_at AP1S3 2.11 201315_x_at IFITM2 -2.25 
1553386_at MFSD2A 2.11 1554240_a_at ITGAL -2.24 
212089_at LMNA 2.11 204061_at PRKX -2.24 
37028_at PPP1R15A 2.10 209995_s_at TCL1A -2.24 
201626_at INSIG1 2.10 221669_s_at ACAD8 -2.24 
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1555487_a_at ACTR3B 2.09 201753_s_at ADD3 -2.23 
244600_at LOC100506589 2.08 202869_at OAS1 -2.23 
206173_x_at GABPB1 2.08 223269_at POLR3GL -2.23 
216056_at CD44 2.08 1294_at UBA7 -2.23 




1555384_a_at LARP4 2.07 206219_s_at VAV1 -2.22 
225341_at MTERFD3 2.07 39318_at TCL1A -2.22 
237498_at NEDD4L 2.07 231455_at FLJ42418 -2.22 
1558569_at LOC100131541 2.06 219505_at CECR1 -2.22 
218984_at PUS7 2.05 1553055_a_at SLFN5 -2.22 
203622_s_at PNO1 2.04 235173_at LOC401093 -2.21 
226998_at NAA15 2.03 219863_at HERC5 -2.21 
224282_s_at AGPAT3 2.02 227224_at RALGPS2 -2.21 
228980_at RFFL 2.02 203434_s_at MME -2.21 
229029_at CAMK4 2.00 203198_at CDK9 -2.21 
223376_s_at BRI3 2.00 205882_x_at ADD3 -2.21 
223183_at AGPAT3 2.00 208206_s_at RASGRP2 -2.20 
225400_at TSEN15 1.99 39248_at AQP3 -2.20 
223184_s_at AGPAT3 1.99 230128_at IGL@ -2.20 




206975_at LTA 1.98 204993_at GNAZ -2.19 
206181_at SLAMF1 1.98 217553_at STEAP1B -2.19 
201952_at ALCAM 1.98 1554343_a_at STAP1 -2.19 
201951_at ALCAM 1.97 242785_at EML6 -2.19 
205180_s_at ADAM8 1.97 228055_at NAPSB -2.18 
219648_at MREG 1.97 210176_at TLR1 -2.18 
221563_at DUSP10 1.97 235353_at SEL1L3 -2.18 
224716_at SLC35B2 1.96 227189_at CPNE5 -2.18 
209212_s_at KLF5 1.96 200764_s_at CTNNA1 -2.17 
222666_s_at RCL1 1.96 220214_at ZNF215 -2.16 
218507_at C7orf68 1.96 213326_at VAMP1 -2.16 
204385_at KYNU 1.96 232024_at GIMAP2 -2.16 
244786_at SNHG10 1.95 1552701_a_at CARD16 -2.16 
218460_at HEATR2 1.94 218149_s_at ZNF395 -2.16 
200799_at HSPA1A 1.94 214047_s_at MBD4 -2.16 
203724_s_at RUFY3 1.94 223849_s_at MOV10 -2.16 
204790_at SMAD7 1.93 204415_at IFI6 -2.16 
212201_at ANKLE2 1.93 230036_at SAMD9L -2.15 
234968_at DENND4C 1.92 200923_at LGALS3BP -2.15 
228087_at CCDC126 1.92 209200_at MEF2C -2.14 
206035_at REL 1.92 227168_at MIAT -2.14 
242807_at FSD1L 1.91 213174_at TTC9 -2.14 
213746_s_at FLNA 1.91 218943_s_at DDX58 -2.14 
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223172_s_at MTFP1 1.90 209607_x_at SULT1A3 /// SULT1A4 -2.14 
215207_x_at NUS1 /// NUS1P3 1.90 214084_x_at NCF1C -2.13 
226262_at DHX33 1.89 204867_at GCHFR -2.13 
212609_s_at AKT3 1.89 38521_at CD22 -2.13 
201473_at JUNB 1.89 212981_s_at FAM115A -2.13 
218886_at PAK1IP1 1.88 209606_at CYTIP -2.13 
226117_at TIFA 1.88 1558827_a_at ZNF831 -2.12 
220118_at ZBTB32 1.88 213343_s_at GDPD5 -2.12 
205377_s_at ACHE 1.88 224451_x_at ARHGAP9 -2.12 
213816_s_at MET 1.87 1552390_a_at C8orf47 -2.11 
33197_at MYO7A 1.87 203522_at CCS -2.11 
200859_x_at FLNA 1.87 223216_x_at ZNF395 -2.11 
200894_s_at FKBP4 1.87 205352_at SERPINI1 -2.11 
233231_at MCCC2 1.86 213916_at ZNF20 /// ZNF625 -2.11 
201565_s_at ID2 1.86 1553102_a_at CCDC69 -2.11 
225615_at IFFO2 1.86 206039_at RAB33A -2.11 
209318_x_at PLAGL1 1.86 239585_at KAT2B -2.10 
235783_at MRTO4 1.86 226431_at FAM117B -2.10 
232504_at LOC285628 1.85 219911_s_at SLCO4A1 -2.09 
232045_at PHACTR1 1.85 208913_at GGA2 -2.09 
225023_at GOPC 1.84 209911_x_at HIST1H2BD -2.09 
209725_at UTP20 1.84 204735_at PDE4A -2.09 
208712_at CCND1 1.84 214933_at CACNA1A -2.09 
212200_at ANKLE2 1.84 225008_at ASPH -2.09 
48659_at MIIP 1.84 229005_at MCTP2 -2.08 
203685_at BCL2 1.83 229656_s_at EML6 -2.08 
227215_at GOPC 1.83 214059_at IFI44 -2.08 
227214_at GOPC 1.83 238669_at PTGS1 -2.08 
212563_at BOP1 1.83 228056_s_at NAPSB -2.08 
37079_at NUS1P3 1.83 205922_at VNN2 -2.08 
1554918_a_at ABCC4 1.83 202203_s_at AMFR -2.08 
218561_s_at LYRM4 1.83 243999_at SLFN5 -2.08 
235072_s_at KIF13A 1.83 228273_at PRR11 -2.07 
217388_s_at KYNU 1.82 53720_at C19orf66 -2.07 
213320_at PRMT3 1.80 210033_s_at SPAG6 -2.07 
213327_s_at USP12 1.80 242624_at ABLIM2 -2.06 
223586_at ARNTL2 1.80 210279_at GPR18 -2.06 
206380_s_at CFP 1.80 209580_s_at MBD4 -2.06 
221270_s_at QTRT1 1.80 211700_s_at TRO -2.06 
218888_s_at NETO2 1.79 222589_at NLK -2.05 
213430_at RUFY3 1.79 235221_at CBLN3 -2.05 
222592_s_at ACSL5 1.79 218272_at TTC38 -2.05 
226121_at DHRS13 1.78 223750_s_at TLR10 -2.05 
223437_at PPARA 1.76 212886_at CCDC69 -2.05 
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33736_at STOML1 1.76 232543_x_at ARHGAP9 -2.04 
224654_at DDX21 1.75 201601_x_at IFITM1 -2.04 
214752_x_at FLNA 1.75 212573_at ENDOD1 -2.04 
218744_s_at PACSIN3 1.75 213475_s_at ITGAL -2.04 
223746_at STK4 1.75 205398_s_at SMAD3 -2.04 
225022_at GOPC 1.75 209447_at SYNE1 -2.04 
210676_x_at RGPD5///RGPD8 1.75 203803_at PCYOX1 -2.03 
220688_s_at MRTO4 1.74 212792_at DPY19L1 -2.03 
225440_at AGPAT3 1.74 228551_at DENND5B -2.03 
242727_at ARL5B 1.73 232693_s_at FBXO16 /// ZNF395 -2.03 
216913_s_at RRP12 1.73 201193_at IDH1 -2.03 
209366_x_at CYB5A 1.73 203567_s_at TRIM38 -2.03 
208029_s_at LAPTM4B 1.72 219211_at USP18 -2.02 
215087_at C15orf39 1.72 210580_x_at SULT1A3 /// SULT1A4 -2.02 
221987_s_at TSR1 1.72 209980_s_at SHMT1 -2.02 
226609_at DCBLD1 1.72 228677_s_at RASAL3 -2.02 
215726_s_at CYB5A 1.71 225327_at KIAA1370 -2.02 
207760_s_at NCOR2 1.71 209282_at PRKD2 -2.02 
227804_at TLCD1 1.71 208442_s_at ATM -2.01 
204335_at CCDC94 1.71 227811_at FGD3 -2.01 
215513_at HYMAI 1.71 225136_at PLEKHA2 -2.00 
220948_s_at ATP1A1 1.71 235372_at FCRLA -2.00 
202138_x_at AIMP2 1.70 242625_at RSAD2 -2.00 
227143_s_at BID 1.70 204484_at PIK3C2B -2.00 
219420_s_at SELRC1 1.70 1552540_s_at IQCD -2.00 
208836_at ATP1B3 1.70 1568752_s_at RGS13 -2.00 
218512_at WDR12 1.69 226158_at KLHL24 -1.99 
238858_at TIFA 1.69 217825_s_at UBE2J1 -1.99 
207574_s_at GADD45B 1.69 216684_s_at SS18 -1.99 
201858_s_at SRGN 1.69 205997_at ADAM28 -1.99 
230272_at LOC645323 1.69 202455_at HDAC5 -1.99 
219540_at ZNF267 1.69 208933_s_at LGALS8 -1.99 
232621_at USP48 1.69 1557915_s_at GSTO1 -1.99 
222292_at CD40 1.68 203420_at FAM8A1 -1.98 
223028_s_at SNX9 1.68 218317_x_at SLX1A /// SLX1B -1.98 
226319_s_at THOC4 1.68 218217_at SCPEP1 -1.98 
220198_s_at EIF5A2 1.68 211071_s_at MLLT11 -1.98 
225285_at BCAT1 1.68 212390_at PDE4DIP -1.98 
201872_s_at ABCE1 1.67 232278_s_at DEPDC1 -1.98 
227369_at SERBP1 1.67 205124_at MEF2BNB-MEF2B -1.97 
226200_at VARS2 1.67 205804_s_at TRAF3IP3 -1.97 
232154_at C19orf76 1.67 38269_at PRKD2 -1.97 
204417_at GALC 1.67 217824_at UBE2J1 -1.97 
238506_at LRRC58 1.66 203806_s_at FANCA -1.97 
147 
209508_x_at CFLAR 1.66 203140_at BCL6 -1.97 
208754_s_at NAP1L1 1.66 219352_at HERC6 -1.97 
212846_at RRP1B 1.66 228252_at PIF1 -1.97 
218982_s_at MRPS17 /// ZNF713 1.66 210640_s_at GPER -1.96 
208634_s_at MACF1 1.65 226372_at CHST11 -1.96 
204700_x_at DIEXF 1.65 217838_s_at EVL -1.96 
214011_s_at NOP16 1.64 225763_at RCSD1 -1.96 
221632_s_at WDR4 1.64 212311_at SEL1L3 -1.96 
201391_at TRAP1 1.64 221957_at PDK3 -1.95 
223027_at SNX9 1.64 203615_x_at SULT1A1 -1.95 
225470_at NUP35 1.63 205034_at CCNE2 -1.95 
214484_s_at SIGMAR1 1.63 209682_at CBLB -1.95 
212074_at SUN1 1.63 221211_s_at C21orf7 -1.95 
41387_r_at KDM6B 1.63 213643_s_at INPP5B -1.94 
208092_s_at FAM49A 1.63 213674_x_at IGHD -1.94 
225678_at POLR3H 1.62 204581_at CD22 -1.94 
212110_at SLC39A14 1.62 212856_at GRAMD4 -1.94 
1557331_at POLR1B 1.62 212310_at MIA3 -1.94 
206445_s_at PRMT1 1.61 204646_at DPYD -1.94 
226963_at BTF3L4 1.60 214368_at RASGRP2 -1.93 
220924_s_at SLC38A2 1.60 1557116_at APOL6 -1.93 
218479_s_at XPO4 1.59 201853_s_at CDC25B -1.93 
204015_s_at DUSP4 1.59 236562_at ZNF439 -1.93 
225585_at RAP2A 1.58 201688_s_at TPD52 -1.93 
210996_s_at YWHAE 1.58 219836_at ZBED2 -1.93 
215966_x_at GK3P 1.57 225144_at BMPR2 -1.93 
203737_s_at PPRC1 1.57 204336_s_at RGS19 -1.93 
212680_x_at PPP1R14B 1.57 226860_at TMEM19 -1.92 
225520_at MTHFD1L 1.57 227053_at PACSIN1 -1.92 
205684_s_at DENND4C 1.56 208869_s_at GABARAPL1 -1.92 
204123_at LIG3 1.56 210045_at IDH2 -1.92 
224793_s_at TGFBR1 1.55 232787_at PRIC285 -1.92 
   213521_at PTPN18 -1.92 
   220059_at STAP1 -1.92 
   225564_at SPATA13 -1.92 
   228868_x_at CDT1 -1.92 
   227122_at LOC100507237 -1.91 
   218031_s_at FOXN3 -1.91 
   225636_at STAT2 -1.91 





   208021_s_at RFC1 -1.91 
   228959_at PDK3 -1.91 
   210347_s_at BCL11A -1.90 
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   217022_s_at 
IGHA1 /// IGHA2 /// 
LOC100126583 
-1.90 
   209512_at HSDL2 -1.90 
   229538_s_at IQGAP3 -1.90 
   219498_s_at BCL11A -1.90 
   211385_x_at SULT1A2 -1.90 
   232035_at LOC100507025 -1.90 
   218073_s_at TMEM48 -1.90 
   221893_s_at ADCK2 -1.90 
   227565_at KLHL5 -1.90 
   1552634_a_at ZNF101 -1.89 
   226136_at GLIPR1 -1.89 
   222482_at SSBP3 -1.89 
   218298_s_at C14orf159 -1.89 
   215299_x_at SULT1A1 -1.89 
   1553690_at SGOL1 -1.89 
   217732_s_at ITM2B -1.89 
   235310_at GCET2 -1.89 
   228230_at PRIC285 -1.89 
   222891_s_at BCL11A -1.89 
   244008_at PARP8 -1.89 
   201204_s_at RRBP1 -1.88 
   218248_at FAM111A -1.88 
   206632_s_at APOBEC3B -1.88 
   225929_s_at RNF213 -1.88 
   202464_s_at PFKFB3 -1.88 
   227606_s_at STAMBPL1 -1.88 
   227684_at S1PR2 -1.88 
   228030_at RBM6 -1.88 
   225558_at GIT2 -1.87 
   220377_at FAM30A -1.87 
   213988_s_at SAT1 -1.87 
   204396_s_at GRK5 -1.87 




   1552532_a_at ATP6V1C2 -1.87 
   206513_at AIM2 -1.87 
   231093_at FCRL3 -1.87 
   1556579_s_at IGSF10 -1.86 
   219676_at ZSCAN16 -1.86 
   235478_at DCLRE1C -1.86 
   235683_at SESN3 -1.86 
   226630_at MIS18BP1 -1.86 
   32502_at GDPD5 -1.86 
   1552619_a_at ANLN -1.86 
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   213305_s_at PPP2R5C -1.86 
   223514_at CARD11 -1.86 
   222779_s_at C17orf85 -1.85 
   203823_at RGS3 -1.85 
   215111_s_at TSC22D1 -1.85 
   214022_s_at IFITM1 -1.84 
   223565_at MZB1 -1.84 
   226533_at HINT3 -1.84 
   213596_at CASP4 -1.84 
   205441_at OCEL1 -1.83 
   200632_s_at NDRG1 -1.83 
   230992_at BTNL9 -1.83 
   209085_x_at RFC1 -1.83 
   238861_at SSBP2 -1.83 
   205301_s_at OGG1 -1.83 
   235508_at PML -1.83 
   225533_at PHF19 -1.83 
   212357_at FAM168A -1.83 
   1552682_a_at CASC5 -1.83 
   202663_at WIPF1 -1.82 
   207219_at ZNF643 -1.82 
   212665_at TIPARP -1.82 
   232005_at DNAH1 -1.82 
   225175_s_at SLC44A2 -1.82 
   225045_at CCDC88A -1.82 
   202524_s_at SPOCK2 -1.82 
   222572_at PDP1 -1.82 
   225618_at ARHGAP27 -1.82 
   202208_s_at ARL4C -1.81 
   228320_x_at CCDC64 -1.81 
   234974_at GALM -1.81 
   221104_s_at NIPSNAP3B -1.81 
   235089_at FBXL20 -1.81 
   232114_at MED12L -1.81 
   239355_at GMCL1 -1.81 
   202729_s_at LTBP1 -1.81 
   204813_at MAPK10 -1.81 
   202019_s_at LANCL1 -1.81 
   202694_at STK17A -1.81 
   212672_at ATM -1.81 
   244687_at DBT -1.80 
   204774_at EVI2A -1.80 
   209709_s_at HMMR -1.80 
   37549_g_at BBS9 -1.80 
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   223303_at FERMT3 -1.80 
   234192_s_at GKAP1 -1.80 
   233483_at TBC1D27 -1.80 
   224946_s_at CCDC115 -1.79 
   223339_at ATPIF1 -1.79 
   202388_at RGS2 -1.79 
   210448_s_at P2RX5 -1.79 
   206206_at CD180 -1.79 
   225024_at RPRD1B -1.78 
   201697_s_at DNMT1 -1.78 
   200940_s_at RERE -1.78 
   229552_at LOC283454 -1.78 
   222233_s_at DCLRE1C -1.78 
   227607_at STAMBPL1 -1.78 
   231810_at BRI3BP -1.77 
   238440_at CLYBL -1.77 
   214453_s_at IFI44 -1.77 
   225182_at TMEM50B -1.77 
   227946_at OSBPL7 -1.77 
   221922_at GPSM2 -1.76 
   205550_s_at BRE -1.76 
   221290_s_at MUM1 -1.76 
   203805_s_at FANCA -1.76 
   205122_at TMEFF1 -1.76 
   209083_at CORO1A -1.75 
   238597_at ANKRD13C -1.75 
   204060_s_at PRKX /// PRKY -1.75 
   223298_s_at NT5C3 -1.75 
   209876_at GIT2 -1.75 
   204951_at RHOH -1.75 
   202732_at PKIG -1.75 
   202645_s_at MEN1 -1.75 
   223220_s_at PARP9 -1.74 
   225630_at EEPD1 -1.74 
   219996_at ASB7 -1.74 
   213659_at ZNF75D -1.74 
   208731_at RAB2A -1.74 
   203027_s_at MVD -1.74 
   213510_x_at LOC220594 -1.74 
   225237_s_at MSI2 -1.73 
   1552334_at TRIOBP -1.73 
   212399_s_at VGLL4 -1.73 
   224811_at LPP -1.73 
   225784_s_at ZC4H2 -1.73 
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   221572_s_at SLC26A6 -1.73 
   221810_at RAB15 -1.73 
   228787_s_at BCAS4 -1.72 
   213005_s_at KANK1 -1.72 
   224818_at SORT1 -1.72 
   226509_at ZNF641 -1.72 
   223980_s_at SP110 -1.72 
   202213_s_at CUL4B -1.72 
   221011_s_at LBH -1.72 
   37577_at ARHGAP19 -1.72 
   227134_at SYTL1 -1.72 
   202548_s_at ARHGEF7 -1.72 
   1554365_a_at PPP2R5C -1.71 
   226001_at KLHL5 -1.71 
   238647_at C14orf28 -1.71 
   212409_s_at TOR1AIP1 -1.71 
   238025_at MLKL -1.71 
   218782_s_at ATAD2 -1.71 
   203117_s_at PAN2 -1.71 
   1553227_s_at BRWD1 -1.71 
   221511_x_at CCPG1 -1.71 
   208912_s_at CNP -1.71 
   217118_s_at KIAA0930 -1.71 
   235139_at GNGT2 -1.70 
   202204_s_at AMFR -1.70 
   204439_at IFI44L -1.70 
   215058_at DENND5B -1.70 
   203564_at FANCG -1.70 
   212579_at SMCHD1 -1.70 
   231182_at WIPF1 -1.70 
   207124_s_at GNB5 -1.70 
   224756_s_at ABHD16A /// LY6G6E -1.70 
   214329_x_at TNFSF10 -1.70 
   209827_s_at IL16 -1.70 
   1552275_s_at PXK -1.69 
   201335_s_at ARHGEF12 -1.69 
   226670_s_at PABPC1L -1.69 
   213616_at C18orf10 -1.69 
   213082_s_at SLC35D2 -1.68 
   215232_at ARHGAP44 -1.68 
   228524_at ADCK5 -1.68 
   201924_at AFF1 -1.68 
   219914_at ECEL1 -1.68 
   222285_at IGHD -1.67 
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   207122_x_at SULT1A2 -1.67 
   209546_s_at APOL1 -1.67 
   221769_at SPSB3 -1.67 
   214189_s_at GGA2 -1.67 
   209262_s_at NR2F6 -1.66 
   202664_at WIPF1 -1.66 
   230193_at WDR66 -1.66 
   219862_s_at NARF -1.66 
   226641_at ANKRD44 -1.66 
   204564_at PCGF3 -1.66 
   213827_at ARHGAP33 -1.66 
   219441_s_at LRRK1 -1.66 
   1552623_at HSH2D -1.66 
   235230_at PLCXD2 -1.66 
   212242_at TUBA4A -1.66 
   213627_at MAGED2 -1.66 
   225250_at STIM2 -1.65 
   209553_at VPS8 -1.65 
   209479_at CCDC28A -1.65 
   228532_at C1orf162 -1.65 
   228816_at ATP6AP1L -1.65 
   202808_at C10orf26 -1.65 
   240159_at SLC15A2 -1.65 
   204820_s_at BTN3A2 /// BTN3A3 -1.65 
   233334_x_at 
SLX1A /// SLX1B /// 
SULT1A3 /// SULT1A4 
-1.64 
   204674_at LRMP -1.64 
   235964_x_at SAMHD1 -1.64 
   215184_at DAPK2 -1.64 
   228139_at RIPK3 -1.64 
   209460_at ABAT -1.64 
   202529_at PRPSAP1 -1.64 
   218429_s_at C19orf66 -1.64 
   212276_at LPIN1 -1.64 
   235061_at PPM1K -1.64 
   202793_at LPCAT3 -1.64 
   209271_at BPTF -1.63 
   232914_s_at SYTL2 -1.63 
   228777_at KBTBD3 -1.63 
   211711_s_at PTEN -1.62 
   244406_at ZNF20 /// ZNF625 -1.62 
   206118_at STAT4 -1.62 
   232112_at RALGPS2 -1.62 
   227352_at C19orf39 -1.62 
   218487_at ALAD -1.62 
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   228298_at FAM113B -1.61 
   36030_at IFFO1 -1.61 
   211430_s_at 
IGHG1 /// IGHG2 /// 
IGHM /// IGHV4-31 
-1.60 
   235432_at NPHP3 -1.60 
   235529_x_at SAMHD1 -1.60 
   1557943_at CNP -1.60 
   205631_at KIAA0586 -1.60 
   202239_at PARP4 -1.60 
   226700_at U2AF1L4 -1.59 
   229937_x_at LILRB1 -1.59 
   220933_s_at ZCCHC6 -1.59 
   223443_s_at AMZ2P1 -1.59 
   212274_at LPIN1 -1.58 
   226763_at SESTD1 -1.58 
   210044_s_at LYL1 -1.58 
   201009_s_at TXNIP -1.58 
   221778_at JHDM1D -1.58 
   209141_at UBE2G1 -1.57 
   221080_s_at DENND1C -1.56 




Table 7.3: Genes regulated by LMP1, not CD40 in GC B cells, which are also concurrently altered in HRS cells 
Genes up by LMP1 and in HL, not by CD40 Genes down by LMP1 and in HL, not by CD40 
Probe Set ID Gene name 
Fold change 
LMP1 
Probe Set ID Gene name 
Fold change 
LMP1 
201564_s_at FSCN1 17.61 216615_s_at HTR3A -4.41 
207900_at CCL17 8.39 215925_s_at CD72 -4.34 
204897_at PTGER4 6.09 206641_at TNFRSF17 -3.72 
201631_s_at IER3 5.53 226799_at FGD6 -3.71 
202734_at TRIP10 5.33 228377_at KLHL14 -3.40 
214023_x_at TUBB2B 4.68 215933_s_at HHEX -3.40 
46665_at SEMA4C 4.17 207761_s_at METTL7A -3.37 
202510_s_at TNFAIP2 4.11 204967_at SHROOM2 -3.28 
201170_s_at BHLHE40 3.79 220068_at VPREB3 -3.25 
202421_at IGSF3 3.78 213906_at MYBL1 -3.22 
225102_at MGLL 3.77 219396_s_at NEIL1 -3.17 
227458_at CD274 3.67 203865_s_at ADARB1 -3.13 
209835_x_at CD44 3.47 201677_at C3orf37 -3.10 
213113_s_at SLC43A3 3.42 230983_at FAM129C -3.08 
224327_s_at DGAT2 3.41 230560_at STXBP6 -3.03 
206729_at TNFRSF8 3.24 201678_s_at C3orf37 -3.01 
201063_at RCN1 3.20 229021_at MCTP2 -2.96 
207030_s_at CSRP2 3.20 225540_at MAP2 -2.96 
226064_s_at DGAT2 3.14 231254_at LOC100507635 -2.92 
219159_s_at SLAMF7 3.11 218692_at SYBU -2.91 
220358_at BATF3 3.00 226809_at LOC100216479 -2.90 
218627_at DRAM1 2.91 242794_at MAML3 -2.87 
202643_s_at TNFAIP3 2.86 214366_s_at ALOX5 -2.85 
203010_at STAT5A 2.85 244467_at SHISA8 -2.83 
202644_s_at TNFAIP3 2.82 208914_at GGA2 -2.78 
206756_at CHST7 2.69 242334_at NLRP4 -2.76 
222838_at SLAMF7 2.67 233463_at RASSF6 -2.75 
1556308_at PRRT3 2.67 225570_at SLC41A1 -2.71 
204489_s_at CD44 2.66 221908_at RNFT2 -2.71 
36711_at MAFF 2.62 203283_s_at HS2ST1 -2.71 
204490_s_at CD44 2.57 220169_at TMEM156 -2.68 
202910_s_at CD97 2.56 219518_s_at ELL3 -2.62 
208683_at CAPN2 2.52 214156_at MYRIP -2.62 
203411_s_at LMNA 2.51 226906_s_at ARHGAP9 -2.61 
209949_at NCF2 2.46 203285_s_at HS2ST1 -2.60 
227645_at PIK3R5 2.44 206100_at CPM -2.59 
205569_at LAMP3 2.36 219667_s_at BANK1 -2.56 
200704_at LITAF 2.31 211379_x_at B3GALNT1 -2.56 
1405_i_at CCL5 2.28 206369_s_at PIK3CG -2.56 
201566_x_at ID2 2.28 1552323_s_at FAM122C -2.53 
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201426_s_at VIM 2.26 204446_s_at ALOX5 -2.52 
229801_at C10orf47 2.24 201752_s_at ADD3 -2.50 
213138_at ARID5A 2.23 203435_s_at MME -2.50 
200916_at TAGLN2 2.17 226666_at DAAM1 -2.49 




219275_at PDCD5 2.13 218807_at VAV3 -2.47 
224925_at PREX1 2.11 229147_at RASSF6 -2.36 
212089_at LMNA 2.11 226456_at RMI2 -2.35 
37028_at PPP1R15A 2.10 203418_at CCNA2 -2.35 
223376_s_at BRI3 2.00 218862_at ASB13 -2.34 
200799_at HSPA1A 1.94 221123_x_at ZNF395 -2.34 
223172_s_at MTFP1 1.90 219901_at FGD6 -2.33 
201473_at JUNB 1.89 226249_at SNX30 -2.32 
220118_at ZBTB32 1.88 219517_at ELL3 -2.30 
201565_s_at ID2 1.86 213772_s_at GGA2 -2.30 
212563_at BOP1 1.83 205297_s_at CD79B -2.29 
206380_s_at CFP 1.80 225637_at DEF8 -2.29 
226121_at DHRS13 1.78 235400_at FCRLA -2.28 
33736_at STOML1 1.76 243109_at MCTP2 -2.27 
214752_x_at FLNA 1.75 209995_s_at TCL1A -2.24 
220688_s_at MRTO4 1.74 201753_s_at ADD3 -2.23 
225440_at AGPAT3 1.74 39318_at TCL1A -2.22 
209366_x_at CYB5A 1.73 231455_at LINC00487 -2.22 
215726_s_at CYB5A 1.71 227224_at RALGPS2 -2.21 
227804_at TLCD1 1.71 203434_s_at MME -2.21 
201858_s_at SRGN 1.69 205882_x_at ADD3 -2.21 
218982_s_at MRPS17 1.66 230128_at IGLL5 -2.20 
214011_s_at NOP16 1.64 221044_s_at TRIM6-TRIM34 -2.19 
201391_at TRAP1 1.64 204993_at GNAZ -2.19 
204015_s_at DUSP4 1.59 1554343_a_at STAP1 -2.19 
212680_x_at PPP1R14B 1.57 242785_at EML6 -2.19 
   235353_at SEL1L3 -2.18 
   227189_at CPNE5 -2.18 
   220214_at ZNF215 -2.16 
   213326_at VAMP1 -2.16 
   218149_s_at ZNF395 -2.16 
   214047_s_at MBD4 -2.16 
   209200_at MEF2C -2.14 
   38521_at CD22 -2.13 
   1553102_a_at CCDC69 -2.11 
   226431_at FAM117B -2.10 
   208913_at GGA2 -2.09 
   229656_s_at EML6 -2.08 
   205922_at VNN2 -2.08 
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   210279_at GPR18 -2.06 
   209580_s_at MBD4 -2.06 
   222589_at NLK -2.05 
   223750_s_at TLR10 -2.05 
   212886_at CCDC69 -2.05 
   209447_at SYNE1 -2.04 
   228551_at DENND5B -2.03 
   225327_at KIAA1370 -2.02 
   208442_s_at ATM -2.01 
   225136_at PLEKHA2 -2.00 
   235372_at FCRLA -2.00 
   1568752_s_at RGS13 -2.00 
   226158_at KLHL24 -1.99 
   217825_s_at UBE2J1 -1.99 
   205997_at ADAM28 -1.99 
   205124_at MEF2BNB-MEF2B -1.97 
   217824_at UBE2J1 -1.97 
   203806_s_at FANCA -1.97 
   203140_at BCL6 -1.97 
   210640_s_at GPER -1.96 
   225763_at RCSD1 -1.96 
   212311_at SEL1L3 -1.96 
   205034_at CCNE2 -1.95 
   213674_x_at IGHD -1.94 
   204581_at CD22 -1.94 
   236562_at ZNF439 -1.93 
   201688_s_at TPD52 -1.93 
   220059_at STAP1 -1.92 
   227122_at LOC100507237 -1.91 
   218031_s_at FOXN3 -1.91 
   208021_s_at RFC1 -1.91 
   210347_s_at BCL11A -1.90 
   219498_s_at BCL11A -1.90 
   218073_s_at TMEM48 -1.90 
   235310_at GCET2 -1.89 
   222891_s_at BCL11A -1.89 
   227684_at S1PR2 -1.88 
   228030_at RBM6 -1.88 
   225558_at GIT2 -1.87 
   220377_at KIAA0125 -1.87 
   202759_s_at AKAP2 -1.87 
   231093_at FCRL3 -1.87 
   1556579_s_at IGSF10 -1.86 
   226630_at MIS18BP1 -1.86 
157 
   213305_s_at PPP2R5C -1.86 
   209085_x_at RFC1 -1.83 
   205301_s_at OGG1 -1.83 
   225045_at CCDC88A -1.82 
   239355_at GMCL1 -1.81 
   212672_at ATM -1.81 
   209709_s_at HMMR -1.80 
   234192_s_at GKAP1 -1.80 
   210448_s_at P2RX5 -1.79 
   206206_at CD180 -1.79 
   201697_s_at DNMT1 -1.78 
   200940_s_at RERE -1.78 
   229552_at LOC283454 -1.78 
   222233_s_at DCLRE1C -1.78 
   231810_at BRI3BP -1.77 
   221922_at GPSM2 -1.76 
   203805_s_at FANCA -1.76 
   209083_at CORO1A -1.75 
   204951_at RHOH -1.75 
   213510_x_at USP32P2 -1.74 
   212399_s_at VGLL4 -1.73 
   224811_at LPP -1.73 
   213005_s_at KANK1 -1.72 
   202213_s_at CUL4B -1.72 
   37577_at ARHGAP19 -1.72 
   227134_at SYTL1 -1.72 
   202548_s_at ARHGEF7 -1.72 
   226001_at KLHL5 -1.71 
   218782_s_at ATAD2 -1.71 
   203117_s_at PAN2 -1.71 
   215058_at DENND5B -1.70 
   209827_s_at IL16 -1.70 
   222285_at IGHD -1.67 
   202664_at WIPF1 -1.66 
   230193_at WDR66 -1.66 
   226641_at ANKRD44 -1.66 
   1552623_at HSH2D -1.66 
   240159_at SLC15A2 -1.65 
   204674_at LRMP -1.64 
   212276_at LPIN1 -1.64 
   235061_at PPM1K -1.64 
   209271_at BPTF -1.63 
   211711_s_at PTEN -1.62 
   228298_at FAM113B -1.61 
158 
   229937_x_at LILRB1 -1.59 
   212274_at LPIN1 -1.58 
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